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Effective Measures of Weight Gain Five Years Post-Kidney Transplantation
Abstract
BACKGROUND
BACKGROUND: Weight gain is commonly observed post-kidney transplantation and is associated with
unfavorable health outcomes, such as graft loss, new onset diabetes, and cardiovascular disease. The
purpose of this study was to determine the most effective measure for assessing body composition after
kidney transplantation.
DESIGN: The study was a descriptive correlational follow-up study from a single kidney transplant site.
SUBJECTS
SUBJECTS: A total of 45 eligible patients from a 2007-2011 parent study were selected, ages of 37 to 78.
MEASUREMENTS: Body composition was obtained 5–8 years posttransplant via anthropometric
measures (waist circumference, body mass index, and dual energy X-ray absorptiometry) and compared
with baseline (pretransplant) values. Similarly, weight and body mass index (BMI) were obtained. Blood
sampling was performed to measure levels of serum glucose, hemoglobin A1C, low-density lipoproteincholesterol, high-density lipoprotein, triglycerides, and coronary risk ratio. Kidney function was monitored
via serum creatinine. Manual blood pressure was taken with two resting blood pressures.
RESULTS: The sample size was N = 45 and included 29 (64.4%) African Americans and 16 (35.6%) Whites.
There were 25 (55.6%) males and 20 (44.4%) females. The ages were 37 to 78, with a mean of 56 (SD
=10.1). Body weight increased from 186.66 ± 42.10 at baseline to 197.89 ± 48.1 at the 5-8 year follow-up,
and BMI increased from 29.03 ± 4.76 to 32.14 ± 9.61. At the 5-8 year follow-up, anthropometric measure
of waist circumference was found to be associated with cardiac risk ratio and weight with diastolic BP. In
contrast, 7 body composition measures were associated with HDL, 4 with cardiac risk ratio, 5 with
creatinine, and 2 with systolic blood pressure. Significant associations were also found with
anthropometric measure BMI obtained at the time of transplant surgery and HDL and LDL 5-8 years later.
There were 13 body composition measures associated with HDL, 6 with cardiac risk ratio, and 2 with
triglycerides during this same time span. Lastly, one change in anthropometric measure from baseline to
5-8 year posttransplant was associated with the 5-8 year cardiac risk factors (cardiac risk ratio and BMI).
There were 18 significant relationships for body compositions measures. These included 7 body
composition measures associated with creatinine, 5 with LDL, 4 with diastolic blood pressure, and 2 with
triglycerides.
DISCUSSION
DISCUSSION: The significant relationships found among dual-energy x-ray absorptiometry and cardiacrelated outcomes suggest this method may provide a better assessment of body fat, weight gain, and
potential cardiac risk factors than does the currently used method. The study continued to examine the
use of dual-energy x-ray absorptiometry to better understand the emerging coronary risk that
accompanies weight gain and as a basis upon which more precisely targeted interventions could be
designed that would improve the health and life expectancy of kidney transplant patients.

Document Type
Dissertation

Degree Name
Doctor of Philosophy (PhD)

Program
Nursing Science

Research Advisor
Donna K. Hathaway Ph.D

Keywords
Body Composition, Cardiovascular, Diabetes, Kidney Transplantation, Obestity, Weight Gain

Subject Categories
Cardiovascular Diseases | Diseases | Endocrine System Diseases | Investigative Techniques | Medicine
and Health Sciences | Nursing | Nutritional and Metabolic Diseases | Other Analytical, Diagnostic and
Therapeutic Techniques and Equipment | Other Nursing

This dissertation is available at UTHSC Digital Commons: https://dc.uthsc.edu/dissertations/468

Effective Measures of Weight Gain Five Years Post-Kidney Transplantation

A Dissertation
Presented for
The Graduate Studies Council
The University of Tennessee
Health Science Center

In Partial Fulfillment
Of the Requirements for the Degree
Doctor of Philosophy
From The University of Tennessee

By
Tara Calico Cherry
December 2018

Copyright © 2018 by Tara Calico Cherry.
All rights reserved.

ii

DEDICATION
First, I dedicate this dissertation to “my dad," the late Mr. Robert Lee Calico, who
instilled the value of education and fostered my dreams to excel in life no matter how
difficult or unrealistic the pathway might become, “keep it moving.” His strength and
love for education was remarkable until his last day in the classroom, 38 days before his
transition from his battle with pancreatic cancer on March 8, 2018. I’m certain he is
rejoicing as I write this dedication. Equally, I dedicate my dissertation to my “momma,”
Anna Black, who supported me in every life event in subtle and effortless fashion. Her
silence and willingness to help support my three adopted children made this dissertation
possible. Next, I dedicate this dissertation to my children, Roy, Kobe, and Xolani for
being unselfish and allowing me to pursue my higher education, by never complaining
when I wasn’t available physically and emotionally but who embraced the idea I am
seeking to make a difference and contribute to our family’s legacy of service. I also
dedicate this dissertation to my two daughters, Ee’ma and Selah, for inspiring me to find
strength in challenges of life and to trust God in all my decisions. I dedicate this
dissertation to my grandchildren, Corian, Jakya, Zachary, Roy III, and Ayden for the
lessons I learned from each of them. I also would like to dedicate this dissertation to
Carolyn Moore, for being supportive during my family’s illnesses and deaths over the last
year. Finally, but without hesitation,
I dedicate this dissertation to Ruby Anderson, Terri Donald, Patricia Bell
Jennings, Terri Oliver, Gregory Strong, and Charles Taylor for their emotional and
financial support and strong words of support during my family’s near-death illnesses and
deaths of my close family members over the last 12 months. I salute my family members
who have transitioned from this earth, starting with my late “dad,” Robert Lee Calico; my
grandma, “Mama” Corine Hampton; my aunt, “Aunt Helen” Helen Carlton; my uncle,
“Uncle Bay” Alvin Tuner; my uncle, “Uncle Billy” Billy Neal; and my kindergarten
teacher, Miss Harmon, who taught me to love to learn. Finally, I dedicate this
dissertation to all Black women and hope to empower them to embrace their fears and
challenge themselves to seek opportunities in the obstacles they will face on this earth; I
encourage them to find the inner strength beyond the known.

iii

ACKNOWLEDGEMENTS
First, I would like to acknowledge Dr. Donna Hathaway for her knowledge,
leadership, motivation and emotional support during my family’s near-death illnesses and
the deaths in my family. I would like to acknowledge my committee members, Dr.
Carolyn Graff, Dr. Carrie Harvey, Dr. Tara O’Brien, and Mr. George Relyea, for their
support and willingness to share their expertise and resources through my journey. I
extend my gratitude to each of my committee members for their time and guidance
through the long journey to complete the PhD program, despite many obstacles. I would
like to acknowledge Dr. Carrie Harvey for her commitment to education and her
willingness to join the committee without hesitation.
Special acknowledgement is extended to Dr. Hathaway, whose program of
research provided the resources that made this dissertation research possible.

iv

ABSTRACT
BACKGROUND: Weight gain is commonly observed post-kidney transplantation and is
associated with unfavorable health outcomes, such as graft loss, new onset diabetes, and
cardiovascular disease. The purpose of this study was to determine the most effective
measure for assessing body composition after kidney transplantation.
DESIGN: The study was a descriptive correlational follow-up study from a single kidney
transplant site.
SUBJECTS: A total of 45 eligible patients from a 2007-2011 parent study were selected,
ages of 37 to 78.
MEASUREMENTS: Body composition was obtained 5–8 years posttransplant via
anthropometric measures (waist circumference, body mass index, and dual energy X-ray
absorptiometry) and compared with baseline (pretransplant) values. Similarly, weight and
body mass index (BMI) were obtained. Blood sampling was performed to measure levels
of serum glucose, hemoglobin A1C, low-density lipoprotein-cholesterol, high-density
lipoprotein, triglycerides, and coronary risk ratio. Kidney function was monitored via
serum creatinine. Manual blood pressure was taken with two resting blood pressures.
.
RESULTS: The sample size was N = 45 and included 29 (64.4%) African Americans
and 16 (35.6%) Whites. There were 25 (55.6%) males and 20 (44.4%) females. The ages
were 37 to 78, with a mean of 56 (SD =10.1). Body weight increased from 186.66 ±
42.10 at baseline to 197.89 ± 48.1 at the 5-8 year follow-up, and BMI increased from
29.03 ± 4.76 to 32.14 ± 9.61. At the 5-8 year follow-up, anthropometric measure of waist
circumference was found to be associated with cardiac risk ratio and weight with
diastolic BP. In contrast, 7 body composition measures were associated with HDL, 4 with
cardiac risk ratio, 5 with creatinine, and 2 with systolic blood pressure. Significant
associations were also found with anthropometric measure BMI obtained at the time of
transplant surgery and HDL and LDL 5-8 years later. There were 13 body composition
measures associated with HDL, 6 with cardiac risk ratio, and 2 with triglycerides during
this same time span. Lastly, one change in anthropometric measure from baseline to 5-8
year posttransplant was associated with the 5-8 year cardiac risk factors (cardiac risk ratio
and BMI). There were 18 significant relationships for body compositions measures.
These included 7 body composition measures associated with creatinine, 5 with LDL, 4
with diastolic blood pressure, and 2 with triglycerides.
DISCUSSION: The significant relationships found among dual-energy x-ray
absorptiometry and cardiac-related outcomes suggest this method may provide a better
assessment of body fat, weight gain, and potential cardiac risk factors than does the
currently used method. The study continued to examine the use of dual-energy x-ray
absorptiometry to better understand the emerging coronary risk that accompanies weight
gain and as a basis upon which more precisely targeted interventions could be designed
that would improve the health and life expectancy of kidney transplant patients.
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CHAPTER 1.

INTRODUCTION

Overview
Kidney recipients often experience weight gain the first year posttransplant
(Baum, 2001a; Cashion et al., 2007; Jezior et al., 2007). These significant may represent
up to 10% of pretransplant weight (Johnson et al., 1993; Moore & Gaber, 1996). Aksoy
(2016) found that the average weight gain within the first 6 months posttransplant ranged
from 6 and 10 kg. Similarly, Cashion et al. (2007) demonstrated mean weight gain
ranging from 5 -10 kg within the first year of transplant. These findings are critical, as
increases in body weight have been well associated with adverse health outcomes.
Previous studies have explored the association between kidney transplant and
weight gain, demonstrating increased morbidity and mortality (Beckmann, Ivanović,
Drent, Ruppar, & De Geest, 2015; Gore et al., 2006). For example, obesity increases
kidney sodium reabsorption, which causes hypertension, and excess accumulation of
adipose tissue may compress the kidney, which increases intrarenal pressure and tubular
reabsorption (Naumnik & Mysliwiec, 2010). Together, these actions make weight gain
following kidney transplantation a serious concern.
The precise etiology responsible for the dramatic weight gain within the postkidney transplant population is poorly understood but likely composed of several
contributing factors, including decreased physical activity during the immediate
posttransplant course, medically indicated dietary changes, and immunosuppressant
therapy. Additionally, weight gain in this population may be attributed (in part) to a
global trend toward obesity within developed nations. In the United States since 1960, the
overall prevalence of disease associated with obesity has increased across all age, gender,
and ethnic groups (Flegal, Carroll, Kuczmarski, & Johnson, 1998). Today, over 60% of
the United States adult population is classified as overweight or obese, largely from
increased adipose stores (Catenacci, Hill, & Wyatt, 2009).
The link between excess body fat weight and health is well established in the
literature (MacLean, Higgins, Giles, Sherk, & Jackman, 2015). Within the general
population, obesity-induced, metabolic syndrome is associated with dyslipidemia,
diabetes mellitus, and hypertension, each representing independent risk factors for
cardiovascular disease (CVD; Gore et al.,2006). Importantly, kidney transplant recipients
are more vulnerable to the physiological changes associated with these diseases (Cashion
et al., 2014; Cupples et al., 2012), yielding more severe health consequences. Obesityinduced vasculopathy may also contribute to chronic allograft nephropathy, decreased
graft function, and survival with concomitant decreased life expectancy for kidney
transplant recipients. This makes monitoring of weight gain and overall body
composition critical for these populations.
Several methods of measuring body composition are described in the literature,
including single anthropometric or nontraditional technological methods, such as
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bioimpedance analysis (BIA), magnetic resonance imaging (MRI), computerized
tomography (CT), air displacement plethysmography (ADP), or dual-energy x-ray
absorptiometry (DXA). To date, few studies have explored quantitative methods useful in
monitoring body fat composition as a predictor of overall health in post-kidney transplant
patients. We propose a novel model of utilizing biomarkers and body composition
methods to better identify patients from this subgroup at high risk for body fat weight
gain and associated adverse outcomes. Early identification, close continued monitoring,
and treatment may greatly improve health outcomes in this population.
Statement of the Problem
Numerous studies have shown the burdensome nature of postoperative weight
gain for kidney transplant patients. This is a common problem and can have negative
effects on health outcomes, quality of life, and mortality rates. In particular, excess body
fat is a potential risk factor for CVD and other medical conditions (Cashion et al., 2007;
Cupples et al., 2012; Gore et al., 2006). The overall problem addressed by our study was
the lack of research on the association between changes in body composition (measured
by DXA and anthropometric indices) and biomarkers (serum glucose, lipid levels) as
predictors of CVD and graft loss after kidney transplant. The specific problem explored
was the distribution of body fat and its relationship to diseases. For example, the amount
of visceral adipose tissue (VAT) in the thoracic and abdominal cavities has been
associated with circulatory disorders and cardiovascular disease. The literature lacks data
to determine which methods and measures of weight (anthropometric or DXA) are most
accurate in evaluating risk of CVD for kidney transplant recipients.
Although studies have shown that CT, DXA, and MRI provide a direct measure
of regional distribution of VAT and have found a strong link between increased
abdominal fat and increased morbidity and mortality, anthropometric methods remain the
preferred choice for clinicians to assess body composition. Anthropometric methods are
commonly preferred due to their relatively low cost and ease of use. The use of
anthropometric methods is problematic, however, because of their limited sensitivity or
specificity, high variability, and poor correlation with disease to outcome. Consequently,
commonly utilized anthropometric approaches provide only a limited assessment of body
composition in kidney transplant populations. Thus, the study quantitatively explored the
associations of anthropometric and DXA methods with cardiac-related outcomes in a
high-risk kidney transplant recipient cohort.
Purpose of the Study
The primary purpose of this prospective longitudinal correlational study was to
investigate if changes in kidney recipients’ body composition measured by DXA or
anthropometric indices are related to serum glucose, lipid levels, coronary artery ratio,
creatinine level, and blood pressure, after 5 years or more. The secondary purpose of this
study was to explore the relationship between changes in body composition measures
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assessed by anthropometric measures such as body mass index (BMI), waist
circumference (WC), and body weight (BW) and DXA measures of the percentage of
body fat %BF, VAT, total body fat mass (TBFM), android fat mass (AFM), gynoid fat
mass (GFM), android/gynoid ratio (A/G), and lean mass (LM) in kidney transplant
patients.
It was anticipated that the main aim of this study would help identify ideal
anthropometric and/or body composition measures useful in predicting increased
cardiovascular risk following kidney transplant surgery. Furthermore, correlating these
findings with elevations within serum glucose, lipid levels, coronary artery ratio,
creatinine, and blood pressure in kidney transplant recipients could potentially aid in the
identification of patients most at risk.
For the purpose of this study, DXA scans were used to exam the distribution of
body mass and body fat. To the author’s knowledge, no similar studies exist with this
population.
Specific Aims
The overall aim of this study was to compare body composition measures
assessed by anthropometric measures and DXA with lab values of serum glucose
(glucose and HgbA1C), lipid levels (triglycerides, high-density lipoprotein [HDL], lowdensity lipoprotein [LDL]) and creatinine and blood pressure of kidney transplant
patients at 1 and 5 or more years post-kidney transplant. Specifically, the study had six
aims:
1. To determine the association between anthropometric measures and serum levels
of glucose, lipids, creatinine, and blood pressure of kidney transplant recipients at
5-8 years posttransplant.
2. To determine the association between body composition measures and serum
levels of glucose, lipids, creatinine, and blood pressure of kidney transplant
recipients at 5-8 years posttransplant.
3. To determine if body composition measures by DXA obtained at the time of
transplant (baseline) are associated with serum levels of glucose, lipids,
creatinine, and blood pressure of kidney transplant recipients at 5-8 years
posttransplant.
4. To determine if anthropometric measures obtained at baseline are associated with
serum levels of glucose, lipids, creatinine, and blood pressure of kidney transplant
recipients at 5-8 years posttransplant.
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5. To determine the association between changes in anthropometric measures from
baseline to 5-8 years posttransplant and serum levels of glucose, lipids, creatinine,
and blood pressure in kidney transplant recipients at 5-8 years posttransplant.
6. To determine the association between changes in body composition measures
from baseline to 5-8 years posttransplant and serum levels of glucose, lipids,
creatinine, and blood pressure at 5-8 years posttransplant.
Research Questions
Following are the research questions we sought to answer relative to our aims:
RQ1: What is the association between anthropometric measures and serum glucose,
lipids, and creatinine levels, and elevated blood pressure in kidney transplant
recipients obtained 5-8 years posttransplant?
RQ2: What is the association between body composition measures and serum
glucose, lipids, and creatinine levels, and elevated blood pressure obtained in kidney
transplant recipients 5-8 years posttransplant?
RQ3: To what degree are body composition measures obtained at the time of
transplant (baseline) associated with serum levels of glucose, lipids, and creatinine,
and elevated blood pressure in kidney transplant recipients at 5-8 years
posttransplant?
RQ4: To what degree are measures of anthropometric obtained at baseline associated
with serum levels of glucose, lipids, and creatinine, and elevated blood pressure in
kidney transplant recipients at 5-8 years posttransplant?
RQ5: To what degree are changes in anthropometric measures from baseline to 5-8
years posttransplant associated with serum glucose, lipids, and creatinine and elevated
blood pressure at 5-8 years posttransplant?
RQ6: To what degree are changes in body composition measures from baseline to 5-8
years posttransplant associated with serum glucose, lipids, and creatinine, and
elevated blood pressure at 5-8 years posttransplant?
Conceptual Model
The Body Composition Assessment Model (BCAM) was developed following a
comprehensive review of the literature to provide direction for this research. This model
(Figure 1-1) represents the scientific-technological link between theoretical principles of
the human body and the empirical constants in fat-estimating equation models and was
used to guide the concepts of methods’ and measures’ usefulness in clinical settings to
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Figure 1-1.

The Body Composition Assessment Model (BCAM).
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improve the evaluation of weight gain and improve health outcomes in transplant
recipients.
The different factors involved in influencing weight gain and adverse changes in
body composition are integrated in the model and represent the effect of overall health
outcomes. Commonly used anthropometric, as well as more advanced technological body
composition methods such as DXA and BIA, are included in the model―all of which
could be used to assess weight and evaluate health outcomes measures in clinical settings.
Body composition monitoring, in particular, provides an ideal method of assessing
overall health risks in disease states. This strategy provides a noninvasive method of
continual evaluation that is well suited for high-risk populations such as kidney transplant
recipients. The knowledge obtained through these assessments could prove valuable as a
guiding principle and benchmark towards improving health outcomes overall.
In Chapter 2, the conceptual model will be examined more in depth. The next
chapter will also discuss an overview of body fat and weight gain in the renal transplant
and general population, factors that contribute to weight gain, and the literature on the
conditions that transplant patients (renal and otherwise) develop. Of special interest will
be the recent history of the use of DXA and the different anthropometric measures used
to determine body fat and weight gain. The conceptual model for this study is illustrated
in Figure 1-1.
The BCAM is a systems-based model that helps health care professionals in the
selection of the most accurate method to evaluate changes in body composition, thereby
improving monitoring of patient outcomes in clinical settings. Ideally, the use of the
BCAM model will bridge the gap in understanding the linkage between body
composition physiology and selection of the most suitable measures for monitoring the
process of variation in body composition. This will be done specifically by
acknowledging the interaction among body compositional changes that occur during
weight gain, aging, the presence or absencs of diseases, and variation in body
composition that exist among ethnic groups. Selection of the more appropriate measure is
critical for use of the correct marker for monitoring risk for chronic diseases and to
evaluate health outcomes.
The BCAM provides an approach to better understand the role of body
composition in kidney transplant populations and identify the best methods for assessing
body composition. Clinicians and researchers will gain knowledge of appropriate body
composition methods and measures for assessing weight gain in the kidney transplant
population. In addition, future research programs can use and expand upon the BCAM to
advance methods used to assess body composition in kidney recipients, yielding
improved health outcomes.
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Significance of the Study
The outcome of this study will contribute to our long-term goal of establishing
clinically useful measures that can reliably identify patients at risk of experiencing
cardiovascular health complications following kidney transplant surgery. Cardiovascular
complications are the leading cause of graft failure and death in this population. The
findings of this study could potentially improve the health and life expectancy of kidney
transplant patients by providing data that could be used to help design and monitor the
efficacy of new treatment modalities, particularly for those patients who experience
substantial posttransplant weight gain. The significance of this study could help increase
long-term survival rates for kidney transplant patients, improve their quality of life, and
provide a means by which they can receive better care, diagnoses, and prognoses.
Assumptions
This study assumed that the outcome measures would be reflective of the
individuals’ cardiac risk status.
Limitations of the Study
Several limitations were present that should be considered when examining the
study results:
1. Use of a single site may not be generalizable to other populations; however, the
study site serves as a diverse representation of the general transplant population.
2. Study measures were taken at different times and by different individuals.
However, all measures were validated and standardized, with the same protocol
and equipment used at all measurement points.
3. Use of a single posttransplant time point approximately 5 years or longer
posttransplant may limit utility of study findings. For example, when weight gain
occurs at 3-4 years or 6-8 years, other medical conditions could worsen along
with CVD risk. However, previous studies suggest these comorbidities generally
occur during the early years following transplant surgery.
4. Only measures of body fat and specific aspects of blood chemistry were
considered even though there are many other factors associated with CVD risk for
kidney recipients and in the general population. However, those used in this study
are stronger predictors and most commonly used in clinical settings.
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Definition of Key Terms
Substantial literature provides consistent definitions for variables and major
concepts, especially scientific concepts. Key terms and definitions we used during our
research follow:
Abdominal obesity. The excessive subcutaneous and visceral fat locate in the
abdominal region also known as upper-body obesity (Heyward & Wagner, 2004).
Adipose tissue. Body fat that is approximately 83%, 2% protein, and 15% water
(Heymsfield, Lohman, Wang, & Going, 2005).
Air displacement plethysmography (ADP): Air displacement method measures
body volume and body density to assess body composition (Heyward & Wagner,
2004).
Anthropometry. The science of measuring body size and proportion (Heyward &
Wagner, 2004).
Android fat mass (AFM). The amount of adipose tissue in the abdominal
area and below the individual neck. It is derived from the fat tissue in the
android region in grams (Tanamas et al., 2012).
Android obesity. Identified by localized excess body fat found in the upper-body; it
is also known as an apple-shaped body (Heyward & Wagner, 2004).
Android/Gynoid Ratio. Android fat is the amount of fat between the
bottom of an individual’s head and the top of the iliac crest in the lowest
20% region. Gynoid fat is the amount of fat located downward from the
android region and from the top of the greater trochanter. It is derived
from percentage of fat in the android region divided by percentage of fat in
the gynoid region (Fu et al., 2014).
Bioelectrical impedance analysis (BIA). A body composition method used to
measure total body water and fat-free mass (Dehghan & Merchant, 2008).
Body composition. Body composition refers to the partitioning of body makeup,
including protein, fat, water, and minerals fat-mass (weight or percentage) and fatfree mass weight (Heymsfield et al., 2005).
Body density (Db). The measure of the total body mass to total body volume
(Heyward & Wagner, 2004).
Body mass (BM). Body weight; total size of the body (Heyward & Wagner, 2004).
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Bone mineral content (BMC). The measure of mineral in bones by the DXA
method that is independent of the body composition calibration method selected
(Heyward & Wagner, 2004).
Cardiovascular disease (CVD). Cardiovascular diseases are disorders involving the
heart and blood vessels, such as hypertension, coronary artery disease, cardiac
dysrhythmias, cerebrovascular disease, heart failure, peripheral vascular disease, and
congenital cardiac abnormalities (World Health Organization [WHO], 2018).
Dual energy x-ray absorptiometry (DXA). Refers to a method used in clinical and
research settings to estimate bone mineral density, bone mineral content, fat, and lean
soft tissue mass (Heymsfield, Wang, Baumgartner, & Ross, 1997).
Essential lipids. These compound lipids are important for cell membrane formation
and make up a small portion of the body the total lipid (Heyward & Wagner, 2004).
Fat-free mass (FFM) density or fat-free body (FFB) density. The measure of
lipid-free chemicals and tissues found in internal organs, connective tissue, muscle,
bone, and water (Heyward & Wagner, 2004).
Fat mass (FM) density. The measure of lipids found in adipose tissue and other
tissues (Heyward & Wagner, 2004).
Four-component models (4-C). 4-C models refers to the development of
technological advances in measuring based on water, minerals, protein, and fat
components in the body at the molecular level (Heyward & Wagner, 2004).
Gynoid fat mass (GFM). The amount of fat in the lower portion of an
individual’s body around the hip area. It is derived from the fat tissue in the
gynoid region in grams (Heyward & Wagner, 2004).
Gynoid obesity. Identified by localized excess body fat found in lower body fat;
pear-shaped. It is known also called pear-shaped body (Heyward & Wagner, 2004).
Healthy body weight. A body weight that does not increase the possibility of
developing a disease risk (Heyward & Wagner, 2004).
Hydrometry. A human body measurement of water (Heyward & Wagner, 2004).
Hydrodensitometry, also called hydrostatic weighing (HW) or underwater
weighing (UUW). A method used to estimate total body volume submerging a
person’s body into water (Heyward & Wagner, 2004). This is a good measure of body
volume.
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Magnetic resonance imaging (MRI). “Technique used to create computerized crosssectional images of the human body radio frequency signals emitted by hydrogen
nuclei” (Heyward & Wagner, 2004, p. 230).
Multifrequency BIA (MFBIA). “A BIA approach in which a wide range of
frequencies (1 kHz to 1 MHz) are used to estimate extracellular, intracellular, and
total body water:
Also known as bioelectrical” (Heyward & Wagner, 2004, p. 230).
Multicomponent models. A model composed of three or more components that is
used to develop advanced technology methods and measurements based on variation
in water, mineral, and protein in the fat-free mass of the human body (Heyward &
Wagner, 2004).
Nonessential lipids. Triglycerides found in the adipose tissue in the human body
(Heyward & Wagner, 2004).
Percentage of body fat or relative body fat (%BF). %BF is an individual total
amount of fat divided by total body weight Percent Fat (android + gynoid regions). %
BF = 100 × (Fat Mass)/Mass. %BF will be lower for the “classic” calibration
(Heymsfield et al., 2005).
Reference method. Refers to direct measures of human body components that are
used and considered “gold standard” in the development of models, methods, and
prediction equations for assessing body compositions (Heyward & Wagner, 2004).
Six-component models (6-C). 6-C models refer to the development of technological
advances based on direct measure of chemical composition in vivo of six components
in the body: water, calcium, potassium, sodium, nitrogen, and chloride (Heyward &
Wagner, 2004).
Three-component models (3-C). 3-C models refer to the development of
technological advances based on water, minerals, and tissues components in the body.
These components are divided into three levels called 3-C water molecular level, 3-C
mineral molecular level, 3-C cellular level, or 3-C tissue level (Heyward & Wagner,
2004).
Total body water (TBW). The total amount of extracellular and intracellular fluid
found in the different areas of the body (Heyward & Wagner, 2004)
Total body bone mineral (TBBM). A measure of all the bone mineral content in the
body (Heyward & Wagner, 2004).
Total body mineral (TBM). The amount of mineral found in the human body bone
and cells (Heyward & Wagner, 2004).
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Total bone mineral density (TBMD). The measure of mineral in bone and cells
measured by DXA and for this study, is independent of the body composition
calibration method selected of the 4500 HolgicA equipment (Heyward & Wagner,
2004).
Total fat mass (TFM). An indirect measurement of body fat that is estimated from
total body water or the mean density of the whole body. The fat mass is measured by
DXA in grams Android + Gynoid regions. Fat mass measures depend on the Body
Composition Calibration Method (Heyward & Wagner, 2004).
Total lean tissue mass (TLM). The total body mass less the bones and fat in an
individual’s body total lean mass in the Android +Gynoid regions. It derived from the
lean standard deviation value. This is known as the soft tissue component of “FatFree” Mass. Lean Tissue Mass = Mass – Fat mass – BMC (Heyward & Wagner,
2004).
Two-component models (2-C). 2-C models are divided into FM and LBM
and assume these components are consistent for all individuals (Heyward &
Wagner, 2004).
Visceral Adipose Tissue (VAT). This is the amount of fat tissue
surrounding an individual’s organs that impacts a wide variety of clinical
risk factors including fasting glucose levels, serum triglycerides, and
cholesterol (Bergman et al., 2006).
Waist circumference (WC). “Measure of central adiposity and upper-body obesity;
waist girth” (Heyward & Wagner, 2004, p. 232).
Waist-to-hip ratio (WHR). Waist circumference divided by the hip circumference;
used “as a measure of upper-body obesity and visceral fat” (Heyward & Wagner,
2004, p. 232).
Whole-body fat. Total body fat measurements provide useful physiological and other
medical conditions information. They are measured in grams by DXA and include all
fat tissues in all regions including extractable lipids from adipose tissue and other
tissues. Also called total body fat mass (TBFM; (Heyward & Wagner, 2004).
For other important abbreviations used in this document, see the List of
Abbreviations in the front matter.
Summary
This prospective correlational study attempted to examine the association of
various methods and measures of body composition and serum glucose, lipid levels,
coronary artery ratio, creatinine, and blood pressure associated with weight gain in

11

kidney transplant patients. The population included individuals who had undergone
kidney transplant procedures 5-8 years prior to this study and had participated in the
parent study. Current blood work was obtained from these individuals to determine serum
glucose, lipid, and creatinine levels.
This chapter outlined the goals and purpose of the study used to address the
research problem and gain knowledge regarding the best measures to assess changes in
body composition that occur during weight gain in kidney transplant recipients. The
translation of this knowledge will bridge the gap in research and clinical settings by
identifying accurate measures to evaluate the risk of CVD. The significance of the
research lies with the potential of how the study’s results may impact further research and
practice in the monitoring and treatment of kidney transplant recipients, as well as others
who are in high cardiac risk groups.
Chapter 2 will provide an overview of the relevant literature, including support
for the conceptual framework, an overview of the CVD and weight gain problems
experienced by kidney and other transplant patients, and a review of studies on body
composition methods and measures.
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CHAPTER 2.

LITERATURE REVIEW

Kidney transplantation has been the preferred choice of treatment for patients
with end-stage renal disease (ESRD) and is the most commonly performed organ
transplantation. However, after transplant, a number of recipients experience short-term
and long-term complications (Urstad, Wahl, Andersen, Oyen, & Fagermoen, 2012).
Short- term complications typically occur in the immediate postoperative course and
include edema, kidney dysfunction, pain, and respiratory insufficiency (Elster et al.,
2008). Powerful immunosuppressive therapies have enabled prolonged survival
enlarging subpopulations that develop long-term complications. Thus, long-term
complications pose the greatest source for morbidity and mortality in posttransplant
recipients. This makes identification and management of long-term complications
critical. One important long-term complication is weight gain. Increased fat mass
accumulation contributing to obesity is a serious concern in kidney transplant recipients.
This chapter will briefly review effects of adipose accumulation on health, morbidity, and
mortality in renal transplant recipients. This is followed by an overview of existing
methods available to quantitate body composition, focusing on those most likely to
accurately predict well-being within this study population.
Body composition assessments vary in precision and in the target tissue (s) of
interest. Both the target body composition tissue (s) such as visceral adipose or android
tissue and the patient health conditions are key players for assessing body composition.
Both are important phenomenon to address to guide clinicians to use anthropometric
methods with cautions. These commonly used methods, such as BMI, WC, and WHR do
not provide suitable body composition measures, specifically body fat, which is critical to
health outcome. The continuous and frequent use of these methods is due to its quick,
simple, and inexpensive use. Clinicians should caution the use of these anthropometric
methods with the general population, as well as in the kidney transplant population due to
possible health threats for people in this country. The continuous use of body
composition methods that yield unsuitable body composition measures may potentially
increase morbidity and mortality rate in kidney recipients (Lee & Gallagher, 2008).
The link between obesity and chronic disease is well established in the literature,
negatively impacting individuals across all ages, races, gender, and ethnic groups. The
literature also begs this question: Why is BMI considered an appropriate method for
assessing body composition and evaluating obesity-related risk in the healthy and
unhealthy population, in the face of a continuous rise in the obesity epidemic?
The literature in this chapter will also explore reasons why simply tracking body
weight is neither adequate for assessing body composition, nor suitable for identifying
risk factors associate with weight gain. In addition, it is important for clinicians to
understand how biological and pathological factors such as age, ethnicity, gender, and
presence or absence of diseases influence changes in body composition versus height and
weight. For this reason, the literature will discuss advantages and disadvantages of
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appropriate advanced technology methods and anthropometric methods in the clinical
setting.
The literature strongly guides and illustrates the need to conduct the study
effective measures of weight gain 5 years post-kidney transplantation. In addition, the
literature outlines numerous influential factors that alter body compositional changes in
the human body, however, the literature lacks a consensus on the most suitable body
composition methods and measures. The literature also provides the foundation for
development of the BCAM platform, which aids selection of the most effective method
and measure for measuring weight, particularly for individuals with chronic conditions
such as kidney recipients.
This chapter presents a review of literature related to the presence and risks
associated with weight gain and obesity, and methods employed to measure body fat and
weight gain. The first section describes the search strategy used to identify literature for
this review followed by sections that discuss the conceptual model, body fat in the
general population and kidney transplant population, weight gain and obesity in the postkidney transplant population in the factors contributing to weight gain and obesity in the
kidney transplant population, measurement of body fat and weight gain; and the
challenges of measuring body fat and weight gain.
Search Strategy
The search strategy for this review used primary sources (e.g., World Health
Organization) and secondary sources (e.g., research method books) from 1991-2018. The
search yield was sorted by scientific rigor and relevance to the topic area. Relevant
articles were identified, and MeSh terms were used to identify other credible and relevant
articles. Endnote and Refworks were used for reference mangers. Relevant reviews and
studies were obtained from the UTHSC library database using PubMed Central, PubMed
Health, and Web of Science. Searches also included database such as CINHAL
Complete, JAMA, JSTOR, Medline Plus, and Goggle Scholar. Searches were limited to
studies on humans, adult kidney transplant recipients, single organ transplant, and studies
published in English. Unpublished studies were not reviewed.
The search also included systematic reviews and meta-analyses, literature
reviews, and other types of research using Boolean search terms that included body
composition measures and methods, body composition and weight gain, weight gain and
kidney transplant population, obesity and kidney transplant population, weight gain and
obesity and kidney transplant population, risk factors and kidney transplant population,
body fat and kidney transplant population, over weight and obesity and kidney transplant
population, complications and kidney transplant population, immunosuppression
medications and kidney transplant population, cardiovascular disease and kidney
transplant population, dietary intake and physical activity and kidney transplant
population, measurement and body fat and weight gain, anthropometric measures and
instrumental scans, DXA and BIA methods and measures, MRI, CT, ADP and body
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composition assessment, body composition and cardiovascular disease, kidney transplant
population, and the measurement of weight and obesity.
Studies were considered for inclusion whether they were observational, crosssectional, cohort, longitudinal, prospective and retrospectives, or comparative. The
participants of the studies included adult kidney/kidney transplant recipients and adults
who used methodological measurement to assess health outcomes, and predictions were
included. Recipients of any transplant other than a kidney transplant were excluded,
including kidney-pancreas transplant recipients.
The literature search was repeated multiple times using these same search terms
prior to publication of the parent study’s findings, and likewise throughout the
preparation for, conduct of, and reporting of results from this follow-up study. New
relevant evidence was found in this search and was included in the current study.
Conceptual Framework
The Body Composition Assessment Model (BCAM) is a novel approach that
incorporates dynamic factors in guiding clinicians to appropriate body composition
analysis, tailored to the unique individual. BCAM provides a conceptual framework for
assessing body composition and may prove beneficial in better identifying specific
etiology for weight gain. This model comprises both system and scientific concepts
(Figure 1-1). System functions involve biological, biometric, health-related (disease),
and lifestyle factors. These four concepts influence body compositional changes, either
directly or indirectly during active weight gain or in the presence of chronic diseases, as
detailed below.
Additionally, there are three science-based concepts involving body composition
measure, body composition variation, and body composition methods which can be used
as a platform to accurately select a body composition method. For example, kidney
transplant recipients who develop complications of kidney dysfunction are prone to fluid
imbalance and may develop fluid shifts from third spacing and fluid overload. Weight
gain from fluid imbalance is difficult to differentiate from weight gain due to other
sources, such as fat accumulation. BCAM could be utilized in this setting to guide
clinicians in selection of appropriate body composition test to better guide treatment.
Science-Based Approach
Science-based approach concepts are organized into three interconnected areas
within the center of the BCAM framework called body composition measure, body
composition method, and body composition variation. Within the clinical setting these
factors are routinely assessed during routine visits. In the following paragraphs, the
author will review these concepts in detail.
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First, body composition variation is the largest science-based concept because it is
a key player in the determination of method selection in this framework. Typically, this is
the first concept assessed during routine clinic visits. Body fat within adult populations is
distributed within whole body and regional locations and comprised of visceral adipose
and subcutaneous fat deposits. Variations in subcutaneous fat can be readily apparent
during physical exam. Patients may exhibit characteristic android or gynoid fat
distribution patterns (defined in body composition assessment section). Visceral adipose
tissue (VAT) describes fat deposits surrounding visceral organ tissue and is more difficult
to assess and quantitate. For example, visceral fat kills healthy patients. Patients that have
undergone kidney transplant are more susceptible to alterations within visceral fat stores.
One underlying assumption in the BCAM is the ongoing direct and/or indirect
relationship between each concept in the system-science based approach with body
composition variation for determining appropriate measures.
Secondly, body composition measures quantify the relationship between the
effective measures and suitable methods. This is an important step to determining the
most effective measure to assess body composition. Components of body composition
are quantified from fat mass (FM), fat-free mass (FFM), protein, mineral, or bone density
(Db) measurements. These measurements are mathematically calculated to estimate body
composition measures such WBF, VF, AFM, GFM, A/G Ratio, and LM (Heymsfield et
al., 1997). The most effective measure to assess body composition is determined by body
composition models and predictive equations. Each model estimates measures such as
%BF, WBF, FM, FFM, AFM, GFM, and A/G ratio from a mathematical equation based
on known or unknown component-, property-based, or combined-based models (Table
2-1) to develop suitable predictive equations to design effective body composition
methods. For example, according to Heyward and Wagner (2004) a known componentbased method (i.e., hydration, Db) measures %BF from FM divided by BW x100 (see
Table 2-1, Heymsfield, et al., 2005). Clinicians’ careful application of the model’s
principles and assumptions are essential to effective measures of weight gain in kidney
recipients.
Lastly, the appropriate method selection is determined by the available measures
of three types of body composition methods referred to as component-, property-, and
combined-based methods. The three methods are the platform for determining the most
appropriate measure and the best method to evaluate body composition in a kidney
transplant population or a general population.
The author argues for population specificity body composition methods based on
disease, gender, age, ethnicity, or physical status are critical to effectively assess weight
gain. Predictive equations are useful in diverse populations as well as a specific
population where alteration in fat distribution and fluid disturbances are common. A 4-C
molecular model should not be considered in kidney transplant recipients or any
population with a chronic disease who may experience fluid disturbance with electrolyte
imbalance. The four elements of the 4-C model are fat, protein, bone mineral, and total

16

Table 2-1.
Methods

Body Composition Measures and Equations Used to Determine

Level
Two-Component
Molecular Level

ThreeComponent
Molecular Level

ThreeComponent
Tissue Level
(DXA)

Model
BW = fat + fat free
body

Body Equation
%BF = [(4.57 / Db) –
4.142] x 100
%BF = [(4.95 / Db) –
4.50] x 100

Reference
Brozek, 1963

BW = fat + water +
(mineral and protein
combined)

%BF = [(2.118 / Db)
– 0.78W – 1.354] x
100

Siri, 1961

BW = fat + mineral
+ (water and protein
combined)

%BF = [(6.386 /Db) – Lohman, 1986
3.961M – 6.090] x
100

BW = bone + bonefree lean tissue fat

%BF = FM / BW x
100

Ellis, 2000

%BF = [(2.559 / Db)
– 0.734W + 0.983B –
1.841] x 100
%BF = [(2.747 / Db)
– 0.714W + 1.146B –
2.053] x 100
%BF = [(2.513 / Db)
– 0.739W + 0.947B –
1.790] x 100
%BF = [2.747 / Db) –
0.718W + 1.148B –
2.050] x 100

Friedl, 1992

FM (kg) = BW –
(TBW + 6.525 TBN
+ 2.709 TBCa + 2.76
TBK + TBNa + 1.43
TBCI)

Wang et al., 1998

Four-Component BW = fat + water +
Molecular Level bone mineral +
protein

Six-Component
Atomic Level

BW = TBW + TBN
+ TBCa + TBK +
TBNa + TBCI

SirI, 1956

Selinger, 1977
Heymsfield, 1996
Baumgartner,
1991

Note. % BF = relative body fat; Db = total body density (g/cc); FM = fat mass (kg); W =
(kg)/BW (kg), where TBW = total body water and BW = body weight; M = TBM = total
body mineral (osseous + cell mineral) and BW = body weight; B = TBBM (kg)/BW (kg),
where TBBM = total body bone mineral (osseous mineral only) and BW = body weight;
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Table 2-1.

Continued.

Constant: TBBM = bone ash x 1.0436; TBM = bone ash x 1279; TBN = total body
nitrogen; TBCa = total body calcium; TBK = total body potassium; TBNa = total body
sodium; TBCL = total body chloride.
Note. Reprinted with permission from author Dale R. Wagner 9-16-18. Originally
published in “Applied body composition assessment”, by Heyward, V. H., & Wagner, D.
(2004), p. 11; out of print.
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body water (Heyward & Wagner, 2004). The multi-compartment (4-C) model is a highly
significant predictor of the relationship between age and ethnicities. For example, Asian
populations have a high level of adipose tissue, especially in the abdominal area and 4-C
model would be a better estimate of body fat than an anthropometric method such as BMI
or WC. The use of anthropometric method such as BMI in an Asian population may
prolong diagnosing individuals who are at risk for cardiovascular disease. Multicomponent models are generally thought to provide more accurate estimates of body fat than
two-component models, especially when one of the assumptions of the two-component
model might be violated, such as constant hydration, which is not likely in the kidney
transplant population (Heyward & Wagner, 2004).
System Approach
The BCAM is a system approach for assessment of body composition in the
clinical setting. The system concept describes the function of biological, health-related,
biometric, and lifestyle factors in guiding optimal body composition assessment in
healthy or unhealthy populations. In the BCAM (Figure 1-1), biological factors influence
body composition variation. First, it is important to understand the body composition
changes at the cellular, the molecular level, and tissue-organ level when determining the
most effective measure for assessing body composition (Baumgartner, Heymsfield,
Lichtman, Wang, & Pierson, 1991; Gao et al., 2008) and the underlying assumptions used
to estimate %BF. For example, health-related factors such as metabolic syndrome,
hyperlipidemia, hypertension, diabetes, cardiovascular disease, graft loss, and mortality
(Anjana et al., 2004) alter body composition changes at the cellular, molecular, or tissueorgan level and during active weight gain.
The health-related concept is essential for determining the most suitable measure
for assessing body composition, and the presence of a specific disease during active
weight gain. For example, kidney recipients often experience fluid disturbance and
accumulation of body fat with increased body weight. As a result, weight gain could alter
fat distribution in different anatomical areas and cause disturbance intra- and extracellular
fluid (Heyward & Wagner, 2004). Both variations in body composition conditions may
cause health-related conditions such as cardiovascular disease or new onset diabetes. A
clinician could apply the presence of a health-related condition to determine the best
measure for assessing body composition in a patient with alteration in fluid disturbance
or distribution of fat. Next, the biometric factors in the BCAM represent the relationship
between anthropometric methods and whole body composition (WBC). The
anthropometric variables are measurable biometric factors used to calculate BMI, WC,
WHR, and skinfold (SKF) methods. These methods include measures of body weight,
body volume, body surface, waist, hip, thigh, arm, bi-iliac, knee, ankle, elbow, height,
and recumbent length. The BCAM describes a direct or indirect relationship between
biometric factors and each factor within the system-based approach and one concept
science-based approach called body composition variation. For example, the BCAM
lifestyle factors such as decreased physical activities and increased caloric intake may
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indirectly influence body composition variation by altering fat distribution throughout the
body.
Collectively, the BCAM concepts and factors demonstrate a direct and/or indirect
interaction between a systematic-science-based approach that helps to identify accurate
measures of body composition to determine the most effective method for assessing body
composition. The understanding of the relationship between components of body
composition and biological and pathological impact on body composition changes is key
to accurate measures and methods and improving health outcomes.
Body Fat in the General Population and Kidney Transplant Population
Body fat is the fat found in adipose tissue, which is stored below the skin and
surrounding the internal organs (Heymsfield, Lohman, Wang, Going, 2005). Percent
BF is an estimate of total body fatness used to evaluate the relationship between excess
body weight, accumulation of adipose tissue, and health (Teixeira, Sardinha, Going, &
Lohman, 2001)). Historically, studies have shown a relationship between BMI, %BF, and
metabolic complications of adiposity, elevated lipoproteins, and cardiovascular
disease (Despres et al., 1990; Kissebah et al., 1982; Teixeira et al., 2001). More critical
findings by Kwakernaak, Toering, and Navis (2013) suggested numerous factors that
contribute to health complications were also associated with excess weight measured by
BMI. Health complications such as chronic kidney disease were strongly linked to central
body fat distribution.
Numerous studies have identified limits in BMI guidelines and variation in
measures in population specificity. For example, some studies found a correlation
between accumulation of visceral fat in the abdominal cavity elevates triglycerides,
reduces high-density lipoprotein cholesterol, elevates blood pressure, and elevates fasting
plasma glucose and measures of body fat by BMI or adiposity (Cofan, Vela, & Cleries,
2005; Ojo et al., 2000). Cofan et al. (2005) found weight gain after transplantation
contributed to the prevalence of obesity, with women significantly higher than men (21%
vs. 13%; P <0.0001). Numerous studies found a link between increased adiposity, %BF,
BMI, and CVD risk factors. However, BMI category and the excessive abdominal fat in
Asians and Europeans were largely different and the Europeans were more susceptible to
CVD and obesity-related health diseases (Gill, 2001).
Another study reported a significant increase in body fat and BMI among women
African American women, 12 months following kidney transplantation (Pantik, Cho,
Hathaway, Tolley, & Cashion, 2017). Another author found Asians with a low BMI had a
higher percentage of fat compared to Caucasians and African Americans, showing BMI
is an unreliable predictor of mortality risk Gallagher et al. (2000a).
There is substantial literature to support BMI limitations, specifically the inability
to accurately assess body fat and predict health outcomes in a diverse population. This
prompts an urgency for future research to address continuous pitfalls of BMI use and
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challenges for the reduction in prevalence of morbidity and mortality found among
weight gainers. In addition, an appropriate future consideration is the identification of
population-specific body composition measures based on age, gender, ethnicity, race,
physical activity, and presence and absence of a disease.
Weight Gain and Obesity in the General Population
According to WHO (2018), the prevalence of overweight and obese adults has
tripled and continues to rise in the general population. In 2016, over 1.9 billion adults
were categorized as overweight and 650 million were considered obese. This was
approximately 13% of the world’s adult population and 15% women and 11% men.
Within this population, it was reported that 39% of the adults were overweight and 13%
obese with an estimated 35.5% women and 32.5% men (WHO, 2018).
More alarming, by 2030, if the current trend continues to rise at a steady rate, the
future prevalence of BMI measures in the unhealthy category is projected at 86.6 % in the
adult population. More specifically, Black women (96.9%) and Mexican American
women (91.1%) will be most affected in the adult population. The study also suggested
by 2048, all adults’ BMI measures could be classified as unhealthy, and by 2034, Black
women will be among the first group to reach unhealthy BMI measures (Wang, Beydoun,
Liang, Caballero, & Kumanyika, 2008). Another study projected 65 million more obese
adults in this country by 2030 (Wang, McPherson, Marsh, Gortmaker, & Brown, 2011).
According to the Centers for Disease Control and Prevention (CDC, 2014), the obesity
trend differs among racial and ethnic groups, and for adults ages 20 or older is as follows:
1. Hispanic population 8.5% for Central and South Americans, 9.3% for Cubans,
13.9% for Mexican Americans, and 14.8% for Puerto Ricans;
2. Asian American population including Chinese (4.4%), Filipinos (11.3%), Asian
Indians (13.0%);
3. American Indian (8.8%) and Alaska Natives (6.0%), and 24.1% of the American
Indians in southern Arizona.
The CDC (2014) also reported the prevalence of diabetes was expected to rise
based on prediabetes cases in 2009-2012. In the U.S., the prediabetes cases are different
between ethnic and racial groups. The percentages of nonHispanic Whites, nonHispanic
blacks, and Hispanics diagnosed with prediabetes were 35%, 39%, and 38%,
respectively. In 2012, 37% of the prediabetes cases in the U.S. were adults ages 20 or
older, and 51% ages 65 or older. The total number of prediabetes cases for the American
population was 86,000,000 for ages 20 and over. Monitoring of body composition and
weight gain should be examined to include measures more suitable for estimating body
fat and identifying health risk.
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BMI is commonly used to classify individuals based on abnormal or excess
accumulation of fat (Beckmann, Ivanović, Drent, Ruppar, & De Geest, 2015). WHO
defines healthy BMI measures as 18.5 to 24.9, while unhealthy BMI measures range from
≥25 to ≥30. The unhealthy ranges are categorized as overweight and obese, as shown in
Table 2-2.
Regardless of the exact percentage of increase, the rising rate of obesity in the
United States and worldwide has serious ramifications for the health of the population
and concomitant demands on the health care system, due to the associated chronic
conditions accompanying excessive weight gain. For example, short-term complications
from significant weight gain and obesity are delays in wound healing and wound
infection (Zrim, Furlong, Grace, & Meade, 2012), while long-term complications include
development of chronic diseases such as Type 2 diabetes, CVD, hypertension (HTN), and
other comorbidities (Lafranca, IJermans, Betjes, & Dor, 2015a; Silkensen, 2000).
Adversely, the rise in the prevalence of weight gain and unhealthy BMI measures in
adults yields an increased burden in several diseases such a cardiovascular diseases and
diabetes. The classification for BMI is shown in Table 2-2 (DiCecco & Francisco-Ziller,
2014).
Weight Gain and Obesity in the Post-Kidney Transplant Population
Obesity is a common problem in the post-kidney transplant population. However,
more critical is the accumulation of excess weight gain in areas that specifically
contribute to the prevalence of life-threatening clinical and subclinical diseases. The
severity and complications of these diseases are associated with the quantity and
distribution of body fat in the kidney recipients. In addition, the increase in body fat may
influence fluid disturbance and increase distribution of visceral adipose tissue in the
body. As a result, kidney recipients may develop NODAT or CVD (Cashion et al., 2007).
DM and CVD whether preexisting or new-onset following transplantation are common
diseases diagnosed in transplant recipients and cause life-threatening health
complications (Calò et al., 2017; Neale & Smith, 2015; Ogden, Carroll, Kit, & Flegal,
2013; Paripovic, Kostic, Spasojevic, Kruscic, & Peco-Antic, 2010b).
The precise extent to which obesity affects the health of the general population is
uncertain; however, it is known that weight gain influences changes in body
compositions that are magnified in kidney transplant recipients. While weight gain and
obesity are risk factors for hyperlipidemia, hypertension, atherosclerosis, and decreased
life expectancy in the general population, these threats are exacerbated for kidney
transplant recipients and accompanied by additional risks for allograft nephropathy and
graft loss. It is also noteworthy that the enhanced CVD risk following transplant is
manifested by nearly all recipients with experiences of elevated blood pressure, high lowdensity lipoprotein and low high-density lipoprotein-cholesterol levels (elevated total
cholesterol), elevated insulin levels and blood glucose, and abnormal blood lipids. Given
the prevalence of chronic health conditions that are typically associated with obesity,
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Table 2-2.

World Health Organization Classification of Weight Status by BMI
Body Mass Index, kg/m2
<18.5
18.5-24.9
25-29.9

Weight Status
Underweight
Normal Weight
Overweight
Obese
Class I obesity
Class II obesity
Class III obesity

30-34.9
35-39.9
>49

Note: Adapted with permission from World Health Organization (2018). Global Database
on Body Mass Index, 2018. Retrieved from
http://www.assessmentpsychology.com/icbmi.htm
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abdominal (visceral) adiposity is undoubtedly responsible for cardiovascular-related
events being the leading cause of graft loss. In addition to increasing the risk for CVD,
visceral adiposity has also been identified as a risk factor for DM and specifically
associated with insulin resistance, dyslipidemia, and hyperinsulinemia (Banerji, Faridi,
Atluri, Chaiken, & Lebovitz, 1999).
Excessive body weight and obesity pose significant serious threats to health
outcomes of transplant recipients compared to individuals in the general population
(Beckmann et al., 2015). Typically, a weight gain of 10 kg occurs during the first year
following transplant surgery and may double to 32 kg after the first year (Beckmann et
al., 2015; Cashion et al., 2007; Cupples et al., 2012; Lentine et al., 2008; Stanfill et al.,
2015). Consequently, the incidence of short-and long-term health complications
associated with weight gain is higher in the transplant population compared to the general
population (Beckmann, Ivanović, Drent, Ruppar, & De Geest, 2015). In addition, several
studies have reported that the average weight gain that occurs following transplant
surgery is an independent risk factor for graft loss (Cashion et al., 2007; Jezior et al.,
2007; Stanfill, Bloodworth, & Cashion, 2012) and serves as a negative predictor of
patient survival (Gore et al., 2006).
The following sections will discuss weight gain and obesity risk on cardiovascular
disease post-kidney transplant recipients; the influences of posttransplant fluid and fat
distribution on their weight; and the relationships among donor source, gender, race, and
posttransplant weight gain.
Weight Gain, Obesity Risk, and Cardiovascular Disease Post-Kidney Transplant
The evidence of health complications associated with excess body weight and the
prevalence of increased body weight and fat following kidney transplantation remains a
constant, as well as a serious impact on health conditions. In the United States, since
1960, the overall prevalence of a metabolic diseases has been associated with increased
weight gain across all age, gender, and ethnic groups (Flegal et al., 1998).
More critically, weight gain leads to progressive changes in the quantity and
distribution of certain compartments of body composition such as visceral adipose tissue
(VAT) and often results in two major diseases including CVD and Type 2 diabetes
(Cashion et al., 2007; Fernandes et al., 2013; Lafranca, Ijermans, Betjes, & Dor, 2015b).
Additionally, there is convincing evidence that VAT volume, rather than subcutaneous
fat, is correlated with the presence of other CVD risk factors such as dyslipidemia and
hyperinsulinemia (Banerji et al., 1999).
The risk of CVD associated with weight gain highlights the importance of
monitoring and periodically measuring changes in body composition in the kidney
transplant population. A study by Rao and Coates (2018) found an association between
CVD risk factors such as hypertension and dyslipidemia and diabetes following kidney
transplantation. Alshehri (2010) found that measures such as abdominal adiposity,
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elevated blood pressure, high low-density lipoprotein and low high-density lipoproteincholesterol levels (elevated total cholesterol), elevated insulin and blood glucose, and
abnormal blood lipids were significant markers for cardiovascular risk and other health
complications.
For the above reasons, this study explores the association between markers of
CVD identified in the literature and body composition measured by anthropometrics and
DXA (Baum, 2001b; Fernandes et al., 2013; Lafranca et al., 2015b; Rao & Coates, 2018).
As studies have shown, individuals with extreme levels of body fat are at greater risk for
developing CVD (Shah & Braverman, 2012). Therefore, a goal of this study was to better
understand the effective monitoring of body weight and measures, and to evaluate the
level of body fat that falls at or near extreme levels that could result in serious health
problems and effectively reduce quality of life in kidney transplant recipients.
Cardiovascular Disease
CVD is one of the leading causes of mortality and long-term morbidity in kidney
transplant recipients (Fernandes et al., 2013; Lentine et al., 2010; Neale & Smith, 2015).
The number of deaths due to CVD was estimated at 36% for the kidney transplant
population (Elli, Traversi, & Ponticelli, 2000). On the other hand, in general, a
prospective study in 2007 estimated the deaths associated with CVD at 66% in
individuals with central obesity compared to 44% with non-central obesity (Orazio et al.,
2007), while the estimated deaths in the after kidney transplant population ranged from
30% to 50% (Dimeny, 2002). Following transplantation, CVD risk is manifested by
more than half of the recipients experiencing elevated BP, high low-density lipoprotein
(LDL), low high-density lipoprotein (HDL), elevated total cholesterol, elevated insulin
levels and blood glucose, and abnormal blood lipids (Dimeny, 2002; Elli et al., 2000;
Neale & Smith, 2015). These health conditions, typically associated with excess
abdominal (visceral) adiposity, are susceptible markers for CVD, which is one of the
leading causes of allograft loss (Neale & Smith, 2015).
Patients with CKD and on dialysis have a higher risk of developing CVD
(Marcén, 2006; Neale & Smith, 2015) compared to the general population (Jun, Lv,
Perkovic, & Jardine, 2011). Although kidney transplantation reduces the recipients’ risk
of cardiovascular (CV) events (Neale & Smith, 2015), the presence of excess fat
increases the patients’ risk of developing CVD (Armstrong, Campbell, Hawley, Johnson,
& Isbel, 2005; Baum, 2001b; Cashion et al., 2007; Chan, Garneau, & Hajjar, 2015;
Cordeiro et al., 2013; Dimeny, 2002; Fernandes et al., 2013; Lafranca et al., 2015a) or
worsening CV events (Armstrong et al., 2005). CVD can lead to morbidity and mortality
for posttransplant patients (Marcén, 2006), dialysis patients, and CKD patients as an
individual’s kidney function continues to decline (Steiber, 2014).
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New Onset Diabetes Mellitus
According to Ogden, Carroll, Kit, and Flegal (2014), more than one third of U.S.
adults (34.9%) are obese. On the other hand, Eckel et al. (2011) stated that 34% of the
U.S. adult population is obese, with more than 11% of individuals over the age of 20
diagnosed with diabetes and the number is expected to increase 21% by 2050. Many
individuals who are obese will develop Type II diabetes (Eckel et al., 2011). Eckel et al.
(2011) stated that a connection between obesity and Type II diabetes exists, but the
connection remains unclear.
Diabetes is diagnosed with excess blood glucose within the body (Shivaswamy,
Boerner, & Larsen, 2016) and may lead to kidney failure (Ogden et al., 2013). DM is
diagnosed in 3% to 20% of the kidney transplant population (Baum, 2001a). Historically,
in 2011–2012, 36.5% of the U.S. chronic kidney disease adults aged 20 years or older
were diagnosed with diabetes based on fasting elevated blood sugar levels or HgbA1C
(CDC, 2017). Similarly, in 2015, the CDC estimated, 30.2 million people are affected
with diabetes, which represents 7.2 million of the U.S. population who are undiagnosed
with diabetes. Prediabetes is found in 48.3 % of adults aged 65 years or older. Also in
2015, approximately, 84.1 million American adults were diagnosed with prediabetes
based on HgbA1C (CDC, 2017).
Consequently, if the prevalence of excess weight gain in the kidney transplant
population continues to rise (Kwan, Hajjiri, Metwally, Finn, & Perkins, 2016), it is
possible the prevalence of new onset diabetes mellitus after transplantation (NODAT)
will continue to rise (Olyaei, deMattos, & Bennett, 1999; Shivaswamy et al., 2016; Yu et
al., 2016b). Approximately 4% to 25% kidney transplant recipients will develop NODAT
(Peev, Reiser, & Alachkar, 2014). NODAT can result in graft loss and poor survival rates
for kidney recipients (Kwan et al., 2016; Yu et al., 2016a). Obesity pre and posttransplantation may worsen NODAT (Peev et al., 2014; Yu et al., 2016a), especially since
several immunosuppression medications to reduce transplant rejection increase
diabetogenic potential (Peev et al., 2014).
New onset diabetes mellitus following transplantation (NODAT) occurs in the
presence of excessive weight gain and increased triglyceride levels following transplant
surgery (Olyaei et al., 1999; Pham, Pham, Pham, Pham, & Pham, 2011; Shivaswamy et
al., 2016; Yu et al., 2016a); (Kim et al., 2013). In addition, up to 50% of kidney
transplant recipients are reported to develop NODAT (Pham et al 2011), which often
presents severe, life-threatening comorbidities.
Hypertension
According to Paripovic, Kostic, Spasojevic, Kruscic, and Peco-Antic (2010a),
suggested hypertension is a serious and common problem after kidney transplantation;
therefore, early intervention should begin immediately after surgery. The acute and
chronic complications experienced after kidney transplant are critical to survivability of
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the allograft; therefore, new onset HTN should be avoided after kidney transplant. With
respect to HTN guidelines, formerly, HTN was classified as BP above 140 mmHg
systolic blood pressure (SBP) and above 90 mmHg diastolic blood pressure (DBP)
(Mafutha & Wright, 2013). However, the Whelton et al. (2018) guidelines identify two
stages to classify HTN: Stage I defines HTN as SBP >130-139 mmHg and DBP >80-89
mmHg. However, stage two defines HTN as SBP >140 mmHg and DBP > 90
mmHg. Azancot et al. (2015) found an association between hypertension and subclinical
inflammation and atherosclerosis 24 hours after kidney transplant with elevated SBP
(p<.0001). Another study found 50% to 90% of the kidney transplant population were
diagnosed with HTN (Fernandes et al., 2013).
There are several factors that contribute to HTN in the kidney transplant
population, which are more critical when patients gain weight while taking
immunosuppressive medications. First, a high percentage of transplant recipients
experience a sedentary lifestyle, which contributes to the obesity, thus influences the
onset of HTN (Neale & Smith, 2015; Paripovic et al., 2010b). Secondly, the life-long use
of immunosuppression after kidney transplantation, such as corticosteroids and
calcineurin inhibitors (CNIs), may trigger elevated blood pressure and HTN (Calò et al.,
2017; Neale & Smith, 2015; Paripovic et al., 2010b). Next, the use of corticosteroids by
kidney recipients may cause hypernatremia that could lead fluid disturbance, such as
fluid retention. Unfortunately, fluid retention is a common problem in the kidney
transplant population, which may trigger elevated BP, leading to HTN (Tantisattamo,
2017). Lastly, the use of CNIs prevents acute organ rejection and prolongs graft survival
(Hoorn et al., 2012; Kalluri & Hardinger, 2012; McPartland & Pomposelli, 2007),
yielding favorable post-kidney transplant outcomes. Lastly, the use of CNIs causes
vasoconstriction in the kidney and often induces HTN (Hoorn et al., 2012).
Influence of Posttransplant Fluid and Fat Distribution on Weight Gain
Heyward and Wagner (2004) stated that fluid disturbance influences body
compositional changes and is altered by weight gain; specifically, declines in lean body
mass and total body water (TBW) lead to increased total body fat. The decline in TBW
and a rigorous medication regimen following kidney transplantation can induce a severe
fluid imbalance and additional complications, such as congestive heart failure, poor
kidney function, insulin resistance, ascites, and edema. For example, kidney transplant
recipients routinely take medications from several drug classes, which influences
symptomatic changes, such as fluid retention or loss and hyper- and hyponatremia.
Unlike in the general population, kidney recipients are more susceptible to developing
hyponatremia from volume overload, a serious condition that can cause death in the
kidney recipients (Gore et al., 2006).
Fat distribution can influence body composition changes that affect cardiac
structure and function, impacting outcomes and contributing to major complications in
kidney transplant patients (Weiner et al., 2012). For example, increased fat distribution
leads to decreased cardiac function, which can cause myocardial infarction. The cardiac
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structure is altered by large deposits of adipose tissue in the atrioventricular groove and
right ventricular epicardium. These compositional changes influence aortic stiffness and
can cause cardiac complications, including systolic blood pressure fluctuations and
atherosclerosis. The latter is strongly influenced by cholesterol levels, which is important,
because changes in total cholesterol and triglyceride levels in kidney transplant recipients
could affect metabolism and increase the risk for CVD (Weiner et al., 2012).
Donor Source, Gender, Race, and Posttransplant Weight Gain
Donor Source
The prospective study by Moore and Gaber (1996) aimed to determine the
relationship between weight gain and donor gender in 50 kidney allograft transplant
recipients. The study participants included living related donor recipients (N = 11) and
cadaver donor recipients (N = 39). The study examined the relationship between kidney
function in diabetic and non-diabetic recipients who gained weight compared to nonweight gainers. The collection of data occurred at the time of transplant and 6 months
posttransplant. As a result, 76% of the participants gained a mean average of 4 kg, while
the other 30% either lost weight or did not gain weight. The women’s average weight
gain was 8 kg, while the men’s average weight gain was 7 kg (Moore & Gaber, 1996).
Moore and Gaber (1996) reported that Live renal donor allograft recipients had a weight
gain of 6 kg ± 2 kg, which was higher than the cadaveric recipients (p < .0001) and
participants with diabetes gained 5 kg while nondiabetics gained 4 kg (p < .0001). No
association was found between weight gain and kidney function (p > .0001) (Moore &
Gaber, 1996).
Gender and Race
Some studies explored the difference between weight gain in African Americans
and Whites. Between 1983 and 1999, a retrospective review examined the records of 506
kidney transplant recipients following kidney transplantation (Baum et al., 2002). The
study found that African Americans gained significantly more weight than Whites (13.6
kg versus 9.1 kg; p < 0.05) during the first year following transplantation (Baum et al.,
2002). Similarily, 2 and 3 years following transplant surgery African-Americans
continued to gain more weight than Whites (16.2 kg and 16.4 kg, versus 11.5 kg and 11.1
kg, respectively; p < 0.05; Baum et al., 2002). In addition, Clunk, Lin, and Curtis (2001)
found a significantly higher weight gain in African Americans compared to Whites, as
did Gallagher et al. (2000a) in a retrospective review of 974 kidney recipients. In another
study Gallagher et al. (2000b) confirmed weight gain after kidney transplantation is
common, with an average weight gain of 10.3 kg. The study also found that over 87% of
the weight gainers averaged a minimum of 2 kg over 12 months.
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Cashion et al. (2007) conducted a more comprehensive retrospective analysis of
weight changes in 171 individuals one year following kidney transplant surgery from
January 1998 to January 2002. The recipients were women and men, and African
American and White (Cashion et al., 2007). Study outcomes included fasting glucose,
triglycerides, creatinine levels, and BMI (Cashion et al., 2007). Descriptive analysis
found that all 171 kidney transplant recipients had a significant increase in mean weight
(6.2 kg ± 10.7 kg; p < 0.05) and BMI (2.1 kg ± 3.8 kg; p < 0.05) one year following
kidney transplantation (Cashion et al., 2007). In addition, most of the African Americans
(30.5 kg) were more obese than Whites (29.5 kg), and more women (31.4 kg) were obese
than men (29.2 kg), regardless of ethnicity and gender (Cashion et al., 2007). The study
also found higher levels of triglyceride in the obese compared to nonobese transplant
recipients (Cashion et al., 2007).
Collectively, these studies confirm weight gain occurs following kidney
transplantation with significant gain presented one year following kidney transplantation,
with a particular difference among population specificity. For example, women had a
greater weight gain than men, and African Americans had a greater weight gain than
Whites. The seemingly predictable weight gain and obese status following kidney
transplantation could possibly threaten the viability of the new kidney, as well as, the
recipient’s life, and even more so for African American recipients, who also have a
higher incidence of hypertension.
Other Factors Contributing to Excess Weight Gain in the Kidney Transplant
Population
There is substantial literature that suggests weight gain following kidney
transplantation is a well-known occurrence. Attempts to explain this phenomenon have
been attributed to several factors including immunosuppression medications (de Oliveira
et al., 2014; McPartland & Pomposelli, 2007; Ryan et al., 2014) increased caloric intake
due to history of reduced dietary restrictions (Bloodworth, Ward, Relyea, & Cashion,
2014; Cupples et al., 2012; de Oliveira et al., 2014; Ryan et al., 2014), decreased level of
physical activities following transplant surgery (Cupples et al., 2012; de Oliveira et al.,
2014; Ryan et al., 2014; Sanchez et al., 2007), and consequences of concomitant chronic
diseases (Ryan et al., 2014).
Immunosuppression Medications
Weight gain often associated with immunosuppression medications (McPartland
& Pomposelli, 2007) can increase rejection and decrease the viability of kidney function
(Allison, 2016; Bamoulid et al., 2016; Saemann & Sunder-Plassmann, 2008; Snowsill et
al., 2017). Other complications associated with immunosuppression medications and
weight gain include new onset of HTN, hyperglycemia, Type II diabetes, CVD, and
hyperlipidemia (McPartland & Pomposelli, 2007). According to Aksoy (2016), there is
an association between weight gain and posttransplant steroid therapy use. This study
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found, after 36 months, 9% of kidney recipients experienced weight gain due to increased
appetite. The use of immunosuppressive medications, such as steroid therapy, may cause
hypernatremia and fluid disturbance, which lead to other health-related complications
(Calò et al., 2017).
A retrospective study investigated the association between weight gain and impact
of immunosuppressive therapy, without steroids, in 203 kidney transplant recipients from
January 2005 to December 2009 (de Oliveira et al., 2014). The average weight gain
found was approximately 15 pounds, after first months, and 9% of the participants gained
weight after 36 months, post-kidney transplantation (de Oliveira et al., 2014). de Oliveira
et al. (2014) suggested a negative impact of steroid therapy on weight gain following
kidney transplantation; instead the study reported significant weight gain was associated
with creatinine levels in young female recipients and donors.
Dietary Intake
Following kidney transplant, recipients often experience weight gain that is
attributed to increased appetite and an increased food consumption. Some studies have
shown immunosuppression medications and steriod therapy increased the recipients’
appetites, thus increased body weight and BMI (Elster et al., 2008). Bloodworth et al.
(2014) found significant weight gain after kidney transplantation, with an average weight
gain of 4.2 kg in a year. The study reported an increase in BMI (p < .05) for participants
(n = 229) that lived within 1 mile of a grocery store near the kidney recipients were
asssociated with an increase in BMI (p < 0.05); however, fast food restaurants and
convenience stores did not significantly lead to BMI changes.
Physical Activity
Physical activity plays a role in reducing weight gain and obesity, and in
improving overall health after transplant, although few transplant recipients engage in
physical activity (Dontje et al., 2014; Sanchez et al., 2007). O'Brien and Hathaway
(2016) reported physical activity is essential following transplantation; however, they
found no specific standards or recommendations for increasing posttransplant physical
activity in the literature. Nevertheless, guidelines in performing physical activity should
be compatible with the kidney recipient’s cardiac tolerance and physical ability (Bellizzi,
Cupisti, Capitanini, Calella, & D'Alessandro, 2014). As health care providers begin to
encourage and prescribe activity regimens for transplant recipients, it will be critical to
select methods, like DXA scans, which have the ability to assess body components such
as visceral fat tissue.
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Measurement of Body Fat and Weight Gain
In general, there are several measures available to monitor body weight and body
composition components. The anthropometric measurements assess the ratio of size and
proportion of the body’s composition such as BMI and WC. These measurements are
advantageous because they are widely available, rapid, safe, and inexpensive, making
them ideal for clinical and hospital settings. Anthropometric measures do not directly
measure body fat and therefore lack the ability to assess body fat and predict new onset
and progression of diseases as well as other health complications found in kidney
recipients.
In kidney recipients, DXA provides indirect measures of regional and whole-body
composition. DXA measures masses of soft tissue and fat and lean tissues. Unlike
anthropometric measures, DXA assesses visceral fat, whole body fat, subcutaneous fat,
and lean mass and is useful to predict health risk in kidney recipients. In addition, DXA
provides a precise whole-body measurement and can explain variations in predicting
outcomes post-kidney transplants (Heyward & Wagner, 2004).
The monitoring of weight gain and subsequent obesity following transplant
surgery is essential in order to assess and evaluate new onset and progression of
concurrent chronic conditions. The more precise measurement of weight gain and obesity
requires assessment of body composition (Duren et al., 2008; Heyward & Wagner, 2004).
One option for measurement is called the direct method. A direct method refers to body
composition methods that provide validated estimates of %BF, FFM, muscle, bone
density (Db), hydration, or other body components, while indirect methods refer to the
methods of measuring body composition that estimate %BF, FFM, muscle, Db,
hydration, or other body components (Heyward & Wagner, 2004). Regardless of the
underlying cause, the need exists for accurate measures that reflect not just weight or
BMI, but more specifically the distribution of body fat in areas most associated with
weight-related morbidities. Such measures could be used not only to identify individuals
who are at high risk but also more accurately monitor efforts to reduce fat mass.
Body Composition Methods
Early body composition research developed some important concepts; however,
the methods were not practical nor precise for clinical settings due to the environmental
conditions required for assessment. Later, an anthropometric model evolved, to estimate
total body muscle mass which was an important contribution to body composition
research. Today, many clinicians use simple and practical methods to measure FM and
FFM with different measurement methods such as the two-compartment models and
hydrodensitometry, air displacement plethysmography (ADP), anthropometric, or BIA
three-and four compartment models, and multicompartment models. This section will
discuss anthropometric methods and regional and whole-body composition measures, and
the underlying assumptions of each method, accuracy, precision, reliability and validity,
and population specificity measures and methods.
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Anthropometric Measurement
According to Duren et al. (2008), anthropometric body composition
measurements involves several parameters relevant to measures such as area; body
volume; body weight; lengths at the knee height, arm span, and stature; skinfold
thickness; breadths of the elbow, bi-iliac, ankle, wrist, and biacromial; and bodily
circumference at the head, trunk, waist, hip, calf, wrist, arm, and chest. These
anthropometric variables are useful in the predictive equations in the determination of
quantitative techniques used to measure an individual's body fat composition. For
example, estimation of body composition measurements from skinfold thickness
measurement is primarily based on the large proportion of total body fat that is located
underneath the skin (Heyward & Wagner, 2004). Therefore, by obtaining measures from
skinfold thickness and using a method such as underwater weighing, the percentage of
body fat could be estimated in a healthy population. Unfortunately, anthropometric
measures are limited when used as a single measure (Heymsfield et al., 2005).
Common anthropometric measures assess total and regional body composition.
BMI, WHR, and WC are relatively simple and inexpensive methods to assess body
composition (Vazquez, Duval, Jacobs Jr, & Silventoinen, 2007). These anthropometric
measures are useful and widely used to assess body weight and several health-related risk
factors associated with excess adiposity (Heymsfield, Peterson, Thomas, Heo, & Schuna,
2016). However, anthropometric methods are not useful when tissue-based measurements
such as VAT compartment performed by DXA and CT scans are needed to capture the
association between adiposity and health-related conditions (Cordeiro et al., 2013;
Vatanparast et al., 2009).
Body Mass Index
BMI, a ratio of weight (kg) and height², is an attribute of obesity. BMI guidelines
assume there is an association between body fat and body mass, but there is not.
Furthermore, BMI lacks the ability to calculate an individual’s body composition and
assess body fat. Since body fat is known as a primary physiological risk factor for
morbidity and mortality (Gallagher et al., 2000b; Josse, Azizian, French, Kramer, &
Phillips, 2011), BMI is not a good measure to predict cardiac mortality (Josse et al.,
2011) and its utility as a measure is limited in the general as well as the kidney transplant
population.
According to Heymsfield et al. (2016), BMI is an acceptable measure for
estimating total body fat and assessing adiposity. BMI measures are a problem for two
reasons. First, they lack the ability to estimate body fat among different ages, genders,
ethnicity groups, and athletic build (Schoeller et al., 2005), which are factors that affect
the relationship between BMI and %BF. Secondly, BMI measures often inaccurately
misclassify individuals as underweight, overweight, or obese because of their age,
gender, or ethnicity (Carpenter et al., 2013; Daniels, 2009; Heyward & Wagner, 2004).
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For example, Heymsfield et al. (2016) found that the relationship between BMI and
adiposity differed across race and ethnic groups, specifically among Whites, AfricanAmericans, and Mexican-Americans. This finding raises questions about the suitability of
BMI use in different race and ethnic groups.
Waist-to-Hip Ratio
Waist-to-hip ratio (WHR) is an indirect measure used for assessing body
composition and determining risk factors associated with cardiovascular and metabolic
diseases. Table 2-3 provides the waist-to-hip circumference ratio norms for men and
women. The WHR measure is a simple calcualtion of WC in centimeters divided by hip
circumference in centimeters (Heyward & Wagner, 2004; Simmons, 2001). According to
(WHO), the cutoff point for at-risk metabolic complications for men is WHR ≥ 0.90 cm
and WHR ≥ 0.85 cm for women. (Alberti, Zimmet, & Shaw, 2006). However, the
International Diabetes Federation recommended a different set of cutoff points for
different ethnic groups: for Europids men the WHR ≥ 94 cm and WHR >80 cm for
women. Meanwhile, the recommendations for South Asians, Chinese, and Japanese men
suggest WHR > 90 cm and WHR > 80 cm for women (Alberti et al., 2006).
The distribution of upper body fat called the android and lower body fat called
gynoid typically is different in men and women. The upper body fat or central obesity is
more common in men, while lower body fat appears more in women deposited on the
hips and thighs. However, if a person is obese, they are often categorized into either
group. The location of body fat is important when using WHR for examining excess
weight and disease risk, especially in different genders and ethnic groups. Although
WHR is a useful anthropometric measure for central adiposity and visceral fat, there are
limitations between gender and ethnicity. One study found an association between
increase in WHR and postmenopausal women (Donato, Fuchs, Oppermann, Bastos, &
Spritzer, 2006), because women experience a menopause fat distribution pattern that is
similar to men during menopause. Murray (2006) found an association between increased
WHR and myocardial infarction, for women at 0.83 and for men at 0.9. Asians, typically,
have a strong association between increased WHR and cardiac mortality (Josse et al.
(2011). This is due to the waist circumference association with visceral fat. However, the
WHR measure is limited in the kidney transplant population because the hip
circumference is subcutaneous fat deposition and the waist circumference is
subcutaneous and visceral fat.
Air Displacement Plethysmography
ADP is used to estimate body volume and does not provide measurements of the
regions. It is a less expensive validated and accurate method to measure %BF in obese
and extremely obese kidney transplant patients compared to DXA (Heymsfield, 2005).
ADP makes assumptions regarding other tissue density to estimate %BF. ADP measures
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Table 2-3.

Waist-to-Hip Circumference Ratio Norms for Men and Women
Risk

Gender
Men

Women

Age
20-29
30-39
40-49
50-59
60-69
20-29
30-39
40-49
50-59
60-69

Low
<0.83
<0.84
<0.88
<0.90
<0.91
< 0.71
<0.72
<0.73
<0.74
<0.76

Moderate
0.82-0.88
0.84-0.91
0.88-0.95
0.90-0.96
0.91-0.98
0.71-0.77
0.72-0.78
0.73-0.79
0.74-0.81
0.76-0.83

High
0.89-0.94
0.92-0.96
0.96-1.00
0.97-1.02
0.99-1.03
0.78-0.82
0.79-0.84
0.80-0.87
0.82-0.88
0.840.90

Very High
<0.94
<0.96
<1.00
<1.02
<1.03
< 0.82
<0.84
<0.87
<0.88
<0.90

Note. Reprinted with permission from author Dale R. Wagner 9-16-18. Originally
published in “Applied body composition assessment”, by Heyward, V. H., & Wagner, D.
(2004), p. 78; out of print.
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are derived from 3-C compartment consisting of fat mass, lean body mass, and bone
mass. These measures should be used with caution in the elderly and children because of
the alteration in the density of FFM (Baumgartner et al., 1991).
Dual-Energy X-Ray Absorptiometry
DXA is one of the most popular methods for measuring whole body and regional
body. DXA is able to discriminate between soft tissue mass, total body adipose, bone
mineral, and bone mineral density. DXA remains a widely used indirect method for
estimation of total body mineral density (TBMD), total body mineral (Mo), bone mineralfree lean tissue mass (LTM), fat mass (FM), fat-free mass (FFM=LTM=BMC), and soft
tissue mass (STM=LTM+FM) compositional changes in human body composition
research (Dordevic et al., 2018; Heyward & Wagner, 2004; Ng et al., 2018). DXA
provides a more precise and accurate measurement of estimating %BF compared to
anthropometric measures, because it can assess regional body composition at the tissue
level (Heyward & Wagner, 2004; Teixeira et al., 2001; Vatanparast et al., 2009),
especially in men (Ball, Altena, & Swan, 2004).
While DXA was not originally developed to measure body fat, it can be useful in
this regard because the scans can be focused on a single area. This can be employed to
measure visceral fat, which is a critical factor for renal transplant patients. The scans used
can also be whole-body to measure overall body fat percentage.
Additional advantages include low exposure to radiation and no requirements for
restriction prior to testing regarding eating, drinking, or exercise for renal recipients.
DXA can distinguish VAT, a marker for increased risk for Type 2 diabetes and
cardiovascular diseases (Latt, Maestu, & Jurimae, 2018; Ng et al., 2018) from other
tissues.. DXA also provides precise and accurate estimates of body composition such as
percentage of body fat (%BF) from three-body compartments (3-C) that consist of fat
mass (FM), lean body mass, and bone mass (Table 2-4).
These whole-body and regional body measurements provided by DXA are based
on a 3-C model that is part of two equations (soft tissue + bone and lean tissue + fat
tissue). Assessment of regional body areas such as legs, arms, and trunk are advantageous
in kidney transplant recipients to estimate fat, lean mass, and total regional bone mineral
density (BMD; Heymsfield, 2005). Other estimates of soft-tissue composition such as
FM and lean tissue mass are used to determine percentage of body fat (%BF) and fat-free
mass (FFM). It is the estimate of soft tissue composition that contributes to the major
assumptions of DXA methods and limitations of DXA (Heyward & Wagner, 2004).
The DXA method has several limitations. One limitation is that it does not offer
high resolution of soft tissue imaging; therefore, it cannot accurately assess soft tissue
composition in the presence of large bone areas. DXA only directly measures two tissue
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Table 2-4.

Bioelectrical Impedance Analysis Approaches and Uses

Approach
Traditional BIA
(whole body
tetrapolar, single
frequency)

Model
Series

Recommended Use
To estimate TBW and FFM in healthy clients with
normal hydration status and normal fluid
distribution

Parallel To estimate ICW and BCM
Segmental BIA

Series

To measure fluid distribution or regional fluid
accumulation in clinical populations

Parallel To measure regional or segmental ICW
Multifrequency BIA

Cole

To estimate ECW, ICW, and TBW; to monitor
changes in the ECW/BCM and ECW/TBW ratios in
clinical populations

Upper-body (hand-tohand) BIA and lowerbody (leg-to-leg) BIA

NA

To estimate %BF in healthy clients with normal
hydration status and normal fluid distribution

Note: BCM = body cell mas; FFM = fat-free mass; ECW = extracellular water; ICW =
intracellular water; TBW = total body water; NA = not applicable (these analyzers are
based on series model but do not provide impedance or resistance data).
Note. Reprinted with permission from author Dale R. Wagner 9-16-18. Originally
published in Applied body composition assessment”, by Heyward, V. H., & Wagner, D.
(2004), p. 93; out of print.
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compartments (i.e., FM and FFM); therefore, soft tissue measurements such as fat and
lean tissue mass can only be measured in anatomical locations without bone. DXA
measures cannot distinguish between the components of abdominal adipose tissue, like
VAT and subcutaneous adipose tissue (SAT). The accuracy of estimates of body
composition components measures by DXA are determined by the manufacturers’
software which accounts for the inconsistencies in measurements (Heymsfield et al.,
1997; Heyward & Wagner, 2004).
Other limitations of DXA include in adults and an older kidney transplant
population, especially when the underlying assumed value is not met, the validity of the
results are compromised and the %BF is either over- or underestimated (Heyward &
Wagner, 2004, p. 124). Variables that influence measurement errors include age,
exercise, and diet. For example, age affects the assumed value of fat-free mass body
density (FFBd), which changes the FFM value. FFBd value in men and women > 65
years old ranges from 1.093 and 1.099 g/cc, compared to < 65 years old, which assumes
the value of 1.1000 g/cc (Heyward & Wagner, 2004, p. 124). This is also true for relative
hydration of FFM in older women (73.6-75.6% FFM) and older men (72.4-74.4% FFM),
which affects body composition in the kidney transplant population. This variable
contributes to the limitation of DXA and typically underestimates %BF in an older
population (Heyward & Wagner, 2004, p. 133). Need to look quotes up out of book
The validity of DXA is challenged for several reasons. The validity of DXA is
difficult to evaluate because the assumptions used to derive body composition estimates
of soft tissue body composition are considered proprietary by DXA manufacturers (i.e.,
Lunar, Hologic, and Norland). The DXA method has body size restrictions based on the
width and length of the equipment table. The ability to perform DXA scan in a morbidly
obese patient poses a challenge because of a maximum weight restriction.
Bioelectrical Impedance Analysis
Bioelectrical impedance analysis (BIA) is a rapid, noninvasive method used for
measuring body composition. Bioelectrical impedance indirectly estimates the volume of
the body’s TBW or FFM when a low-level electrical current is carried by water and
fluids through the body. Therefore, there are certain assumptions and principles
surrounding this method. However, this section will describe the two principles of BIA
(Dehghan & Merchant, 2008; Ng et al., 2018). First, the principle of BIA is based on the
biological characteristic of tissues acting as conductors or insulators, and the direction of
the electrical current transmitting through the path of least resistance. For example, FFM
contains ~73% of water and electrolytes, which makes it a better conductor than fat,
which is considered anhydrous with a poor electrical conduction (Heyward & Wagner,
2004). This method uses the two factors that human body is composed of highly
conductive tissue referred to as lean body mass and less conductive tissue with an
insulator such as body fat and measured impedance reflects the ratio between conductive
tissue and nonconductive tissue, which is why it is called bioelectrical impedance
analysis. Secondly, impedance is a function of resistance and reactance. Resistance is a
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measure of pure opposition to current flow through the body, and the reactance is the
opposition to current flow caused by voltage storage produced by the cell membrane
(Gonzalez, Orlandi, Santos, & Barros, 2018). Clients must meet certain conditions prior
to BIA:
•
•
•
•
•
•

No eating or drinking within 4 hours of the test.
No exercise within 12 hours of the test.
Client should urinate within 30 minutes of the test.
No alcohol consumption within 48 hours of the test.
No diuretic medications within 7 days of the test.
No testing of female clients who perceive they are retaining water during that stage
of their menstrual cycle.*

The advantage of using BIA is that it is a quick, noninvasive, and inexpensive
method that can be used in the clinical or field setting to estimate body composition with
obese patients, and it does not require a highly skilled technician (Heyward & Wagner,
2004). The BIA method is recommended for assessing percent of body fat in a pre- and
posttransplantation heart, liver, and lung population (Heyward & Wagner, 2004). A
disadvantage in using BIA is that it may lead to measurement error. To avoid
measurement errors, the test individual must adhere to the BIA pretesting client
guidelines just shown.
Computed Tomography
Computed tomography (CT) uses radiation to create an image to assess BC at the
tissue and organ level (Heyward & Wagner, 2004; Heymsfield et al., 2005). CT
accurately measures body composition, such as bone, adipose, and lean tissues (Heyward
& Wagner, 2004). There are two advantages of CT. First, it is more reliable than MRI
(Heyward & Wagner, 2004). Second, CT can measure large body sizes (Duren et al.,
2008). However, there are several disadvantages, including the cost and exposure to
radiation, requirement of a skilled technician (Heyward & Wagner, 2004), the need for
special software, and only regional not whole body imaging of body composition (Duren
et al., 2008).
Magnetic Resonance Imaging
Magnetic resonance imaging (MRI) measures body composition at the tissue level
(Heyward & Wagner, 2004; West et al., 2018). MRI produces a computer-generated
* Reprinted with permission from author Dale R. Wagner 9-16-18. Originally published
in “Applied body composition assessment”, by Heyward, V. H., & Wagner, D. (2004), p.
94; out of print.
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image using a radio frequency signal from hydrogen nuclei. The hydrogen nuclei act like
a little magnet (Heyward & Wagner, 2004). The advantage of MRI is that it can be used
for full body scan in patients with normal weight or moderately overweight (Duren et al.,
2008). The disadvantages of MRI are the same as for CT.
The Challenge of Measuring Body Fat and Weight Gain
Body composition measures are important components to monitor short-term and
long-term impact in the general population and health outcomes. Weight gain and
increased body fat cause enlarged adipocytes and increased VAT in the abdominal area,
which could subsequently lead to diabetes or CVD (Pi-Sunyer, 2018). Obesity is a global
epidemic (Despres, 2012; Ghoorah et al., 2016; Kovesdy et al., 2017) and risk factors for
chronic diseases and poor health outcomes in transplant recipients. Several direct (e.g.,
human cadaver) and indirect BC methods (e.g., anthropometric method, BIA and DXA)
can be used to measure body fat and weight gain and have been previously discussed.
While these methods are used to measure body fat and weight gain in the general
population, challenges exist with using indirect methods to measure body fat and weight
gain in the general population and those with clinical conditions. Age, ethnicity/race, and
clinical conditions impact the measurement of body fat and weight gain in the general
population and/or kidney transplant population.
Age
Physiological changes occur with aging and significantly affect changes in body
composition. During the aging process, water, mineral, and protein components of FFM
are altered, which affects the FFMd (Heymsfield, Peterson, Thomas, Heo, & Schuna,
2016; Heyward & Wagner, 2004; Jura & Kozack, 2016; Shaw et al., 2007). For example,
as the body ages, excessive body weight in the older population versus the younger
population is characterized by increased FM and may contribute to an increase in
distribution of internal deposits of visceral fat, leading to medical conditions associated
with abdominal fat such as diabetes. The presence of increased visceral fat is associated
with a concurrent decrease of muscle mass (Kathryn, Shelley, Julia, & Connie, 2016;
Sharp, Andrew, Burchfiel, Violanti, & Wactawski-Wendek, 2012).
Obesity in an older population is characterized by an increase in body weight,
which results in an increase in deposits of visceral fat and abdominal fat in the body
(Elia, 2001; Heyward & Wagner, 2004; Jura & Kozack, 2016). Increased deposits of
visceral fat and abdominal fat in the body are subsequently accompanied by an increased
risk of morbidity and mortality (Elia, 2001) from chronic diseases (Heyward & Wagner,
2004; Jura & Kozack, 2016). In addition, the physiological changes in the older
population affect measurements of BC. For this reason, problems exist with using
anthropometric measurements such as SKF to measure BC in the older population,
particularly because of decreased elasticity and skin hydration, as well as, the shrinkage

39

in fat cells may cause an increase in the measurement for SAT and connective tissues
(Guerra, Amaral, Marques, Mota, & Restivo, 2010).
Snead, Birge, and Khort (1993) studied age-related differences in BC by
hydrodensitometry (HD) and DXA to determine if %BF was overestimated with HD in
older male and female population because aging leads to a decrease in bone mineral
content. The studied consisted of 113 women and 72 men between the ages of 21 to 81
(Snead, Birge, & Khort, 1993). Snead et al. (1993) found that HD and DXA
underestimated %BF in the older population, with DXA significantly underestimating it
by 4% to 5% (Snead et al., 1993).
Shaw et al. (2007) used DXA BC and anthropometric measurements to study
aging in a population-based older cohort. Seven hundred and thirty adults between the
ages of 50 to 79 who were men and women were measured with standardized
measurements of BMI, WC, WHR, and DXA scan from March 2002 to January 2004
(Shaw et al., 2007). The DXA scan focused on four measurements: total body fat mass,
% total body fat, % trunk fat, and lean body mass (Shaw et al., 2007). Three separate
statistical analyses were performed on men and women. Linear regression was used to
test the trends in BC with the separate age categories of men and women (Shaw et al.,
2007). Partial correlations and Bland-Altman analysis were used to measure if a
consensus occurred between DXA and anthropometric measurements (Shaw et al., 2007).
Results showed lean body mass with DXA decreased significantly with the advancing
age of the men and women (p < 0.05). In males, BMI and body weight decreased with
advancing age (p < 0.01). In aging females, DXA showed an increase in fat, %BF (p <
0.02), % trunk fat (p < 0.05), and WHR (p < 0.05; Shaw et al., 2007). No differences
existed between DXA total body fat, WC, or hip circumference (Shaw et al., 2007).
These results showed a high consensus existed between DXA measurements, BMI, and
WC in the measurement of BC in the older cohort population. However, WHR was not
consistent with DXA measurements of BC in the older cohort population. This study
concluded there was an overall consensus between the BC measurement of DXA and
anthropometric methods except WHR, which suggests that WHR is not a suitable BC
measurement in the older population (Shaw et al., 2007).
Ethnicity/Race
Obesity differentially impacts certain ethnic and racial groups (Heyward &
Wagner, 2004; Richmond et al., 2015; Wang et al., 2017). A report from a national
survey (2011-2012) in the United States showed Asians have the lowest percentage of
obesity and Blacks have the highest (Wang et al., 2017). The survey specifically reported
obesity rates for Asians were 10.8%, Whites 32.6%, Hispanics 42.5%, and African
Americans 47.8% (Wang et al., 2017). Wen and Kowaleski-Jones (2012) corroborated
results of the national survey reporting the highest rate of obesity was found in Hispanics
and African Americans, with Asians and Whites experiencing lower rates.
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While the rate of obesity differs among the four ethnic groups, specific BC
measurements (e.g., BMI and WHR) may not accurately estimate %BF, resulting in
misclassification of some individuals to high- or low-risk groups (Heyward & Wagner,
2004). For example, in a study by Heyward and Wagner (2004), DXA classified 25% of
American-Indians as obese, but HD and a three- body composition classified 78% of
American-Indians as obese. The different estimation of obesity with the DXA, HD, and
3-body composition showed problems exist with using these three BC methods to classify
obesity in American Indians. According to Heyward and Wagner (2004), ethnic
differences exist across the groups with subcutaneous fat distribution from the trunk to
the extremity and limb lengths to total height. These differences may make it difficult to
estimate %BF among the different ethnic groups accurately; therefore, a multicomponent
model should be used as a reference method since 2-C models and DXA are the only
models used to accurately estimate %BF in the different ethnic groups (Heyward &
Wagner, 2004). Thus, standardized BC methods and equations must be developed to
estimate %BF accurately in different ethnic groups.
Clinical Conditions
Clinical conditions may make certain BC methods unsuitable for accurate
assessment of %BF. It is important to acknowledge DXA measures and reference
databases should not be used to diagnose disease or conditions, nor provide
recommendations for treatment regimens. Instead, the presence or absence of certain
diseases is a critical step for selecting accurate methods and measures in body
composition. The clinical conditions discussed as exemplars are pregnancy and kidney
failure and dialysis, although other examples exist such as trained athletes and muscular
wasting or fluid retaining chronic conditions (Heyward & Wagner, 2004).
Pregnancy
One anthropometric method used to safely assess body composition in pregnant
women is SKF (Heymsfield et al., 2005). However, a study found that SKF
overestimated %BF in pregnant women. Robic et al. (2018) examined the best
anthropometric methods to use in pregnant women to measure body fat and concluded
that body height, body weight, SKF, and limb circumferences were the best measures.
The three methods provided a wide range of prediction equations for estimating body fat
in pregnant women.
Kidney Failure and Dialysis
Kidney failure results in metabolic waste accumulation in the body from a decline
in kidney function. The treatment for kidney failure is dialysis. Dialysis removes
metabolic waste and excess fluid from the body (Heyward & Wagner, 2004), thereby
influencing body composition, yet there is no standardized method to assess BC in
dialysis patients. The methods used to assess BC have led to varying results, either
overestimating or underestimating %BF in kidney failure and dialysis patients (Heyward
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& Wagner, 2004). This suggests total body water is strongly associated with
hypertension.
Cooper et al. (2000) studied 54 patients with end-stage kidney disease. Deuterium
dilution technique was used to estimate TBW and compared to estimates from
anthropometric methods, 58% body weight, Watson equations, and BIA. FFM produced
from anthropometric methods was also used to estimate TBW and compared with BIA
estimates of TBW. Last, measurements of total body nitrogen (TBN; p = 0.04) were
linked with TBW estimates and BIA-derived resistance. The results showed the Watson
equation significantly underestimated TBW (p = 0.01), and overestimated body weight.
The BIA equation did not significantly differ from the gold standard methods used to
estimate TBW (p = 0.12. Nevertheless, the agreement varied on the equation methods
used to estimate TBW, but BIA obtained resistance accurately estimated TBW and other
body composition components (Cooper et al., 2000).
Kang, Cho, Park, Yoon, and Do (2014) studied 41 Asian patients on maintenance
peritoneal dialysis to determine the effect of peritoneal dialysate on BIA measurement of
BC. Prior to multifrequency BIA measurement, dialysate was drained from the abdomen
with the patients standing (D-) (Kang, Cho, Park, Yoon, & Do, 2014)(Kang, Cho, Park,
Yoon, & Do, 2014). Dialysate was administered in the patients and measurement was
taken and repeated (D+). Bland–Altman was used to analyze agreement and bias. Bias
was D+ measurement and D- measurement (Kang et al., 2014). The presence of
peritoneal dialysate increased ICW (D-: 20.33 ± 3.72 L; D+: 20.96 ± 3.78 L), ECQ (D:13.53 ± 2.54 L; D+: 14.10 ± 2.59 L), and TBW (Kang et al., 204). The increase of ICW
and ECW in the presence of peritoneal dialysate was significant (p < 0.001). In the
presence of peritoneal dialysate, total and trunk edema indices were higher, but both
extremities were not significantly different (Kang et al., 2014). Moreover, mineral
content and FFM for total body and trunk were overestimated and body fat was
underestimated (Kang et al., 2014). In the presence of peritoneal dialysate, trunk had a
lower BIA measurement, but in both extremities, no changes were found in BIA
measurements (Kang et al., 2014). Biases were found in soft lean mass (1.53 kg), FFM
(1.68 kg), fat mass (-1.71 kg), and edema index (0.003 kg). The overall findings from the
Kang et al. (2014) study showed in the presence of peritoneal dialysate agreements and
biases exist with BIA measurements.
Multicompartment Methods
There are five distinct body composition levels: atomic, molecular, cellular,
tissue-organ, and whole-body. Each level is divided into discrete components, except the
whole-body level, which is divided into regions. First, the atomic level contains four
major elements that make up 96% percent of body mass: oxygen, carbon, hydrogen, and
nitrogen. These major elements are used by various models to estimate total body fat,
body cell mass, and protein. In addition, seven other elements compile the atomic level,
including calcium, phosphorous, potassium, sodium, sulfur, chlorine, and magnesium.
On the other hand, there are six major components at molecular level: protein, bone
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mineral, lipid, water, carbohydrate, and soft tissue mineral. These components are used to
develop complex models that consist of three to six components referred to as
multicomponent models. The cellular level is compiled of three components:
extracellular solids, extracellular fluids, and cells. At this level, the cells are further
metabolized into fat and body cell mass (BCM) components. The fourth level of body
composition is the tissue-organ level. The major components at the tissue-organ level
include adipose tissue, skeletal muscle, visceral organs, bone, and other single organs
such as brain, heart, liver, and spleen. The final body composition level is the whole-body
level. This level is divided into three regions: appendage, trunk, and head. The regions at
this level provide anthropometric measures such as skinfolds, length, and circumference,
which are used in estimation of prediction equations.
According to Wang, Pierson Jr, and Heymsfield (1992), the two-compartment (2C) model was developed to standardize a basic method for assessing body fat,
particularly in the absence of weights of measure components (Table 2-1). Twocomponent models divide the body into fat and fat-free body components. The limitation
of the two-component and the DXA method (Withers et al., 1998) involves the
assumption of constant hydration of water of 73% in FFM, sex, and body size, which is
inaccurate. The three-component model (3-C) model divides the body into fat, water or
mineral and residual components. The 3-C model precision is better for estimating body
composition variation of body fat, and is preferred when compared to the 2-C reference
methods, including hydrodesitometry (HD) and TBW. The HD method evolved into a 3-,
4-, and 6- model. This model is useful in DXA, BIA, and ADP devices.
The Siri’s three-component (3-C) hydrodensitometry method was derived from
the Behnke’s two-component (2-C) method, which was composed of known and constant
proportions of fat-free mass (FFM). The 3-C method is composed of fat, water, and
residual components. The expansion of the 3-C method led to the estimation of three
quantifiable measures that included body mass, body volume, and total body water
(TBW). The inclusion of TBW reduced the errors associated with Behnke’s 2-C method.
Later, the 3-C method expanded to the four-component (4-C) method by adding a bone
mineral content, which reduced possible measurement errors associated with bone
mineral. These 4-C multicomponent methods quantify the following measures: body
volume, TBW, body mass, and bone mineral. On the other hand, the six-component (6C) methods such as neutron activation method include fat, total body water, protein, bone
mineral, soft tissue mineral, and glycogen, whereas the 6-C total body carbon method
includes components at the molecular level such as fat, protein, and glycogen; it requires
direct analysis of the chemical composition of the body in vivo.
The 3-C model is not recommended in the KTR population or any population
with impaired kidney function and physiological compensation related to age or disease.
Additionally, it is recommended that the 3-C (water) or the 4-C (water) should be used to
obtain reference measures of body composition of older adults. The FFM is the model
divided by its own water content and the additional solids, primarily protein and
minerals. Three-component calculations combine fat, density of water, fat, and body
solids to estimate body fat mass. An inaccurate estimate may occur if an individual has a
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significant decline in body protein mass, BMM, or when there is estimated density for
solid compartments (Heyward & Wagner, 2004).
Heyward and Wagner (2004) found that age, sex, and ethnic group body
composition differed during body compositional changes at the molecular level: lipid
metabolism, protein, nutrition area, water balance, bone and mineral, and homeostasis.
Measurable properties at this level are DXA method, which are used to assess wholebody composition. Because adipose and fat are measured at different component levels,
MRI and CT would not be a suitable reference for estimates of fat by another method
such as DXA underwater weighing (UWW). Fat is at the molecular level and DXA lacks
direct measures in the regional areas and can only provide estimates of percentage of
body fat from soft tissue mass, fat mass, and lean body mass.
The multicompartment (4-C) model is a highly significant predictor of the
relationship between age and ethnicity. For example, Asian populations have a high level
of adipose, and an anthropometric method such as BMI could prolong the risk for
cardiovascular disease. MRI would not be a suitable reference comparison for estimates
of fat by another method that considers the variability of water or mineral content of the
fat-free body, or both. They are generally thought to provide more accurate estimates of
body fat than 2-component models, especially when one of the assumptions of the 2component model might be violated, such as constant hydration, which is not likely in the
kidney transplant population (Heyward & Wagner, 2004).
In addition, in vivo neutron activation analysis (NAA), the 4-C model, measures
bone density and unknown quantity of mass for each body compartment. The unknown
values are obtained from DXA measures, which have the ability to quantify bone mineral
content or NAA that quantify the protein content. The indirect pathway to estimate FM
from two additional methods, DXA and NAA, makes the 4-C UWW method
cumbersome and time consuming for technicians and participants. However, the 4-C
UWW and DXA are more commonly used than 4-C UWW and NAA (Heyward &
Wagner, 2004). UWW, which is also referred to as hydrostatic weighing, is considered
the gold standard for measuring body composition from body density. There are several
methodological issues that occur when comparing a person’s underwater weight to their
dry-land weight, which is the inversely proportional to body fat, including the following:
subject position, residual volume, number of trials and selection criteria, alternative lung
volumes, and head placement. The subjects’ positions include sitting, kneeling, or prone,
which generally depends on the size of the tank. However, measurement errors may
occur if the subject is tall or has a large abdomen. In addition, UWW requires the subject
to exhale completely under the water; therefore, potential measurement errors may occur
if the subject lacks the ability to completely exhale underwater, thus reducing the
accuracy and reliability of the measurements of the subjects. The technician’s ability to
accurately determine the repeated measurements of a subject is another possible
measurement error (Heymsfield et al., 2005). UWW method is limited in specific
populations including young children, disabled, elderly, sick, and other special groups.
The complete submersion in water could cause complications and may not be possible in
certain populations.
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The 4-C DXA component model is preferred for an aging population for
estimating %BF. This model calculation assumes the bone mineral calcium and bone
mineral in carbon and the measures are adjusted for variation in an older population due
to the decline in bone and muscle components. If the 4-C is not available, the 2-C is an
alternative method to improve measures for estimating %BF, by averaging the value of
fat-free body density (FFBd). This adjustment for FFBd is critical in different ethnic and
racial groups because of the variation in bone density mass (Heyward & Wagner, 2004).
A 4-C molecular model should not be considered in kidney transplant recipients
or any population with chronic disease who may experience fluid disturbance such those
individuals with electrolyte imbalance. Transplant recipients often experience fluid
disturbance and electrolyte imbalance, in which the 4-C components of fat, protein, bone
mineral, and total body water (Heyward & Wagner, 2004) can be used to derive a
suitable predictive equation.
Studies have shown (Heyward & Wagner, 2004) BIA equation accurately
estimates changes in FFM and TBW in obese women on a low caloric diet. Several
studies have shown that the BIA method is sensitive to detect body composition change
relative to weight loss. On the other hand, BIA method FFM is not accurately reported if
weight loss occurs. The BIA method is not useful if hydration is altered or there is a fluid
disturbance. However, the NIR method was recommended in subjects with fluid
disturbance such as a dialysis patient.
Studies have shown BIA measures derived from SKF are suitable for predicting
percentage of body fat (Heyward & Wagner, 2004). BIA estimate is suitable body
composition in obese population for several reasons.
Disease-Specific Population
The BIA method is best for disease-specific populations. Predictive equations are
useful in a population with metabolic syndrome, particularly in a disease-specific
population with alteration in fat distribution and fluid disturbance. Two diseases, known
as Type 2 diabetes or thyroid diseases, do not have a predictive equation. The BIA
method or Segal fat-specific measure are the best measures and methods to use in obese
and Type II diabetes populations. The Leiter Disease-Specific Predictive BIA equation is
more preferred in a disease-specific population compared to the BIA method.
Understanding the interaction between methods and measures could be a challenge in
clinical practice when selecting suitable methods to improve outcomes.
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Disease-Gender Population
Heyward and Wagner (2004) used a disease-gender prediction equation to
estimate percentage of fat in a cardiopulmonary population. The BIA method and
Geneva predictive equation DXA measures are suitable for chronic obstructive
pulmonary disease. This predictive equation is used in equipment called Xitron-4000
BIA. In some cases, the measure and method must factor in disease and gender. For
example, the BIA –BIO-Z method is suitable for men and women with cystic fibrosis. On
the other hand, the measure is not gender specific. Men with cystic fibrosis could use
DXA measures and the Geneva predictive equation for more accurate assessment of %BF
compared to women using measures by Kotler.
Studies have shown (Heyward & Wagner, 2004) BIA equation accurately
estimates changes in FFM and TBW in obese women on a low caloric diet. Several
studies have shown that the BIA method is sensitive to detect body composition change
relative to weight loss, except when weight loss occurs rapidly. BIA method is not useful
if hydration is altered or fluid disturbed. However, the NIR method was recommended in
subjects with fluid disturbance such as a dialysis patient. Studies have shown BIA
measures derived from SKF are suitable to predict percentage of body fat in an obese
population but not in an extremely obese population (Heyward & Wagner, 2004). Other
recommendation UWW method included limited in specific populations including young
children, disabled, elderly, sick, and other special groups. The complete submersion in
water could cause complications and may not be possible in certain populations.
Summary
In summary, kidney transplantation is the preferred choice of treatment for
patients with ESRD. After transplantation, kidney recipients experience short-term and
long-term complications, such as weight gain. In the kidney transplant population, weight
gain is a serious issue. Factors affecting weight gain in the kidney transplant population
posttransplant are immunosuppression medications, increased caloric intake from
reduced dietary restrictions, decreased level of physical activities, and consequences of
concommittent chronic diseases. The monitoring of weight gain and subsequent obesity
following transplant surgery is essential to assess and evaluate new onset and progression
of concurrent chronic conditions. Although indirect methods, such as anthropometric
method, BIA, and DXA, are commonly used methods to measure body fat and weight
gain in the general and kidney transplant population, challenges exist with using indirect
methods to measure body fat and weight gain with patients with certain biological and
pathological conditions.
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CHAPTER 3.

METHODS

There is little consensus on which method of measuring body composition is
superior for identifying patients at increased risk for CVD. Therefore, the overall aim of
this study was to compare associations of anthropometric measures versus those obtained
by DXA scan with cardiac-related risk factors at 5-8 years following kidney
transplantation. The specific aims addressed by this study were:
1. To determine the association between anthropometric measures and serum levels
of glucose, lipids, creatinine, and blood pressure of kidney transplant recipients at
5-8 years posttransplant.
2. To determine the association between body composition measures and serum
levels of glucose, lipids, and creatinine and blood pressure of kidney transplant
recipients at 5-8 years posttransplant.
3. To determine if body composition measures by DXA obtained at the time of
transplant (baseline) are associated with serum levels of glucose, lipids, and
creatinine and blood pressure of kidney transplant recipients at 5-8 years
posttransplant.
4. To determine if anthropometric measures obtained at baseline are associated with
serum levels of glucose, lipids, and creatinine and blood pressure of kidney
transplant recipients at 5-8 years posttransplant.
5. To determine the association between changes in anthropometric measures from
baseline to 5-8 years posttransplant and serum levels of glucose, lipids, and
creatinine and blood pressure in kidney transplant recipients at 5-8 years
posttransplant.
6. To determine the association between changes in body composition measures
from baseline to 5-8 years posttransplant and serum levels of glucose, lipids,
creatinine, and blood pressure at 5-8 years posttransplant.
The remainder of this chapter describes the methodology used to address the
above research aims, including the research design, setting and sample, instrumentation,
method and subjects, data analysis, statistical assumptions, and a summary.
Research Design
A quantitative, descriptive follow-up study was conducted that included data
acquired during a parent study conducted between 2008 and 2011 (Cashion et al., 2014),
which examined genetic, environmental, and lifestyle factors contributing to post-kidney
transplant obesity. The parent study data were collected at the time of transplantation and
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served as baseline measures. Additional data were collected for this follow-up study,
which took place 5 years following completion of the parent study.
Setting and Sample
Setting
The parent study was conducted in a large sized midsouth university with an
affiliated transplant institute that has been performing kidney transplants for over 40
years. Demographic characteristics of the 120 to 130 individuals receiving kidney
transplants each year in this institute was reflective of the regional population. The
immediate urban area surrounding the transplant institute was predominately of African
Americans descent, many of whom resided in lower socioeconomic communities. The
transplant institute also provided services to individuals located in rural communities and
other urban cities in the region and across the country. Data from 2016 to the present
indicated demographic characteristics of kidney transplant recipients at this center had
remained relatively stable with 27.7 to 28.4% being Whites, and 69.1 to 69.6% African
Americans; 1.6 to 1.9 % Hispanics, 1.6 to 1.0% Asians; 2.8 to 65.6% were males and
47.1 to 34.3% were females; 12.1 to 10.7% were 8-34 years, 34.9 to 28.4% were 5-49
years, 44.4 to 46% were 0-64 years, and 11.3 to 14.7% were 65+. This study, although
reflective of the population served, had a higher proportion of African American patients
receiving transplants than do other high-volume centers.
Sample
The parent study (Cashion et al., 2014) included 96 post-kidney transplant
recipients who were 18 years or older; 42.71% were females and 57.9% males. By
ethnicity, 53.12% were Non-Hispanic and 2.08% Hispanic. By race, 65% were African
Americans, 31% were Whites, and 4% were other. Of the 96 participants in the parent
study, 45 patients received DXA scans at the transplant baseline time-point and 54
received a scan at 1 year. Because additional study participants received DXA scans at
the 1 year following posttransplant, all 96 participants of the parent study were screened
for eligibility for the follow-up study.
Inclusion Criteria
Participants in the parent study who had a DXA during the peritransplant and/or 1
year after kidney posttransplant were included in this study.
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Exclusion Criteria
•
•
•

Current hospitalization.
Loss of the transplanted graft.
Receipt of steroid therapy prior to the time of transplantation to control for the
effect of steroid use on baseline weight.
Instrumentation

In the current study, empirical data were obtained using a) anthropometric
assessment, (b) body composition assessment, and (c) physiological assessment.
Anthropometric Assessment
Anthropometric assessments included measurement of Body Mass Index (BMI),
Body Weight (BW), and Waist Circumference (WC). These measures are defined as
follows:
•

Body Mass Index (BMI) measures weight and height by calculating
weight in kilogram (kg) divided in height in meter squared (m2)
(Caballero, 2014).

•

Body Weight (BW) measures human body total mass in kilograms or
pounds.

•

Waist Circumference (WC) measures the central abdominal area.

Height, weight, and waist measurements were obtained from each participant by
the principal investigator. Each participant was required to remove shoes and bulky outer
garments before height and weight were measured. Height was obtained using a wallmounted scale and measured to the nearest centimeter. A calibrated balance scale was
used to assess each participant’s weight in kilograms. BMI was calculated using each
participant’s weight in kilograms divided by the height in meters squared (Antillon &
Towfighi, 2011; Beckmann et al., 2015; Caballero, 2014; Ghoorah et al., 2016; WHO,
2018). A tape measure was used to measure each participant’s WC by holding the end of
the tape measure at the participant’s navel and then bringing it around the participant’s
waist and back to the front.
Body Composition Assessment
The DXA scan was performed by a DXA-certified research nurse to measure the
distribution of fat and lean mass in various compartments of the body. Specifically, the
android and gynoid ratio quantifies the adipose tissues that accumulate in the abdominal
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region and around the hips, total body mass percentage (total body mass minus bone and
fat), and the amount of fat tissue located deep in the abdomen and around the internal
organs (Heyward & Wagner, 2004), as follows:
•

Android/Gynoid Ratio: Android fat is the amount of fat between the
bottom of an individual’s head and the top of the iliac crest in the lowest
20% region. Gynoid fat is the amount of fat located downward from the
android region and from the top of the greater trochanter. It is derived
from % fat in the android region divided by % fat in the gynoid region.

•

Android Fat Mass (AFM) is the amount of adipose tissue in the
abdominal area and below the individual’s head. It is derived from the
fat tissue in the android region (grams).

•

Gynoid Fat Mass (GFM) is the amount of fat in the lower portion of an
individual’s body around the hip area. It is derived from the fat tissue in
the gynoid region (grams).

•

Total Fat Mass (TFM) is the fat mass in grams (android + gynoid
regions). It is derived from the standard deviation value.

•

Lean Mass (LM) is the total body mass less the bones and fat in an
individual’s body total lean mass (android + gynoid area). It is derived
from the lean standard deviation value.

•

Percentage of Body Fat (%BF) is an individual’s total amount of fat
divided by total body weight percent fat (android + gynoid regions).

•

Visceral Adipose Tissue (VAT) is the amount of fat tissue surrounding
an individual’s organs that impacts a wide variety of clinical risks
(Bergman et al., 2006). VAT is a valid predictor of cardiometabolic risk
factors and the study found that DXA clinical thresholds were validated
in White men (154cm2) and women (143cm2) compared to African
American men (101cm2) and women (114 cm2). VAT is derived from
fat tissue in the largest visceral fat region in grams (Heyward & Wagner,
2004).

Physiological Assessment
The blood collection for glucose, total cholesterol, LDL-cholesterol, HDLcholesterol, and triglycerides was performed in the clinical research center by a registered
nurse at no cost to participants. Forty cubic centimeters (about 3 tablespoon) was
collected from each participant in a BD vacutainer SST tube for serum determination in
ethylenediaminetetraacetic acid (EDTA) tubes for anticoagulation. Each tube was
inverted after the blood samples were collected to prevent clotting. The blood samples
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were stored on ice for no more than two hours before blood sample centrifugation. The
plasma and serum were separated into cryotubes and stored at -80 °C until processed.
Table 3-1 summarizes the normal value of the blood samples in the physiological
assessment.
Method and Subjects
Prior to research, approval from the university Institutional Review Board (IRB)
was obtained (IRB Approval Supplement) as well as approval of the parent study by the
principal investigator. Potential study participants were identified from the parent study
database; those who met inclusion criteria (n = 96) were contacted by phone, the followup study described, and the opportunity for them to participate in the study offered.
Twenty-one out of the 96 transplant patients were excluded from the study due to loss of
graft functions or death (n = 45), two participants declined, and those expressing interest
in the study were scheduled to meet with the Principal Investigator at the General Clinical
Research Center (GCRC). Appointments were coordinated with an upcoming routine
clinic appointment, or another time at the potential study participant’s convenience. The
GCRC was located in the same building, just a few floors above the transplant clinic;
research staff met potential participants in the transplant clinic and escorted them to the
GCRC, if needed.
After greeting the potential study participant, the research staff described the
study again in detail and reviewed the consent page by page. Questions were solicited,
and the potential participants understood their participation in the study was voluntary
and that no additional appointments were required. Each potential participant was assured
they had the right to opt out of the study at any time and that such a decision would not
affect their current or future medical treatment. Additionally, each person was informed
that there would be no cost to them for the study procedures, including the DXA scan and
blood studies, and that the results of these tests would be shared with them per request.
After the 45 participants signed the participant-informed consent (Participant
Informed Consent Supplement), health records were reviewed as electronic medical
records. The data retrieved from the parent study participants were laboratory values, BP,
height, weight, and previous DXA scans. If a participant was a female of childbearing
age, a urinary pregnancy test was performed prior to the scan.
During the single clinical visit, 40 cubic centimeters (about 3 tablespoons) of
blood was drawn from each participant followed by a Whole-Body DXA scan using a
DXA scanner die body composition estimate (Hologic QDR 4500A, software version
4.5.2.1, Bedford, MA). DXA equipment has set values for the fat standard deviation
value, which is 68, and the standard deviation value for lean tissue, which is always -10.
The calibration for this software estimate was the %fat 3-4% higher than the Classic
software and underestimates that FM compared to the criterion methods in adults
(Schoeller et al., 2005).
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Table 3-1

Normal Value of the Blood Sample

Blood Sample
Glucose
Hemoglobin A1C
Total Cholesterol
LDL-Cholesterol
HDL-Cholesterol

Normal Value in mg/dl
65-100 mg/dl
4.6-5.6 %
< 200 mg/dl
< 100 mg/dl
males > 40 mg/dl and females > 50
mg/dl
< 150 mg/dl

Triglycerides
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FATMassNHANES = FATMassClassic + 0.054  LeanSoftTissueMassClassic
LeanSoftTissueMassNHANES = TotalMass − BMC − FATMassNHANES
According to Wang et al. (1992), FFM (in kg) was calculated as the difference between
body weight (W, in kg) and body fat mass measured by the four-component model as the
criterion, independent of gender, race, and age.

Each DXA scan was performed by a DXA-certified research nurse.
Upon completion of study procedures, participants were given a $30 Visa or
Walmart gift card in honor of their time and effort, and to help defray and costs (e.g.,
parking, meals) associated with their participation in the study.
Data Analysis
An initial descriptive analysis was conducted to review measures of central
tendency and assure assumptions regarding adequate variability and normality were met.
Because all research questions sought to determine whether relationships existed among
various measures of body mass and cardiac risk factors, Pearson Product Moment or
Spearman Rho correlation coefficients were determined and used to address all the
research questions.
Statistical Assumptions
There are three statistical assumptions for the Pearson Moment Correlation
Coefficient:
1. Independent observations between the participants. The scores for each
participant should be independent of all other participants’ scores.
2. The X scores should be continuous.
3. Bivariate normality for scores on X and Y. Each participant’s scores on Y should
be normally distributed in the population X and Y should be normally distributed
in the population among the X scores.
SAS 9.6 version was used for the data analysis with a-priori p-values set at 0.05.
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Summary
This chapter described the methods to address the aims of the study and research
questions, including the research design, setting and sample, inclusion and exclusion
criteria, and the data collection procedures. The analyses used to address the research
questions were described along with statistical assumptions. Results of these analyses are
presented in Chapter 4.
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CHAPTER 4.

RESULTS

Description of the Sample
The study sample consisted of 45 participants (see Table 4-1); 29 (64.4%) were
African American and 16 (35.6%) were White. There were 25 (55.6%) males and 20
(44.4%) females. The age of the sample, at 5 years or longer years posttransplant followup, ranged in age from 37 to 78 with a mean of 56 (SD =10.1) in Table 4-2.
Anthropometric and cardiac-related outcome measures of study participants obtained at
the time of transplant and 5 years or more follow-up are presented in Table 4-3 below
followed by measures of body composition components at the same measurement points
in Table 4-4.
Descriptive Findings
Tables 4-3 to 4-5 show the descriptive statistics for lab values (creatinine,
glucose, Hgb A1C, triglyceride, HDL, LDL, and coronary risk ratio), elevated blood
pressure (systolic and diastolic), BC (VFAT, AFM, GFM, A/G ratio, LM, FM, and %BF)
and anthropometric (BMI, weight, and waist circumference) measurements.
Correlation Findings
Research Question 1
Research Question 1 asked, What is the association between anthropometric
measures and serum glucose, lipid, and creatinine levels and elevated blood pressure in
kidney transplant patients obtained five to eight years posttransplant? Findings that
address this question are shown in Table 4-6, which reports the correlational analyses of
cardiac-related outcomes and anthropometric measures of BMI, weight, and WC at 5-8
years post-kidney transplant. A significant relationship exists with coronary risk ratio and
waist circumference (r = 0.33; p = 0.05) and with diastolic BP and weight (r = 0.28; p =
0.06). Relationships reaching levels of significance (p ≤ 0.20) that warrant continued
consideration in fully powered studies include weight and HDL (r = -0.26; p = 0.09),
LDL (r = -0.22; p = 0.16), and coronary Risk Ratio (r = -0.28; p = 0.09) as well as waist
circumference and diastolic BP (r = 0.30; p = 0.07), and BMI and LDL (r = -0.21; p =
0.18). These correlations are considered to be weak in strength and positive in direction
(Sheskin, 2011). This means that as coronary risk ratio increases so does BMI, weight,
and WC. As weight increases so does diastolic BP, HDL, LDL and coronary risk ratio.
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Table 4-1.

Demographic Characteristics
Variables
Race
White
African-American
Gender
Male
Female

Table 4-2.

Total Sample n (%)
16 (35.6%)
29 (64.4%)
25 (55.6%)
20 (44.4%)

Age of the Participants

N
45

M ± SD
56.5 ± 10.1

Min
37

Max
78

Table 4-3.
Anthropometric and Cardiac-Related Outcome Measures at 5-8
Years Post-Kidney Transplantation
Variables
Anthropometric
BMI
Weight
Waist reading

M ± SD

Min

Max

32.14 ± 9.62
197.89 ± 48.15
41.39 ± 7.12

16.21
89.80
23.75

55.95
305.80
54.00

Blood Constituents
Creatinine
Glucose
Hgb AIC
Triglyceride
HDL
LDL
Coronary risk ratio
Systolic BP
Diastolic BP

1.65 ± 0.85
142.41 ± 91.38
6.93 ± 2.22
178.40 ± 119.38
52.71 ± 16.85
92.30 ± 36.57
3.78 ± 1.31
134.42 ± 17.85
78.80 ± 8.47

0.84
54.00
5.00
38.00
25.00
3.85
2.10
99.00
59.00

5.65
574.00
16.40
665.00
96.00
184.00
8.68
181.00
98.00

Note. BMI = body mass index; Hgb = Hemoglobin; HDL = high density lipoprotein;
LDL = low density lipoprotein; BP = blood pressure.
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Table 4-4.
Anthropometric, Body Composition, and Cardiac-Related Outcome Measures at Time of Transplant and at 5-8
Years Post-Kidney Transplantation
Variables
Anthropometric
BMI
Weight
Body Composition
Total Fat
Total Lean
Total Mass
Total PFat
Android Fat
Android Lean
Android Mass
Android PFat
Android/ Gynoid Ratio
Android Percent Fat
Gynoid Fat
Gynoid Lean
Gynoid Mass
Gynoid PFat
VFat Body Fat
VFat Body Lean
VFat Body Mass
VFat Body PFat
Total Fat Mass
Fat Mass Ratio
Total Whole Body Fat
Total Whole Body Lean
Total Whole Body Mass
Total Whole Body PFat

At Time of Transplant
M ± SD
Min
Max

M ± SD

5-8 Years Posttransplant
Min
Max

29.03 ± 4.76
186.66 ± 42.10

19.91
112.4

42.24
277.7

32.14 ± 9.61
197.89 ± 48.1

16.21
89.8

55.94
305.80

7334 ± 2372
12238 ± 2998
19572 ± 4558
37.12 ± 7.76
2726 ± 1101
4440 ± 1266
7166 ± 2052
37.21 ± 8.88
1.01 ± 0.16
36.73 ± 9.22
4607 ± 1440
7797 ± 1828
12405 ± 2674
36.90 ± 7.94
1428 ± 608.45
2555 ± 579.06
3983 ± 998.67
34.71 ± 9.32
29590 ± 9877
1.03 ± 0.15
28508 ± 9545
55024 ± 13063
83531 ± 18689
33.90 ± 8.12

2351
6872
10731
18.17
826.79
2376
3879
17.47
0.71
17.47
1524
4208
6852
18.54
340.28
1400
2243
13.02
10301
0.70
7480
32189
47975
12.07

12099
19647
27897
51.42
5215
8356
11958
54.49
1.38
54.49
7623
11291
16796
53.88
2831
4308
5813
51.73
48639
1.40
48639
78965
120691
48.58

8535 ± 3377
12199 ± 3413
20733 ± 6166
40.19 ± 8.10
3399 ± 1676
4301 ± 1289
7700 ± 2693
42.14 ± 10.53
1.08 ± 0.21
42.14 ± 10.52
5136 ± 1878
7898 ± 2207
13034 ± 3626
38.81 ± 7.72
1833 ± 876.70
2563 ± 595.90
4396 ± 1305
39.61 ± 11.16
35287 ± 1587
1.09 ± 0.201
35151 ± 13362
54514 ± 13901
89665 ± 23949
38.40 ± 8.41

2002
6353
9051
20.31
462.30
2213
3002
15.40
0.6047
15.39
1540
4140
6044
22.6
206.24
1260
1638
10.29
8121
0.73
8121
28387
40816
19.02

16522
19120
34147
52.80
6823
7348
13130
56.06
1.55
56.06
9860
12035
21895
52.91
3411
3909
6690
53.81
58531
1.534
58531
81653
135562
51.19
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Table 4-4.

Continued

Note. M = mean; SD = standard deviation; Min = minimum; Max = maximum; BMI = body mass index; PFat = percent fat; VFat =
visceral fat.
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Table 4-5.
Changes in Anthropometric and Body Composition Measures from
Baseline to 5-8 Years Post-Kidney Transplantation
Variables
Anthropometric
Weight Change
BMI Change
DXA Composition
Total Fat
Total Lean
Total Mass
Total PFat
Android Fat
Android Lean
Android Mass
Android PFat
Android Gynoid Ratio
Android Percent Fat
Gynoid Fat
Gynoid Lean
Gynoid Mass
Gynoid PFat
VFat Body Fat
VFat Body Lean
VFat Body Mass
VFat Body PFat
Total Fat Mass
Fat Mass Ratio
Total WB Fat Change
Total WB Lean Change
Total WB Mass Change
Total WB PFat Change

M ± SD

Min

11.20 ± 34.33
3.05 ± 7.99
1201 ± 2670
-39.26 ± 1795
1162 ± 3735
3.07 ± 8.13
672.63 ± 1317
-138.60 ± 782.80
534.0 ± 1705
4.93 ± 10.47
0.080 ± 0.15
5.411 ± 9.981
528.9 ± 1440
100.20 ± 1107
629.10 ± 213
1.90 ± 7.19
405.28 ± 704.25
7.86 ± 323.7
413.15 ± 799.02
4.900± 11.36
56961 ± 9325
0.065 ± 0.116
6644 ± 16424
-509.79 ± 19193
4.50 ± 10.31
6134 ± 32149

Max

-94.90
-10.08

85.34
21.35

-7908
-4567
-10224
-29.29
-2743
-2162
-4886
-31.51
-0.411
-31.51
-5165
-2434
-6395
-28.42
-1696
-595.42
-1914
-34.25
-2537
-0.247
-29458
-40183
-21.75
-66194

6243
4081
9669
15.25
3516
2222
4794
21.73
0.312
21.73
3139
2803
5412
13.80
1537
809.75
2072
23.10
22788
0.267
36866
38939
22.33
71662

Note. M = mean; SD = standard deviation; Min = minimum; Max = maximum; PFat =
percent fat; VFat = visceral fat; BMI = body mass index; WB= whole body.
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Table 4-6.
Relationship Among Cardiac-Related Outcomes and Anthropometric
Measures at 5-8 Years Post-Kidney Transplantation.
Variable
Creatinine
Glucose
Hgb-AIC
Triglyceride
HDL
LDL
Coronary Risk Ratio
Systolic BP
Diastolic BP

BMI
r (p value)*
0.11 (0.44)
0.04 (0.98)
0.04 (0.81)
0.05 (0.73)
-0.25 (0.10)
-0.21 (0.18)
0.27 (0.07)
0.05(0.74)
0.22 (0.15)

Weight
r (p value)*
-0.02 (0.88)
0.46(0.80)
0.10 (0.50)
0.009 (1.00)
-0.26 (0.09)
-0.22 (0.16)
0.28 (0.09)
0.15 (0.49)
0.28 (0.06)

Waist Circumference
r (p value)*
-012(0.49)
0.12(0.47)
0.13(0.45)
0.15(0.36)
-0.19(0.26)
-0.15(0.39)
0.33(0.05)
-0.087(0.60)
0.30 (0.07)

Note. *Pearson Correlation Coefficients: Prob > [r] under Ho: Rho=0
BMI = body mass index; Hgb = hemoglobin; HDL = high density lipoprotein; LDL =
low density lipoprotein; BP = blood pressure; r = correlation coefficient; p value ≤ 0.05
and ≤ 0.20.
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Research Question 2
Research Question 2 asked, What is the association between body composition
measures and serum glucose, lipid, and creatinine levels and elevated blood pressure
obtained in kidney transplant recipients 5-8 years posttransplant? Findings that address
this question are shown in Tables 4-7 to 4-12, which report the correlational analyses of
cardiac-related outcomes and BC measures by DXA at 5-8 years post-kidney transplant.
The relationship with creatinine and total fat (r = -0.30; p = 0.02), creatinine and
total percent fat (r = -0.42; p = 0.004), HDL and total lean (r = -0.40; p = 0.01), and HDL
and total mass (r = -0.16; p = 0.01) are inversely related (Table 4-7). Relationships
reaching levels of significance (p ≤ 0.20) that warrant continued consideration in fully
powered studies include HDL and total fat (r = -0.30; p = 0.09), LDL and total lean (r = 21; p = 0.18), coronary risk ratio and total lean (r = 0.27; p = 0.075), coronary risk ratio
and total mass (r = 0.26; p = 0.09), systolic and total percent fat (r = -022; p = 0.15),
diastolic and total mass (r = 0.24; p = 0.12), and diastolic and total percent fat (r = 0.25; p
= 0.10). These correlations are considered to be weak to moderate in strength. Some are
negative, and some are positive in direction (Sheskin, 2011). As total fat and total
percentage of fat go up, creatinine goes down and when total lean and total mass go up,
HDL goes down. For relationships reaching levels of significance (p ≤ 0.20) that warrant
continued consideration in fully powered studies, these correlations are also weak in
strength. As total fat increases, HDL goes down. As total lean increases, LDL decreases
while coronary risk ratio increases. As total mass increases so do coronary risk ratio and
diastolic blood pressure. As total percentage of fat increases so does diastolic pressure
while systolic blood pressure decreases.
Table 4-8 demonstrates a significant inverse relationship between creatinine and
android percentage fat with (r = -0.45; p = 0.001), HDL and android fat (r = -0.32; p =
0.03). A significant relationship exists with coronary risk ratio and android lean (r = 0.38;
p = 0.01) and coronary risk ratio and android mass (r = 0.35; p = 0.02), and systolic blood
pressure and android percent fat (r = -0.30; p = 0.05). Relationships reaching levels of
significance (p ≤ 0.20) that warrant continued consideration in fully powered studies
include creatinine and android fat (r = -0.27; p = 0.07), Hgb A1C and android fat (r =
0.21; p = 0.18), coronary risk ratio and android fat (r = 0.27; p = 0.07), diastolic and
android fat (r = 0.23; p = 0.13), diastolic and android mass (r = 0.22; p = 0.14), and
diastolic and android percent fat (r = 0.24; p = 0.10). HDL and android lean (r = -0.40; p
= 0.006), and HDL and android mass (r = -0.39; p = 0.008) are inversely related. These
correlations are considered to be weak in strength. Some are negative, and some are
positive in direction (Sheskin, 2011). As android fat goes up, creatinine goes down and
when android fat percentage goes up HDL goes down. As coronary risk ratio goes up so
do android mass and android lean. For, relationships reaching levels of significance (p ≤
0.20) that warrant continued consideration in fully powered studies, these correlations are
also weak in strength. As android fat increases, creatinine goes down; while Hgb A1C
goes up. Coronary risk ratio increases as android fat increases. Diastolic blood pressure
goes up with android mass and android percent fat.
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Table 4-7.
Relationship Among Cardiac-Related Outcomes and Body
Composition Measures of Total Fat, Total Lean, Total Mass, and Total Percent Fat
at 5-8 Years Post-Kidney Transplantation
Variables
Creatinine
Glucose
Hgb AIC
Triglyceride
HDL
LDL
Coronary risk
ratio
Systolic BP
Diastolic BP

Total Fat
r (p value)*
-0.30(0.05)
0.13(0.40)
0.19(0.22)
0.03(0.87)
-0.30(0.09)
-0.08(0.61)
0.19(0.22)

Total Leanr (p value)*
0.06(0.69)
0.08(0.59)
0.12(0.44)
0.02(0.88)
-0.40(0.01)
-0.21(0.18)
0.27(0.08)

Total Massr (p value)*
-0.13(0.42)
0.12(0.44)
0.17(0.27)
0.03(0.86)
-0.36(0.01)
-0.16(0.31)
0.26(0.09)

Total PFatr (p value)*
-0.42(0.004)
0.13(0.40)
0.12(0.43)
0.04(0.78)
-0.01(0.93)
0.16 (0.32)
0.07(0.67)

-0.13(0.40)
0.27(0.78)

0.08(0.59)
0.167(0.27)

-0.02(0.87)
0.24(0.12)

-0.22(0.15)
0.25(0.10)

Note. *Pearson Correlation Coefficients: Prob > [r] under Ho: Rho=0; Hgb =
hemoglobin; HDL = high density lipoprotein; LDL = low density lipoprotein; BP = blood
pressure; PFat = percent fat; r = correlation coefficient; p value ≤ 0.05 and ≤ 0.20.

Table 4-8.
Relationship Among Cardiac-Related Outcomes and Body
Composition Measures of Android Fat, Android Lean, Android Mass, and Android
Percent Fat at 5-8 Years Post-Kidney Transplantation
Variables
Creatinine
Glucose
Hgb A1C
Triglyceride
HDL
LDL
Coronary risk ratio
Systolic BP
Diastolic BP

Android
Fat
r (p value)*
-0.27(0.07)
0.16 (0.31)
0.21(0.18)
0.11(048)
-0.32(0.03)
-0.14(0.37)
0.27 (0.07)
-0.16 (0.28)
0.23 (0.13)

Android
Lean
r (p value)*
0.12 (0.43)
0.10 (0.64)
0.10 (0.51)
0.15(0.32)
-0.40(0.006)
-0.18(0.25)
0.38(0.01)
0.14(0.34)
0.16 (0.29)

Android
Mass
r (p value)*
-0.11 (0.48)
0.15(0.34)
0.18 (0.25)
0.14 (0.36)
-0.39(0.008)
-0.17(0.27)
0.35(0.02)
-0.03(0.87)
0.22(0.14)

Android
PFat
r (p value)*
-0.45(0.001)
0.15(0.33)
0.16(0.30)
0.09(0.55)
-0.14(0.37)
0.09(0.60)
0.15(0.29)
-0.30 (0.05)
0.24(0.10)

Note. *Pearson Correlation Coefficients: Prob > [r] under Ho: Rho=0; Hgb =
hemoglobin; HDL = high density lipoprotein; LDL = low density lipoprotein; BP = blood
pressure; PFat = percent fat; r = correlation coefficient; p value ≤ 0.05 and ≤ 0.20.

62

Table 4-9.
Relationship Among Android Gynoid Ratio and Cardiac-Related
Outcomes at 5-8 Years Post-Kidney Ttransplantation
Variables
Creatinine
Glucose
Hgb A1C
Triglyceride
HDL
LDL
Coronary risk ratio
Systolic BP
Diastolic BP

Android Gynoid Ratio
r (p value)**
-0.28(0.06)
0.13(0.39)
0.14(0.38)
0.09(0.56)
-0.27(0.07)
-0.06(0.71)
0.21(0.71)
-0.29(0.05)
0.12 (0.5)

Note. **Pearson Correlation Coefficients: Prob > [r] under Ho: Rho=0; Hgb A1C =
hemoglobin A1C; HDL = high density lipoprotein; LDL = low density lipoprotein; BP =
blood pressure; r = correlation coefficient; p value ≤ 0.05 and ≤ 0.20.

Table 4-10. Relationship Among Cardiac-Related Outcome and Body
Composition Measures of Gynoid Fat, Gynoid Lean, Gynoid Mass, and Gynoid
Percent Fat at 5-8 Years Post-Kidney Transplantation
Variables
Creatinine
Glucose
Hgb A1C
Triglyceride
HDL
LDL
Coronary
risk ratio
Systolic BP
Diastolic BP

Gynoid Fat
r (p value)*
-0.28(0.06)
0.09(0.55)
0.15(0.32)
-0.05(0.74)
-0.18(0.24)
-0.02(0.91)
0.10(0.52)

Gynoid Lean
r (p value)*
0.02(0.88)
0.07(0.65)
0.13(0.41)
-0.06(0.72)
-0.38(0.10)
-0.22(0.16)
0.20(0.20)

-0.09(0.58)
0.27(0.07)

0.04(0.77)
0.16(0.28)

Gynoid Mass
r (p value)*
-0.13(0.39)
0.09(0.56)
0.16(0.31)
-0.06(0.69)
-0.32(0.03)
-0.14(0.36)
0.17(0.26)
-0.02(0.91)
0.24 (0.11)

Gynoid PFat
p value)*
-0.34(0.02)
0.09(0.54)
0.08(0.62)
-0.02(0.92)
0.09(0.54)
0.20(0.20)
- 0.003(0.98)
-0.12(0.42)
0.23(0.14)

Note. *Pearson Correlation Coefficients: Prob > [r] under Ho: Rho=0;Hgb = hemoglobin;
HDL = high density lipoprotein; LDL = low density lipoprotein; PFat = percent fat; BP =
blood pressure; r = correlation coefficient; p value ≤ 0.05 and ≤ 0.20.
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Table 4-11. Relationship Among Cardiac-Related Outcome and Body
Composition Measures of VFat, VBody Lean, VBody Mass, and VPercent Fat at 5-8
Years Post-Kidney Transplantation
Variables

VFat
r (p value)*

CreatinineGlucose
Hgb A1C
Triglyceride
HDL
LDL
Coronary risk ratio
Systolic BP
Diastolic BP

-0.30(0.05)
0.16(0.30)
0.18(0.23)
0.07(0.64)
-0.28(0.07)
-0.09(0.58)
0.23(0.13)
-0.19(0.21)
0.26(0.09)

VFat Body
Lean
r (p value)*
0.20(0.20)
0.15(0.33)
0.10 (0.50)
0.15 (0.33)
-0.37(0.02)
-0.19(0.38)
0.37 (0.01)
0.17(0.26)
0.19 (0.21)

VFat Body
Mass
r (p value)*
-0.17(0.49)
0.18(0.25)
0.17(0.27)
0.12(0.44)
-0.34(0.02)
-0.12(0.45)
0.32(0.03)
-0.05(0.74)
0.26(0.09)

VFat Body
PFat
r (p value)*
-0.47(0.001)
0.15(0.34)
0.15(0.33)
0.06(0.72)
-0.15(0.33)
0.09 (0.55)
0.15 (0.34)
-0.29 (0.05)
0.26(0.09)

Note. *Pearson Correlation Coefficients: Prob > [r] under Ho: Rho=0;Hgb = hemoglobin;
HDL = high density lipoprotein; LDL = low density lipoprotein; VFat = visceral fat; BP
= blood pressure; PFat = percent fat; r = correlation coefficient; p value ≤ 0.05 and ≤
0.20.
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Table 4-12. Relationship Among Cardiac-Related Outcomes and Body
Composition Measures of Whole Body Total Fat, Whole Body Total Lean, Whole
Body Total Mass, and Whole Body Total Percent Fat at 5-8 Years Post-Kidney
Transplantation
Variables
Creatinine
Glucose
Hgb AIC
Triglyceride
HDL
LDL
Coronary risk ratio
Systolic BP
Diastolic BP

WBTotal Fat
r (p value)*
-0.24(0.11)
-0.28(0.07)
-0.27(0.08 )
0.11 (0.48)
0.16(0.31)
-0.13(0.44 )
-0.04( 0.81)
-0.27(0.07)
-0.23(0.16)

WBTotal
Leanr (p value)*
-0.05 (0.76 )
-0.11(0.49)
-0.11(0.46)
0.15(0.33 )
0.12(0.44)
-0.06(0.69)
0.02(0.88)
-0.43(<0.001)
-0.20(0.20)

WBTotal
Massr (p value)*
-0.16 (0.28)
-0.22(0.15)
-0.22(0.16)
0.15(0.33)
0.15(0.44)
-0.11(0.49)
-0.01(0.97)
-0.40( 0.01)
-0.24( 0.11)

WBTotal
PFatr (p value)*
-0.26(0.08)
-0.26(0.09)
-0.23(0.14)
0.01(0.92)
0.04(0.80)
-0.14(0.39)
-0.06( 0.68)
-0.08(0.61)
-0.15(0.32)

Note. WB= Whole-body; Hgb = hemoglobin; HDL = high density lipoprotein; LDL =l
density lipoprotein; PFat = percent fat; BP = blood pressure; r = correlation coefficient; p
value ≤ 0.05 and ≤ 0.20.
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An inverse relationship with significance exists with systolic BP and android
gynoid ratio (r = -0.29; p = 0.05). The relationships between glucose and Hgb A1C (r =
0.91; p = 0.001) and triglyceride and Hgb A1C (r = 0.225; p = 0.137) are both significant
(Table 4-9). Relationships reaching levels of significance (p ≤ 0.20) that warrant
continued consideration in fully powered studies include creatinine and android gynoid
ratio (r = -0.28; p = 0.06) and HDL and android gynoid ratio (r = -0.27; p = 0.07). These
correlations are considered weak to strong in strength and some are negative, and some
are positive in direction (Sheskin, 2011). As the android gynoid ratio increases, systolic
blood pressure decreases. For relationships reaching levels of significance (p ≤ 0.20), as
android gynoid ratio increases, creatinine and HDL decrease.
Table 4-10 demonstrates a significant relationship with an inverse relationship
existing with creatinine and gynoid percent fat (r = -0.34; p = 0.02) and HDL and gynoid
mass (r = -0.32; p = 0.03), which are presented in Table 4-10. Relationships reaching
levels of significance (p ≤ 0.09) that warrant continued consideration in fully powered
studies include creatinine and gynoid fat (r = -0.28; p = 0.06), and diastolic and gynoid
fat (r = 0.27; p = 0.07).
Table 4-11 demonstrates a significant relationship with coronary risk ratio and
visceral fat body lean (r = 0.37; p = 0.01), and coronary risk ratio and visceral fat body
mass (r = 0.32; p = 0.03). An inverse relationship exists with creatinine and visceral fat (r
= -0.30; p = 0.05), HDL and visceral fat body lean (r = -0.34; p = 0.02), HDL and
visceral fat body mass (r = -0.34; p = 0.02), and systolic pressure and visceral fat body
percent fat (r = -0.29; p = 0.05). Relationships reaching levels of significance (p ≤ 0.20)
that warrant continued consideration in fully powered studies include creatinine and
visceral fat body lean (r = 0.20; p = 0.20), HDL and visceral fat (r = -0.28; p = 0.07),
coronary risk ratio (r = 0.23; p = 0.13), diastolic and visceral fat (r = 0.26; p = 0.09),
diastolic BP and visceral fat body mass (r = 0.26; p = 0.09), and diastolic BP and visceral
fat body percent fat (r = 0.26; p = 0.09). These correlations were weak in strength. For
relationships reaching levels of significance (p ≤ 0.20), as visceral fat body lean
increases, so does creatinine. As visceral fat increases HDL decreases and coronary risk
ratio and diastolic BP increase. Diastolic pressure also increases as visceral fat body mass
and visceral fat body percent increase. These correlations are considered to be weak in
strength and are positive (Sheskin, 2011).
The relationships with WB total lean and systolic BP (r = -0.43; p = <0.001) and
WB total mass and systolic BP (r =-0.40; p = 0.01) are inversely related (Table 4-12). In
addition, an inverse relationship reaching significance of (p ≤ 0.20) was found with
systolic and WB total fat (r = -0.27; p = (0.07). An inverse relationship with creatinine
and WB total fat (r = -0.24; p = 0.11), creatinine and WB total PFat (r = -0.26; p = 0.08);
and glucose and WB total fat (r = -0.28; p = 0.07), glucose and WB total mass (r = -.022;
p = 0.15), and glucose and WB total PFat (r = -0.26; p = 0.09. These correlations are
considered to be weak in strength and negative in direction. As systolic BP increases, WB
total lean, WB total mass, and WB total fat decrease. For relationships reaching levels of
significance (p ≤ 0.20) that warrant continued consideration in fully powered studies,
these correlations are considered weak in strength and negative in direction. An inverse
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relationship with HgbA1C and WB total fat (r =-0.27; p = 0.08); HgbA1C and WB total
mass (r =-0.22; p = 0.16); and HgbA1c and WB total PFat (r = -0.23; p = 0.14); diastolic
BP and WB total fat (r = -0.23; p = 0.16), diastolic BP and WB total lean (r=-0.20; p =
0.20); diastolic BP and WB total mass (r=-0.24; p = 0.11). As WB total fat and WB total
PFat go up, the creatinine and glucose levels go down. The glucose level also goes down
when WB total mass goes up. As diastolic BP and HgbA1C go up, WB total fat and WB
total pfat go down. Diastolic BP also goes down when WB total lean values increase. As
HgbA1c decreases, so does WB total mass.
Research Question 3
Research Question 3 asked, To what degree are body composition measures
obtained at the time of transplant associated with serum levels of glucose, lipids, and
creatinine and elevated blood pressure in kidney transplant recipients at 5 to 8 years
posttransplant? Tables 4-13 to 4-18 report the correlational analyses of cardiac-related
outcomes and BC measures at time of transplant is associated with recipients at 5-8 years
post-kidney transplant.
An inverse relationship with significance was found with HDL and total fat (r = 0.34; p = 0.02), HDL and total lean (r = -0.50; p = <0.001), and HDL and total mass (r =
-0.51; p = 0.0004). A significant relationship exists with coronary risk ratio and total lean
(r = 0.42; p = 0.004) and coronary risk ratio and total percent fat (r = 0.38; p = 0.01)
(Table 4-13). Relationships reaching levels of significance (p ≤ 0.20) that warrant
continued consideration in fully powered studies include glucose and total fat (r = 0.20; p
= 0.18), LDL and total fat (r = -0.20; p = 0.20), and coronary risk ratio (r = 0.25; p =
0.24). Relationships reaching levels of significance (p ≤ 0.20) that warrant continued
consideration in fully powered studies include as glucose levels increase so does total fat,
and as LDL increases, so does total fat.
A significant relationship was found with triglyceride and android lean (r = 0.30;
p = 0.050), coronary risk ratio and android fat (r = 0.32; p = 0.03), and coronary risk ratio
and android mass (r = 0.47; p = 0.001). An inverse relationship exists with HDL and
android fat (r = -0.46; p = 0.001), HDL and android lean (r = -0.45; p = 0.002) and HDL
and android mass (r = -0.53; p = <0.001); Table 4-14). Relationships reaching levels of
significance (p ≤ 0.20) that warrant continued consideration in fully powered studies
include glucose and android fat (r = 0.24; p = 0.12), Hgb A1C and android fat (r = 0.21; p
= 0.16), and triglyceride and android mass (r = 0.28; p = 0.07). The correlations range
from weak to moderate in strength. As android lean increases so do triglyceride levels;
coronary risk ratio increases with android fat, android, and android mass increases. HDL
decreases as android lean, fat, and mass increase. For relationships reaching levels of
significance (p ≤ 0.20), glucose and HgbA1C go up with android fat, and triglycerides go
up with android mass.
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Table 4-13. Relationship Among Cardiac-Related Outcomes at 5-8 Years PostKidney Transplantation and Body Composition Measures of Total Fat, Total Lean,
Total Mass, and Total Percent Fat Obtained at Time of Transplant
Variables
Creatinine
Glucose
Hgb A1C
Triglyceride
HDL
LDL
Coronary risk ratio
Systolic BP
Diastolic BP

Total Fatr (p value)
-0.03(0.86)
0.20(0.18)
0.19(0.21)
0.08(0.61)
-0.34(0.02)
-0.20(0.20)
0.25 (0.24)
0.05(0.76)
0.07(0.66)

Total Lean
r (p value)
0.11 (0.46)
0.11(0.48)
0.07(0.63)
0.18(0.24)
-0.50( <0.001)
0.01(0.95)
0.42(0.004)
0.08(0.61)
0.09(0.54)

Total Mass
r (p value)
0.061(0.69)
0.18(0.25)
0.01(0.33)
0.16 (0.29)
-0.51(0.0004)
-0.12(0.46)
0.38(0.01)
0.075(0.625)
0.096(0.528)

Total PFat
r (p value)
-0.13(0.39)
0.12(0.44)
0.11(0.46)
-0.03(0.86)
-0.01(0.96)
-0.16(0.30)
-0.09 (0.54)
-0.04(0.79)
-0.03(0.86)

Note. *Pearson Correlation Coefficients: Prob > [r] under Ho: Rho=0; Hgb =
hemoglobin; HDL = high density lipoprotein; LDL =l density lipoprotein; PFat = percent
fat; BP = blood pressure; r = correlation coefficient; p value ≤ 0.05 and ≤ 0.20.

Table 4-14. Relationships Among Cardiac-Related Outcomes at 5-8 Years PostKidney Transplantation and Body Composition Measures of Android Fat, Android
Lean, Android Mass, and Android Percent Fat Obtained at Time of Transplant
Variables
Creatinine
Glucose
Hgb A1C
Triglyceride
HDL
LDL
Coronary risk ratio
Systolic BP
Diastolic BP

Android Fat
r (p value)*
-0.01(0.97)
0.24(0.12)
0.21 (0.16)
0.17 (0.26)
-0.46 (0.001)
-0.19(0.23)
0.32(0.03)
0.03(0.82)
0.01(0.97)

Android Lean Android Mass
r (p value)*
r (p value)*
0.07(0.63)
0.04(0.78)
0.08(0.60)
0.18(0.25)
0.03(0.81)
0.14(0.38)
0.30(0.05)
0.30(0.07)
-0.45(0.002)
-0.53(<0.001)
-0.023(0.88)
-0.09(0.56)
0.32(0.008)
0.47(0.001)
0.07(0.64)
0.06(0.68)
0.023(0.88)
0.02(0.91)

Android PFat
r (p value)*
-0.09(0.58)
0.17(0.28)
0.16(0.30)
-0.10(0.51)
-0.19(0.22)
-0.16 (0.31)
-0.03(0.83)
-0.04(0.78)
-0.01(0.90)

Note. *Pearson Correlation Coefficients: Prob > [r] under Ho: Rho=0; Hgb =
hemoglobin; HDL = high density lipoprotein; LDL = low density lipoprotein; PFat =
percent fat; BP = blood pressure; r = correlation coefficient; p value ≤ 0.05 and ≤ 0.20.
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Table 4-15. Relationship Among Cardiac-Related Outcomes at 5-8 Years PostKidney Transplantation and Body Composition Measures of Gynoid Fat, Gynoid
Lean, Gynoid Mass, and Gynoid Percent Fat Obtained at Time of Transplant
Variables
Creatinine
Glucose
Hgb A1C
Triglyceride
HDL
LDL
Coronary risk ratio
Systolic BP
Diastolic BP

Gynoid Fat
r (p value)*
-0.04(0.79)
0.15(0.32)
0.16(0.31)
-0.002(1.0)
-0.21(0.18)
-0.19(0.23)
0.06(0.72)
0.05(0.74)
0.10(0.49)

Gynoid Lean
r (p value)*
0.14(0.38)
0.12(0.44)
0.094(0.54)
0.093(0.55)
-0.51<0.001)
-0.03(0.83)
0.36 (0.02)
0.08(0.62)
0.14 (0.36)

Gynoid Mass
r (p value)*
0.07(0.64)
0.17(0.28)
0.15(0.33)
0.06(0.68)
-0.46 (0.001)
-0.13(0.41)
0.28(0.07)
0.08(0.60)
0.15(0.32)

Gynoid PFat
r (p value)*
-0.15(0.32)
0.08(0.61)
0.08(0.61)
-0.04(0.81)
0.14(0.36)
-0.14(0.37)
-0.16(0.29)
-0.03(0.86)
-0.02 (0.90)

Note. *Pearson Correlation Coefficients: Prob > [r] under Ho: Rho=0; Hgb =
hemoglobin; HDL = high density lipoprotein; LDL = low density; BP = blood pressure;
PFat = percent fat; r = correlation coefficient; p value ≤ 0.05 and ≤ 0.20.

Table 4-16. Relationship Among Cardiac-Related Outcomes at 5-8 Years PostKidney Transplantation and Body Composition Measures of Visceral Fat Body Fat,
Visceral Fat Body Lean, Visceral Fat Body Mass, and Visceral Fat Body Percent Fat
Obtained at Time of Transplant
Variables
Creatinine
Glucose
Hgb A1CTriglyceride
HDL
LDL
Coronary risk ratio
Systolic BP
Diastolic BP

VFat Body
Fat
r (p value)
-0.003(0.98)
0.19 (0.22)
0.16(0.31)
0.11(0.46)
-0.37(0.01)
-0.18(0.26)
0.26(0.09)
0.04(0.79)
0.05(0.74)

VFat Body
Lean
r (p value)
0.13(0.40)
0.08(0.61)
-0.01(1.00)
0.32(0.04)
-0.34(0.02)
0.055(0.73)
0.52(0.003)
0.13(0.38)
0.13(0.40)

VFat Body
Mass
r (p value)
0.07(0.64)
0.16(0.30)
0.09(0.56)
0.25(0.10)
-0.43(0.003)
-0.08(0.61)
0.45(0.002)
0.10(0.50)
0.10(0.50)

VFat Body
PFat
r (p value)
-0.09(0.54)
0.16(0.31)
0.15(0.32)
-0.01(0.96)
-0.21(0.17)
-0.16(0.32)
-0.04(0.80)
-0.04(0.80)
-0.01(0.90)

Note. *Pearson Correlation Coefficients: Prob > [r] under Ho: Rho=0; Hgb =
hemoglobin; HDL = high density lipoprotein; LDL = low density lipoprotein; BP = blood
pressure; VFat = visceral fat; PFat = percent fat; r = correlation coefficient; p value ≤
0.05 and ≤ 0.20.
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Table 4-17. Relationship Among Cardiac-Related Outcomes at 5-8 Years PostKidney Transplantation and Body Composition Measures of Android Gynoid Ratio,
Android Percent Fat, Total Fat Mass, and Fat Mass Ratio Obtained at Time of
Transplant
Variables
Creatinine
Glucose
Hgb A1C
Triglyceride
HDL
LDL
Coronary risk ratio
Systolic BP
Diastolic BP

Android/
Gynoid Ratio
r (p value)*
0.01(0.97)
0.15(0.34)
0.16(0.30)
0.02(0.89)
-0.46(0.001)
-0.09(0.57)
0.23(0.13)
-0.04(0.81)
0.09(0.56)

Android
Percent Fat
r (p value)*
-0.14(0.35)
0.18(0.23)
0.20(0.19)
-0.003(0.98)
-0.15(0.33)
-0.17(0.27)
0.01(0.94)
-0.04(0.79)
0.09(0.54)

Total Fat
Mass
r (p value)*
-0.05(0.74)
0.28(0.061)
0.26(0.09)
0.13(0.41)
-0.28(0.06)
-0.21(0.17)
0.21(0.16)
0.05(0.75)
0.15(0.33)

Fat Mass
Ratio
r (p value)*
-0.06 (0.68)
0.20(0.20)
0.21(0.17)
0.08(0.60)
-0.39(0.007)
-0.10(0.54)
0.20(0.19)
-0.03(0.85)
0.09(0.57)

Note. *Pearson Correlation Coefficients: Prob > [r] under Ho: Rho=0
Hgb = hemoglobin; HDL = high density lipoprotein; LDL = low density lipoprotein; BP
= blood pressure; r = correlation coefficient; p value ≤ 0.05 and ≤ 0.20.
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Table 4-18. Relationship Among Cardiac-Related Outcomes at 5-8 Years PostKidney Transplantation and Body Composition Measures of Whole Body Total Fat,
Whole Body Total Lean, Whole Body Total Mass, and Whole Body Total Percent
Fat Obtained at Time of Transplant
Variable
Creatinine
Glucose
HgbA1C
Triglyceride
HDL
LDL
Coronary risk
ratio
Systolic BP
Diastolic BP

WBTotal Fat
r (p value)*
-0.09 (0.53)
0.31(0.04)
0.30 (0.05)
0.12 (0.44)
-0.27(0.07 )
-0.22 (0.15)
0.20(0.20)

WBTotal
Leanr (p value)*
0.13 (0.39)
0.12(0.44)
0.09 (.56)
0.13(0.39)
-0.45(0.002)
-0.06 (0.72)
0.41(0.001)

WBTotal
Massr (p value)*
0.04(0.77)
0.24(0.11)
0.21 (0.16)
0.15 (0.31)
-0.45(0.002)
-0.16( 0.32)
0.39(0.001)

WBTotal
PFatr (p value)*
-0.20(0.20)
0.20(0.20)
0.20 (0.20)
0.03(0.83)
0.04(0.79)
-0.15 (0.33)
-0.07(0.66)

0.05 (0.73)
0.15 (0.34)

0.12 (0.41)
0.19(0.22)

0.11(0.45)
0.20(0.18)

-0.03 (0.85)
0.02(0.91)

Note. *Pearson Correlation Coefficients: Prob > [r] under Ho: Rho=0; WB= Whole-body;
Hgb = hemoglobin; HDL = high density lipoprotein; LDL = low density lipoprotein; BP
= blood pressure; PFat = percent fat; r = correlation coefficient; p value ≤ 0.05 and ≤ 0.20
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Table 4-15 shows an inverse relationship exists with HDL and gynoid lean (r = 0.51; p = <0.001) and HDL and gynoid mass (r = -0.46; p = 0.001). The relationship with
coronary risk ratio and gynoid lean (r = 0.36; p = 0.02) was significant. Relationships
reaching levels of significance (p ≤ 0.20) that warrant continued consideration in fully
powered studies include HDL and gynoid fat (r = -0.21; p = 0.18) and coronary risk ratio
(r = 0.28; p = 0.07). The correlations range from weak to moderate in strength and
negative to positive in direction. As gynoid lean increases, so does coronary risk ratio.
HDL decreases as gynoid mass and gynoid lean increases. For relationships reaching
levels of significance (p ≤ 0.20), as coronary risk ratio increases so does gynoid mass,
while HDL decreases as gynoid fat increases.
A significant relationship also exists with triglyceride and visceral fat body lean
(r = 0.32; p = 0.04) and coronary risk ratio and visceral fat body lean (r = 0.52; p =
0.003). An inverse relationship exists with HDL and visceral fat body fat (r = -0.37; p =
0.01), HDL and visceral fat body lean (r = -0.34; p = 0.02), HDL and visceral fat body
mass (r = 0.07; p = 0.65). A positive relationship exists with coronary risk ratio and
visceral fat body learn (r = 0.52; p = 0.003) and with visceral fat body mass (r = 0.45; p =
0.002; Table 4-16). Relationships reaching levels of significance (p ≤ 0.20) that warrant
continued consideration in fully powered studies include triglyceride and visceral fat
body mass (r = 0.25; p = 0.10), HDL and visceral fat body percent fat (r = -0.21; p =
0.17), and coronary risk ratio and visceral fat body fat (r = 0.26; p = 0.09). The
correlations range from weak to strong in strength and some are negative and some are
positive in direction. As visceral fat lean increases, so do triglyceride levels and coronary
risk ratio. As HDL increases, visceral fat lean, visceral body fat, and visceral fat mass
decrease. For relationships reaching levels of significance (p ≤ 0.20), triglyceride and
coronary risk ratio goes up, as do visceral fat and visceral fat mass. When visceral body
percentage fat goes up, HDL goes down.
An inverse relationship exists with HDL and android gynoid ratio (r = -0.46; p =
0.001) and with HDL and fat mass ratio (r = -0.39; p = 0.007), which are presented in
Table 4-17. Relationships reaching levels of significance (p ≤ 0.20) that warrant
continued consideration in fully powered studies include coronary risk ratio and android
gynoid ratio (r = 0.23; p = 0.13), Hgb A1C and android percent fat (r = 0.20; p = 0.19),
glucose and total fat mass (r = 028; p = 0.06), Hgb A1C and total fat mass (r = 0.26; p =
0.09), HDL and total fat mass (r = -0.28; p = 0.06), LDL and total fat mass (r = -0.21; p =
0.17), coronary risk ratio and total fat mass (r = 0.21; p = 0.16), Hgb A1C and fat mass
ratio (r = 0.21; p = 0.17), and coronary risk ratio and fat mass ratio (r = 0.20; p = 0.19).
The correlations range from weak to moderate in strength with some negative and some
positive in direction. As HDL increases, android gynoid ratio and fat mass ratio
decrease. For relationships reaching levels of significance (p ≤ 0.20), as coronary risk
ratio, HgbA1C, and glucose increase, so do android gynoid ratio, android percentage of
fat, total fat mass, and fat mass ratio. As HDL and LDL increase, total fat mass decreases.
Table 4-18 shows a significant relationship was found with glucose and WB total
fat (r = 0.31; p = 0.04), HgbA1C and WB total fat (r = 0.30 p = 0.05), coronary risk ratio
and WB total lean (r = 0.41; p = 0.001), and coronary risk ratio and WB total mass (r =
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0.39; p = 0.001). An inverse significant relationship was found with HDL and WB total
lean (r = -0.45; p = 0.002) and HDL (r = -0.45; p = 0.002). As glucose and HgbA1C
levels increase, so does WB total fat. AsWB total fat goes up, so do HgbA1C and
coronary risk ratio levels. The correlations range from moderate to strong in strength and
some are negative and some are positive in direction.
Table 4-18 also shows relationships reaching levels of significance (p ≤ 0.20) that
warrant continued consideration in fully powered studies include creatinine and WB total
fat (r = -0.20; p = 0.20), HDL and WB total fat (r = -0.27; p = 0.07), LDL and WB total
fat (r = -0.22; p = 0.15) demonstrate an inverse relationship. A positive relationship was
found between coronary risk ratio and WB total fat (r = 0.20; p = 0.20), diastolic blood
pressure and WB total mass (r = 0.20; p = 0.18), WB total PFat and glucose (r = 0.20; p =
0.20), WB total PFat and HgbA1C (r = 0.20; p = 0.20), and WB total mass and glucose (r
= 0.24; p = 0.11), and WB total mass and HgbA1C ( r = 0.21;p = 0.16). The correlations
are weak in strength and some are negative and some are positive in direction. As
creatinine level increases, WB total PFat decreases. As HDL and LDL levels increase,
WB total fat decreases. As coronary risk ratio increases, so does WB total fat. As
diastolic blood pressure increases, so does WB total mass. WB total PFat goes down as
glucose and HgbA1C decrease.
Research Question 4
Research Question 4 asked, To what degree are anthropometric measures
obtained at the time of transplant associated with serum levels of glucose, lipids, and
creatinine and elevated blood pressure in kidney transplant recipients at 5-8 years
postransplant?
Table 4-19 reports the correlational analyses of anthropometric measures of
weight and BMI at the time of transplant and cardiac-related outcomes 5-8 years postkidney transplantation. A significant relationship exists with Hgb A1C and weight (r =
0.29; p = 0.06) and coronary risk ratio and weight (r = 0.33; p = 0.03). An inverse
relationship exists with HDL and weight (r = -0.46; p = 0.001) and between HDL and
BMI (r = -0.34; p = 0.02). An inverse relationship exists with LDL and BMI (r = -0.34; p
= 0.04). Relationships reaching levels of significance (p ≤ 0.20) that warrant continued
consideration in fully powered studies include glucose and weight (r = 0.27; p = 0.079),
LDL and weight (r = -0.24; p = 0.13), diastolic BP and weight (r = 0.198; p = 0.190),
glucose and BMI (r = 0.28; p = 0.06), and HgbA1C and BMI (r = 0.29; p = 0.06). The
correlations range from weak to moderate in strength and some are negative and some are
positive in direction. As body weight increases so does coronary risk ratio while HDL
decreases; as BMI increases LDL decreases. For relationships reaching levels of
significance (p ≤ 0.20), as HgbA1C and glucose levels increase, so does BMI. As
diastolic BP, HgbA1c, and glucose increase, so does body weight.
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Table 4-19. Relationship Among Anthropometric Measures of Weight and BMI at
Time of Transplant and Cardiac-Related Outcomes at 5-8 Years Post-Kidney
Transplantation
Variables
Creatinine
Glucose
Hgb A1C
Triglyceride
HDL
LDL
Coronary risk ratio
Systolic BP
Diastolic BP

Weight
r (p value)*
0.002(1.00)
0.27(0.08)
0.30(0.06)
0.12(0.45)
-0.46(0.001)
-0.24(0.13)
0.33(0.031)
0.11(0.49)
0.20(0.19)

BMI
r (p value)*
-0.04(0.78)
0.28(0.06)
0.29(0.06)
0.15(0.32)
-0.34(0.02)
-0.34(0.03)
0.19 (0.21)
0.01 (0.93)
0.13(0.38)

Note. *Pearson Correlation Coefficients: Prob > [r] under Ho: Rho=0; Hgb =
hemoglobin; HDL = high density lipoprotein; LDL = low density lipoprotein; BP = blood
pressure; BMI = body mass index; r = correlation coefficient; p value ≤ 0.05 and ≤ 0.20
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Research Question 5
Research Question 5 asked, To what degree are changes in anthropometric
measures from baseline to 5-8 years posttransplant associated with serum glucose, lipids,
and creatinine and elevated blood pressure at 5-8 years posttransplant?
Table 4-20 shows the relationship among weight and BMI change with lab values
and elevated blood pressure from baseline to 5-8 years posttransplant. A significant
relationship exists with coronary risk ratio and BMI (r = 0.31; p = 0.04). Relationships
reaching levels of significance (p ≤ 0.20) that warrant continued consideration in fully
powered studies include creatinine and BMI (r = 0.25; p = 0.10). The correlations are
moderate in strength in a positive in direction. As BMI increases so does coronary risk
ratio. For relationships reaching levels of significance (p ≤ 0.20), as creatinine increases
so does BMI.
Research Question 6
Research Question 6 asked, To what degree are changes in body composition
measures from baseline to 5-8 years posttransplant associated with serum glucose, lipids,
and creatinine and elevated blood pressure at 5-8 years posttransplant? Tables 4-21 to
4-26 show the changes in body composition measures from baseline to 5-8 years
associated with serum glucose, lipids, and elevated blood pressure at a prolonged time
posttransplant.
An inverse relationship was found with creatinine and total fat (r = -0.35; p =
0.02) and LDL and total lean (r = -0.37; p = 0.01). The relationship between current LDL
and total percent fat (r = 0.32 p = 0.05) was statistically significant (Table 4-21).
Relationships reaching levels of significance (p ≤ 0.20) that warrant continued
consideration in fully powered studies include creatinine and total mass (r = -0.28; p =
0.07), creatinine and total percent fat (r = -0.28; p = 0.07), triglyceride and total lean (r =
-0.26; p = 0.09), coronary risk ratio and total lean (r = -0.20; p = 0.20), systolic BP and
total fat (r = -0.21; p = 0.18), diastolic BP and total fat (r = 0.28; p = 0.07), diastolic BP
and total mass (r = 0.28; p = 0.07), and diastolic BP and total percent fat (r = 0.27; p
=0.07). The correlations are moderate in strength with some negative and some are
positive in direction. As LDL increases so does total percentage of fat. Creatinine and
LDL increase while total lean and total fat decrease. For relationships reaching levels of
significance (p ≤ 0.20), ascreatinine increases, total mass decrease. As creatinine
decreases, so does total percet of fat. As triglycerides and coronary risk ratio increase,
total lean decreases. As systolic blood pressure increase, total fat decreases, and total
mass, total lean, and total percentage of fat decrease. As total percent fat, total fat, and
total mass increase, so does diabstolic BP. The correlations are moderate in strength with
a positive direction.
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Table 4-20. Relationship Among Cardiac-Related Outcomes at 5-8 Years PostKidney Transplantation and Change in Anthropometric Measures of Weight and
BMI from Time of Transplant to 5-8 Years Post-Kidney Transplantation
Variables
Creatinine
Glucose
Hgb A1C
Triglyceride
HDL
LDL
Coronary risk ratio
Systolic BP
Diastolic BP

Weight
r (p value)*
0.02(0.87)
-0.17(0.27)
-0.09 (0.56)
-0.06(0.69)
0.08(0.60)
-0.01(0.93)
0.01(0.95)
-0.03(0.85)
0.15(0.34)

BMI
r (p value)*
0.25(0.10)
-0.05(0.77)
-0.03(0.83)
0.03(0.86)
-0.15(0.32)
0.07(0.64)
0.31(0.04)
0.05(0.73)
0.18(0.24)

Note: *Pearson Correlation Coefficients: Prob > [r] under Ho: Rho=0; Hgb =
hemoglobin; HDL = high density lipoprotein; LDL = low density lipoprotein; BP = blood
pressure; BMI = body mass index; r = correlation coefficient; p value ≤ 0.05 and ≤ 0.20.

Table 4-21. Relationship Among Cardiac-Related Outcomes at 5-8 years PostKidney Transplantation and Change in Body Composition Measures of Total Fat,
Total Lean, Total Mass, and Total PFat from Time of Transplant to 5-8 Years PostKidney Transplantation
Variables
Creatinine
Glucose
HgbA1C
Triglyceride
HDL
LDL
Coronary risk
ratio
Systolic BP
Diastolic BP

Total Fat
r (p value)*
-0.35(0.02)
-0.02 (0.91)
0.06(0.68)
-0.04(0.81)
-0.02(0.89)
0.08(0.62)
0.08(0.62)

Total Lean
r (p value)*
-0.07(0.64
-0.02(0.90)
0.10(0.50)
-0.26(0.09)
0.00 (0.69)
-0.37(0.01)
-0.20(0.20)

Total Mass
r (p value)*
-0.28(0.065)
-0.021(0.90)
0.095(0.54)
-0.153(0.32)
0.02(0.89)
-0.12(0.44)
-0.04(0.79)

Total PFat
r (p value)*
-0.28(0.07)
0.01(0.93)
0.01(1.00)
0.07(0.66)
-0.02(0.89)
0.32 (0.05)
0.16(0.31)

-0.21(0.18)
0.28(0.07)

0.03(0.85)
0.16(0.30)

-0.13(0.38)
0.28(0.07)

-0.17(0.25)
0.27(0.07)

Note: *Pearson Correlation Coefficients: Prob > [r] under Ho: Rho=0; Hgb =
hemoglobin; HDL = high density lipoprotein; LDL = low density lipoprotein; PFat =
percent fat; r = correlation coefficient; p value ≤ 0.05 and ≤ 0.20.
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Table 4-22. Relationship Among Cardiac Related Outcomes at 5-8 Years PostKidney Transplant and Changes in Body Composition Measures of Android Fat,
Android Lean, Android Mass, and Android PF from Time of Transplant to 5-8
Years Post-Kidney Transplantation
Variables

Android Fat
r (p value)

Android Lean
r (p value)*
0.08(0.60)
0.04(0.80)
0.11(0.48)
-0.44(0.002)
0.06(0.69)
-0.32(0.41)
-0.16(0.29)

Android
Mass
r (p value)*
-0.22(0.14)
0.02(0.900)
0.11(0.47)
-0.13(0.41)
0.027(0.91)
-0.16(0.31)
-0.02(0.92)

Android
PFat
r (p value)*
-0.37(0.01)
0.01(0.96)
0.00(0.89)
0.17(0.26)
0.02(0.89)
0.22(0.16)
0.11(0.47)

Creatinine
Glucose
Hgb A1C
Triglyceride
HDL
LDL
Coronary risk
ratio
Systolic BP
Diastolic BP

-0.34 (0.02)
0.00(0.99)
0.08(0.60)
0.11(0.46)
-0.01(0.93)
-0.00(0.90)
0.08(0.63)
-0.24(0.11)
0.30(0.05)

-0.12(0.43)
0.23(0.13)

-0.13(0.40)
0.33(0.03)

-0.25(0.09)
0.26(0.08)

Note: *Pearson Correlation Coefficients: Prob > [r] under Ho: Rho=0; Hgb =
hemoglobin; HDL = high density lipoprotein; LDL = low density lipoprotein; BP = blood
pressure; PFat = percent fat; r = correlation coefficient; p value ≤ 0.05 and ≤ 0.20.
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Table 4-23. Relationship Among Cardiac-Related Outcomes at 5-8 Years PostKidney Transplantation and Changes in Body Composition Measures of Gynoid
Fat, Gynoid Lean, Gynoid Mass, and Gynoid PFat from Time of Transplant to 5-8
Years Post-Kidney Transplantation
Variables
Creatinine
Glucose
Hgb A1C
Triglyceride
HDL
LDL
Coronary risk ratio
Sytolic BP
Diastolic BP

Gynoid Fat
r (p value)*
-0.33(0.03)
-0.03(0.83)
0.04(0.78)
-0.01(0.68)
-0.03(0.86)
0.17(0.30)
0.07(0.64)
-0.16 (0.29)
0.25(0.10)

Gynoid Lean
r (p value)*
-0.18(0.25)
-0.06(0.70)
0.09 (0.54)
-0.26(0.08)
0.08(0.60)
-0.38(0.01)
-0.20 (0.18)
-0.04 (0.80)
0.10(0.51)

Gynoid Mass
r (p value)*
-0.31(0.04)
-0.05(0.73)
0.08(0.61)
-0.11(0.24)
0.02(0.87)
-0.08(0.60)
-0.06(0.71)
-0.13(0.40)
0.22(0.14)

Gynoid PFat
r (p value)*
-0.20(0.21)
0.01 (0.93)
-0.01(0.97)
0.06(0.70)
-0.06(0.72)
0.37(0.01)
0.18(0.25)
-0.10(0.50)
0.26(0.10)

Note: *Pearson Correlation Coefficients: Prob > [r] under Ho: Rho=0;
Hgb = hemoglobin; HDL = high density lipoprotein; LDL = low density lipoprotein;
PFat = percent fat; r = correlation coefficient; p value ≤ 0.05 and ≤ 0.20.
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Table 4-24. Relationship Among Cardiac-Related Outcomes at 5-8 Years PostKidney Transplantation and Changes in Body Composition Measures of VFat Body
Fat, VFat Body Lean, VFat Body Mass, and VFat Body PFat from Time of
Transplant to 5-8 Years Post-Kidney Transplantation
Variables
Creatinine
Glucose
Hgb A1C
Triglyceride
HDL
LDL
Coronary risk ratio
Systolic BP
Diastolic BP

VFat Body
Fat
r (p value)*
-0.36(0.01)
0.03(0.84)
0.08(0.57)
-0.01(1.00)
-0.02(0.89)
0.05(0.77)
0.07(0.67)
-0.27(0.07)
0.27 (0.07)

VFat Body
Lean
r (p value)*
0.14(0.38)
0.14(0.36)
0.21(0.18)
-0.30(0.05)
-0.01(0.96)
-0.34(0.03)
-0.26 (0.09)
0.07(0.62)
0.13(0.41)

VFat Body
Mass
r (p value)*
-0.27(0.08)
0.09(0.58)
0.16(0.29)
-0.13 (0.41)
-0.02(0.88)
-0.09(0.56)
-0.05(0.77)
-0.21(0.16)
0.29(0.05)

VFat Body
PFat
r (p value)*
-0.36(0.02)
0.01(0.93)
0.02(0.89)
0.06(0.71)
0.02(0.88)
0.23(0.15)
0.11(0.50)
-0.25(0.09)
0.27(0.08)

Note: *Pearson Correlation Coefficients: Prob > [r] under Ho: Rho=0; Hgb =
hemoglobin; HDL = high density lipoprotein; LDL = low density lipoprotein; BP = blood
pressure; VFat= visceral fat; PFat = percent fat; r = correlation coefficient;p value ≤ 0.05
and ≤ 0.20.
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Table 4-25. Relationship Among Cardiac-Related Outcomes at 5-8 Years PostKidney Transplantation and Changes in Body Composition Measures of Android
Gynoid Ratio, Android Percent Fat, Total Fat Mass, and Fat Mass Ratio from Time
of Transplant to 5-8 Years Post-Kidney Transplantation
Variables
Creatinine
Glucose
Hgb A1C
Triglyceride
HDL
LDL
Coronary risk ratio
Systolic BP
Diastolic BP

Android
Gynoid Ratio
r (p value)*
-0.41(0.01)
0.03(0.83)
0.03(0.87)
0.11(0.50)
0.10(0.53)
0.01(0.94)
0.05(0.72)
-0.40(0.01)
0.07 (0.63)

Android
Percent Fat
r (p value)*
-0.33(0.03)
-0.01(0.93)
-0.02(0.89)
0.07(0.65)
-0.01(0.97)
0.25(0.11)
0.13(0.37)
-0.27(0.07)
0.17(0.25)

Total Fat
Mass
r (p value)*
-0.33(0.03)
-0.00(1.00)
0.05(0.75)
0.00(0.99)
-0.06(0.70)
0.08(0.62)
0.11(0.46)
-0.26(0.08)
0.18(0.22)

Fat Mass
Ratio
r (p value)*
-0.40(0.01)
0.13(0.40)
0.14(0.36)
0.11 (0.50)
0.08(0.61)
-0.11(0.50)
0.04(0.80)
-0.24(0.11)
0.21 (0.17)

Note: *Pearson Correlation Coefficients: Prob > [r] under Ho: Rho=0;
Hgb = hemoglobin; HDL = high density lipoprotein; LDL = low density lipoprotein; BP
= blood pressure; r = correlation coefficient; p value ≤ 0.05 and ≤ 0.20.
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Table 4-26. Relationship Among Cardiac-Related Outcomes at 5-8 Years PostKidney Transplantation and Change in Body Composition Measures of WBTotal
Fat, WBTotal Lean, WBTotal Mass, and WBTotal PFat from Time of Transplant to
5-8 Years Post-Kidney Transplantation
Variables
Creatinine
Glucose
Hgb A1C
Triglyceride
HDL
LDL
Coronary risk ratio
Systolic BP
Diastolic BP

WB Total
Fat
r (p value)
-0.14(0.35)
-0.42(0.004)
-0.40 (0.01)
0.02 (0.91)
0.28 (0.06)
0.03(0.87)
-0.15(0.34)
-0.25(0.09)
-0.27(0.07)

WB Total
Lean
r (p value)
-0.12(0.42)
-0.16(0.30)
-0.15 (0.35)
0.02(0.92)
0.39(0.01)
-0.01(1.0)
-0.27(0.08)
-0.40(0.01)
-0.27( 0.07)

WB Total
Mass
r (p value)
-0.15(0.33)
-0.31(0.04)
-0.29 (0.05)
0.02 (0.90)
0.38(0.01)
0.01(0.95)
-0.24(0.12)
-0.37(0.01)
-0.30 (0.05)

WB Total
PFat
r (p value)
-0.06 (0.70)
-0.37 (0.01)
-0.34 (0.02)
-0.01(0.93)
0.00(1.0)
0.01(0.94)
-0.00(1.0)
-0.04(0.80)
-0.14 (0.37)

Note. *Pearson Correlation Coefficients: Prob > [r] under Ho: Rho=0 WB= whole-body;
Hgb = hemoglobin; HDL = high density lipoprotein; LDL = low density lipoprotein; BP
= blood pressure; PFat = percent fat; r = correlation coefficient; p value ≤ 0.05 and ≤
0.20.
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An inverse relationship was found between creatinine and android fat (r = -0.34; p
= 0.02), creatinine and android percent fat (r = -0.366; p = 0.014), and triglyceride and
android lean (r = -0.44; p = 0.002). Diastolic BP and android fat (r = 0.29; p = 0.05) and
diastolic BP and android mass (r = 0.33; p = 0.03) are shown in Table 4-22.
Relationships reaching levels of significance (p ≤ 0.20) that warrant continued
consideration in fully powered studies include creatinine and android mass (r = -0.22; p =
0.14), LDL and android percent fat (r = 0.22; p = 0.16), systolic and android fat (r = 0.24; p = 0.11), systolic BP and android percent fat (r = -0.25; p = 0.09), diastolic BP and
android lean (r = 0.23; p = 0.13), and diastolic BP and android percent fat (r = 0.26; p =
0.08). As creatinine increases, android fat, android mass, and android percentage of fat
decrease. While triglycerides increase, android lean decreases. As diastolic blood
pressure increases so do android fat and android mass. These correlations were weak to
moderate in strength. For relationships reaching levels of significance (p ≤ 0.20), systolic
blood pressure increases as android fat and android percentage of fat decrease. As
creatinine increases, android mass decreases; while LDL increases so does android
percent of fat. These correlations are considered weak to strong in strength and are
positive in direction (Sheskin, 2011).
Table 4-23 indicates a significant relationship was found with LDL and gynoid
percent fat (r = 0.37; p = 0.01). An inverse relationship was found with creatinine and
gynoid fat (r = -0.33; p = 0.03), creatinine and gynoid mass (r = -0.31; p = 0.04), and
LDL and gynoid lean (r = -0.38; p = 0.01). Relationships reaching levels of significance
(p ≤ 0.20) that warrant continued consideration in fully powered studies include
triglyceride and gynoid lean (r = -0.26; p = 0.08), coronary risk ratio (r = -0.20; p = 0.18),
diastolic and gynoid fat (r = 0.249; p = 0.10), diastolic and gynoid mass (r = 0.22; p =
0.14), and diastolic and gynoid percent fat (r = 0.26; p = 0.08). As LDL increases so does
gynoid percentage of fat. While creatinine increases, gynoid fat and gynoid mass
decrease; while LDL increases gynoid lean decreases. These correlations were moderate
in strength. For relationships reaching levels of significance (p ≤ 0.20), triglyceride
increases while gynoid lean and coronary risk ratio decreases. As diastolic blood pressure
increases so do gynoid fat, gynoid mass, and gynoid percentage of fat. These correlations
are weak in strength, and some are negative and some positive (Sheskin, 2011).
An inverse relationship with significance exists with creatinine and visceral fat
body fat (r = -0.36; p = 0.01), creatinine and visceral fat body percent fat (r = -0.36; p =
0.02), triglyceride and visceral fat body lean (r = -0.30; p = 0.05), and with LDL and
visceral fat body lean (r = -0.34; p = 0.03). The diastolic BP and visceral fat body mass (r
= 0.29; p = 0.05) are statistically significant (Table 4-24). Relationships reaching levels
of significance (p ≤ 0.20) that warrant continued consideration in fully powered studies
include creatinine and visceral fat body mass (r = -0.27; p = 0.08), Hgb A1C and visceral
fat body lean (r = 0.21; p = 0.18), LDL and visceral fat body percent fat (r = 0.23; p =
0.15), coronary risk ratio and visceral fat body lean (r = -0.26; p = 0.09), systolic and
visceral fat body fat (r = -0.27; p = 0.07), systolic BP and visceral fat body mass (r = 0.21; p = 0.16), systolic BP and visceral fat body percent fat (r = -0.25; p = 0.09),
diastolic BP and visceral fat body fat (r = 0.27; p = 0.07), and diastolic BP and visceral
fat body percent fat (r = 0.27; p = 0.08). As creatinine increases, visceral fat body and
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visceral body percentage of fat decrease. Triglyceride and LDL increase while visceral
fat body lean decreases. As diastolic BP increases so does visceral fat body mass. These
correlations were weak to moderate in strength. For relationships reaching levels of
significance (p ≤ 0.20), as creatinine and systolic BP go up visceral fat body mass
decreases. As HgbAIC goes up and coronary risk ratio goes down, visceral fat body lean
increases. As LDL and diastolic BP increases, so does visceral fat body percentage. As
systolic BP goes up , visceral fat body mass goes down. These correlations are considered
weak in strength; some are negative and some positive (Sheskin, 2011).
Table 4-25 indicates a relationship was found with creatinine and android gynoid
ratio (r = -0.41; p = 0.01), creatinine and android percent fat (r = -0.33; p = 0.03),
creatinine and total fat mass (r = -0.33; p = 0.03), and creatinine and fat mass ratio (r = 0.40; p = 0.01) and were all inversely related. An inverse relationship was found with
systolic BP and android gynoid ratio (r = -0.40; p = 0.01; Table 4-25). Relationships
reaching levels of significance (p ≤ 0.20) that warrant continued consideration in fully
powered studies include LDL and android percent fat (r = 0.25; p = 0.11),systolic BP and
android/gynoid ratio ( r = -0.40; p = 0.001) systolic BP and total fat mass (r = -0.26; p =
0.08), systolic BP and fat mass ratio (r = -0.24; p = 0.11), and diastolic BP and fat mass
ratio (r = 0.21; p = 0.17). As creatinine goes up, android gynoid ratio, android percent of
fat, total fat mass, and fat mass ratio go down. As systolic BP increases, android gynoid
ratio decreases. These correlations were moderate to strong in strength. For relationships
reaching levels of significance (p ≤ 0.20), as LDL increases so does android percent of
fat. As diastolic BP increases, so does fat mass ratio. While systolic blood pressure goes
up, android gynoid ratio, android percentage of fat, and total fat mass go down. These
correlations are considered to range from weak to strong in strength with some negative
and some positive (Sheskin, 2011).
Table 4-26 indicates an inverse relationship with glucose and WB total fat (r = 0.42; p = 0.004), WB total mass (r =-0.31; p = 0.04) , and WB total PFat (r = -0.37; p =
0.01) and with HgbA1C and WB total fat ( r = -0.40; p = 0.01), WB total mass (r = 0.29; p = 0.05), and WB total PFat ( r = -0.34; p = 0.02), with systolic BP and WB total
lean (r = -0.40; p = 0.01) and WB total mass (r = -0.37; p = 0.01), with diastolic BP and
WB total mass (r = -0.30; p = 0.05). A significant relationship was found with HDL and
WB total lean (r = 0.39; p = 0.01) and HDL and WB total mass (r = 0.38; p = 0.01). The
correlations were weak to strong and some are negative and some positive in direction.
As glucose goes up, so do WB total fat, WB total mass, and WB total PFat. As systolic
BP goes down, WB total lean and WB total mass go up. As diastolic BP goes down, WB
total mass goes up. As HDL goes up, so do WB total lean and WB total mass. As
glucose and HgbA1C levels go up, WB total fat goes down. As WB total lean and WB
total fat go up, HgbA1C and coronary risk ratio levels go down.
Relationships reaching levels of significance (p ≤ 0.20) that warrant continued
consideration in fully powered studies with an inverse relationship include HDL and WB
total fat (r = 0.28; p = 0.06), coronary risk ratio and WB total lean (r =- 0.27; p = 0.08),
coronary risk ratio and WB total mass (r =-0.24;p = 0.12), diastolic BP and WB total fat
(r = -0.27; p = 0.07), diastolic BP and WB total lean (r =- 0.27; p = 0.07), and systolic BP
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and WB total fat (r = -0.25; p = 0.09). The correlations were weak in relationship and
some are negative and some positive in direction. As coronary risk ratio increases, WB
total lean and WB total mass decrease. As diastolic BP increases so do WB total fat and
WB total lean. As HDL level increases, so does WB total fat.
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CHAPTER 5.

DISCUSSION, CONCLUSION, AND RECOMMENDATIONS

Previous studies have reported significant weight gain (between 6 to 10 kg) in
patients the first year post-kidney transplantation (Aksoy, 2016; Cashion et al., 2014).
Weight gain following transplantation is known to increase obesity risk factors and
contribute to comorbid disorders such as HTN Type II diabetes and CVD, which is the
number one cause of mortality in this population (Beckmann, Ivanović, Drent, Ruppar, &
Geest, 2015; Olarte & Hawasli, 2009). Despite the high percentage of individuals gaining
a significant amount of weight following transplantation and the serious consequences
associated with this weight gain, no studies have examined whether weight distribution
throughout the body is associated with cardiac risk factors.
Moreover, while concern exists for the increased cardiac risk that accompanies
post-kidney transplant weight gain; in addition to the differential risks that may be
associated with weight gain distribution, there is a lack of consensus regarding what
measures of body weight provide the best information on these cardiac risk factors.
Typical anthropometric measures of weight often include BMI and waist circumference.
However, measures of body mass by DXA provide more precise data of lean and fat mass
for various compartments of the body, and visceral fat in particular, which is believed to
be associated with increased cardiac risk. Thus, the present study sought to address
whether anthropometric or DXA measures of weight are most closed associated with
cardiac risk factors. This chapter includes a discussion of the significant findings and
compares the study results with existing research. Furthermore, it includes strengths and
limitations of our study, practice implications, theoretical implications, as well as
recommendations for future research and a conclusion.
Demographic Findings
Unlike national data, the majority of our study sample (64.4%) was African
American and reflective of the demographic characteristics of the community from which
the sample was drawn. Moreover, our study cohort also captured a group at particularly
high risk for cardiovascular disease in general and graft failure following kidney
transplant in particular. Our findings, therefore, provide new information particularly
relevant to this high-risk population.
Discussion
Research Question 1
The first research question sought to determine the association between
anthropometric measures and serum glucose, lipid, and creatinine levels and blood
pressure in kidney transplant recipients 5-8 years posttransplant. The study found that
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high waist readings (WC and waist-to-hip ratio) were associated with an increased
coronary risk ratio (r = 0.33; p = 0.05), and that higher diastolic BPs (above 90 mmhg)
were associated with higher posttransplant weight. These findings are consistent with
previous studies that reported posttransplant weight gain and found that it leads to a high
diastolic BP, which in turn increases the renal recipient’s risk of developing CVD
(Mohammadifard et al., 2013; Scherrer et al., 1991) and acute graft loss (Cosio et al.,
2001). Similarly, a high WC also increases the coronary risk ratio, which in turn
increases the kidney recipient risk of developing CVD (Mohammadifard et al., 2013).
Research Question 2
Research Question 2 sought to address the association between body composition measures and serum glucose, lipid, and creatinine levels and blood pressure in
kidney transplant recipients 5-8 years posttransplant. While Research Question 1 found
increased WC and weight to be associated with increased CV risk and diastolic BP,
respectively, several additional associations were found in Research Question 2 results
between serum glucose, lipid, and creatinine levels and elevated blood pressure and
measures of body composition. In addition to CV risk, measures of body composition
were also associated with HDL, systolic BP, and creatinine. It was also found that
android fat, visceral fat, and visceral fat body mass were all found to be associated with
increased CV risk (Table 4-8 to 4-11).
Furthermore, using measures of body composition, relationships with HDL were
found with measures of total, total PFat, VFat, gynoid PFat, android PFat, and VFat body
PFat and with percent gynoid and android fat (Table 4-7 to 4-11). Because approximately
one third of recipients undergoing kidney transplant are significantly burdened with CAD
and many experience subsequent CV events (Neale & Smith, 2015), measures of cardiac
risk warrant careful monitoring.
Instead of the relationships that Research Question 1 results found between
weight and diastolic BP, using measures of body composition, relationships were found
with the more meaningful measure of systolic BP in Research Question 2. Specifically,
measures of visceral percent fat and android fat were found to be associated with systolic
BP. However, surprisingly, these were inverse relationships, thus indicating that
increased fat in these compartments was associated with decreased systolic BP. Last,
using measures of body composition, additional relationships were found with creatinine
levels. Total fat, android Pfat, gynoid Pfat, VFat, and VFat body PFat were all found to
be inversely related to creatinine―that is, as these levels increased, creatinine levels
decreased, which indicates improved function (Tables 4-7 to 4-12). This-result suggests
that elevated levels of total fat, total percent fat, visceral fat, android fat, and gynoid fat
are associated with low creatinine level, which reduces the risk of graft loss. However, a
high level of creatinine, according to Younespour et al. (2016) and Maraghi et al. (2016),
increases graft loss as well as the survivability of the kidney. An inverse relationship
exists with creatinine and android percent fat (r = -0.45; p = 0.001), implying a high
android percent fat lowers creatinine level.
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Research Question 3
Research Question 3 sought to determine the degree to which body
composition measures obtained from recipients at the time of transplant were associated
with serum levels of glucose, lipids, and creatinine and elevated blood pressure obtained
at 5-8 years following the transplant. Significant relationships were found among 11
measures of body composition obtained at the time of transplantation and the HDL level
at 5-8 years posttransplant (Tables 4-13 to 4-18). These measures included both android
and gynoid lean and mass, as well as the android/gynoid ratio, percent body lean and total
lean, percent body fat, fat mass ratio, and total fat and total mass. Because HDL levels at
the time of transplant were not available, it was not possible to determine whether this
association also existed at the time of transplantation. Regardless, it is noteworthy that all
four measures of lean tissue as well as nearly half the remaining compartments measured
at the time of transplant surgery were found to be related to HDL levels 5-8 years later. In
terms of coronary risk ratio, three of the four measures of lean tissue (total, gynoid, and
visceral fat body) were related, along with android fat and mass and total percent fat.
However, total fat and visceral fat body lean were related in an unexpected direction—
i.e., as lean values increased, so did coronary risk. Lastly, lean tissue android and visceral
fat body were also related to triglyceride levels. The prevalence of lean tissue
relationships to measure cardiac health raises a question regarding the perception that fat
mass is of primary concern while increased levels of lean are considered healthier.
In addition, HDL is used to assess patients’ risk for heart disease (Hewing,
Moore, & Fisher, 2012). An inverse relationship was found with HDL and total fat (r = 0.34; p = 0.02) and HDL and total lean (r = -0.50; p = < 0.001), which suggests a high
total fat, total lean, and total mass lowers serum levels of HDL. Low serum levels of
HDL from a high level of total fat, total lean, and total mass can increase the post-kidney
transplant recipients’ risk for CAD, which is corroborated by the Framingham study
(Castelli et al., 1986). The Framingham study showed the risk for CAD increases as
triglyceride, total cholesterol, and LDL increase and those patients with CAD had low
levels of HDL (Castelli et al., 1977; Castelli et al., 1986). In addition, Toth (2004)
indicated that low serum levels of HDL are often seen with patients who have CAD. Low
serum levels of HDL are also an independent risk factor for CAD (Puri et al., 2014; Toth,
2004).
An inverse relationship was found with HDL and visceral body fat (r = -0.46; p =
0.001), HDL and visceral body lean (n = 45); (r = -0.341; p = 0.021), and HDL and
visceral fat body mass (r = 0.07; p = 0.65). This indicates that a high visceral body fat
mass and visceral body lean, lowers serum levels of HDL, which predisposes kidney
recipients to obesity-related health complications. An elevated level of visceral fat in the
abdominal area is linked to health complications such as Type 2 diabetes and CAD
(Purnell et al., 2000).
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An inverse relationship exists with HDL and android fat (r = -0.46; p = 0.001),
HDL and android lean (r = -0.45; p = 0.002), and HDL and android mass (r = -0.53; p <
0.001). Android lean is associated with lower serum levels of HDL, indicating the
participants in this study were at risk for CVD. This finding is surprising because one
would expect that participants with a high android lean would raise the serum levels of
HDL, which would lower the participants’ risk for CVD rather than increase their risk.
Our study found that a high android mass lowers the serum levels of HDL, which is
consistent with Latt et al.'s (2018) finding, which showed that a high android mass
worsens serum levels of HDL, leading to an increased risk for CVD in normal weight and
overweight boys during puberty. It is the overall mass in the abdomen that is the issue
whether lean or fat.
High android fat is associated with lower serum levels of HDL, indicating the
participants in the current study are at risk for CVD. Android fat distribution is associated
with CVD (Kouda, Nakamura, Fujita, Ohara, & Iki, 2012). Min and Min (2014) studied
5,696 adults from 2003 to 2006 to determine which fat percentages from android and/or
gynoid fat predicted CVD. Their findings showed that regardless of gender, android and
gynoid body fat percentages are positively linked to BMI and WC. Moreover, increases
in android fat percentage were positively linked to total cholesterol, triglycerides, and
HDL for males and total cholesterol, HDL, and LDL for females (Min & Min, 2014). On
the other hand, gynoid fat percentage was positively linked to total cholesterol in males.
For females, gynoid fat percentages were positively linked to triglycerides and HDL. Min
and Min (2014) concluded that fat accumulation in the android region was a significant
predictor of CVD compared to that in the gynoid region.
A significant relationship was found with triglyceride and android lean; (r = 0.30;
p = 0.05), which implies that low levels of android lean are associated with lower levels
of triglycerides. Android lean represents the lower body fat. Jensen (2008) posited a
decreased level of lower body fats in the android region decreases patients’ risk of CVD.
An inverse relationship exists with HDL and gynoid lean (r = -0.51; p < 0.001). This
suggests a high gynoid lean lowers the level of HDL, which is surprising because one
would expect that lean body mass in the gynoid region would increase the levels of HDL
rather than decrease them.
A significant relationship exists with coronary risk ratio and total lean (r = 0.42; p
= 0.004), implying that a high total lean leads to a high coronary risk ratio. Huang et al.
(2015) found that high lean mass is an independent factor that increased the survival rates
of Chinese patients with CAD because it protected them from mortality. These findings
were similar to the findings of Han et al. (2010) and Lavie et al. (2011) in showing that
high lean mass is an independent risk factor that increases the survival rates of elderly
patients and patients with CAD. The relationship between coronary risk ratio and total
mass (r = 0.38; p = 0.01) were significant, suggesting a high total percent fat leads to a
high coronary risk ratio.
The relationship between coronary risk ratio and visceral fat body lean (r = 0.52;
p = 0.003) was significant, meaning a lower visceral fat lowers the coronary risk ratio,
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which supports previous findings. Ross and Janiszewski (2008) found weight loss,
particularly in the abdominal area, reduces abdominal fat, which in return reduces the
patients’ risk of CVD. The relationship between coronary risk ratio and android fat (r =
0.32; p = 0.03) and coronary risk ratio and android mass (r = 0.47; p = 0.001) was
significant. This indicates that a high android fat and a high android mass increase the
coronary risk ratio. Despres (2012) found that regional body fat distribution, particularly
android fat and android mass, increases the patients’ risk of having a CV event. A
significant relationship exists with coronary risk ratio and gynoid lean (r = 0.36; p =
0.02), implying that lean body mass lowers gynoid fat, which reduces the coronary risk
ratio; this is consistent with previous findings showing how lowering gynoid fat by
replacing it with lean body mass can improve a patient’s CV outcome.
Research Question 4
Research Question 4 sought to determine whether anthropometric measures
obtained at the time of transplant were associated with serum levels of glucose, lipids,
and creatinine and blood pressure in kidney transplant recipients at 5-8 years
posttransplant. The findings from these analyses reflect those of the body composition
measures (Table 4-19). Similarly, HDL was inversely related to weight, while coronary
risk ratio was positively related to weight.
A significant relationship was found with coronary risk ratio and weight (r = 0.33;
p = 0.03). This implies that an increase in weight increases coronary risk ratio, which
indicates that weight gain increases the coronary risk factors of developing CVD. This is
consistent with previous findings showing how weight gain and CVD are linked (Akil &
Ahmad, 2011; Baum, 2001b; Kannel, D'Agostino, & Cobb, 1996). Kannel et al. (1996)
noted that being overweight worsens the CV risk profile. Baum (2001b) noted that 50%
of the posttransplant population experienced weight gain. Weight gain is a major problem
because of the interaction between obesity and immunosuppression medications, which
increases the risk for CVD.
An inverse relationship exists with HDL and weight (r = -0.46; p = 0.001). This
means that when weight is lowered, HDL increases, which is consistent with prior
findings which show that weight reduction increases HDLand lowers LDL. Dattilo and
Kris-Etherton (1992) studied the effects of weight reduction on blood lipids and
lipoproteins in a meta-analysis. They found, from the 70 studies, that weight reduction
lowered LDL and increased HDL. The relationship between HDL and BMI (r = -0.34; p
= 0.02) is inverse. This suggests that a lower BMI is associated with an increased HDL.
Research Question 5
Research Question 5 asked to what degree changes in anthropometric
measures from baseline to 5-8 years posttransplant are associated with serum glucose,
lipids, and creatinine and elevated blood pressure at 5-8 years posttransplant. The only
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anthropometric measure found to be associated with the cardiac-related outcomes was
BMI, which was associated with coronary risk ratio (r = 0.31; p = 0.04). This finding was
expected, given that obesity has long been recognized as a common risk factor for CVD
(Dimeny, 2002; Ghoorah, Campbell, Kent, Maznyczka, & Kunadian, 2016; Ladhani,
Craig, Irving, Clayton, & Wong, 2017; Lentine et al., 2008; Orazio et al., 2007).
Moreover, obesity-related CVD is more common in kidney transplant recipients than in
the general population (Marcén, 2006).
Although the change in BMI was only 3.11 from baseline (M = 29.03; SD = 4.76)
to 5-8 years posttransplant (M = 32.14; SD = 9.61) in our cohort group, this represented
an elevation to Class I obese (30-34.9). The degree of change, along with the probable
trajectory of the gain, likely accounts for the significant finding. This finding is also
consistent with previous findings (Beckmann, Ivanović, Drent, Ruppar, & Geest, 2015;
Cashion et al., 2007; Cupples et al., 2012; Nuttall, 2015; Stanfill et al., 2015) which
found weight gain increasing by as much as 32 kg after 5-year post-kidney
transplantation.
Research Question 6
Research Question 6 sought to determine the degree to which changes in body
composition measures from baseline to 5-8 years posttransplant were associated
with serum glucose, lipids, creatinine, and elevated blood pressure. In contrast to
anthropometric measures, which found only the change in BMI from time of transplant to
5-8 years later to be associated with coronary risk ratio, multiple measures of body mass
were associated with creatinine, LDL, diastolic BP, triglycerides, and systolic BP (Tables
4-21 to 4-26).
All the relationships with creatinine (Table 4-21) were inverse, which is
consistent with studies which have found that high body fat and high body mass can
reduce excretion of creatinine resulting from the loss of muscle mass associated with
aging and chronic illness (Heymsfield et al., 2005). In addition, Oh, Choi, Lee, & Park
(2017) have also reported that abdominal obesity reduces kidney function, which affects
the kidney’s ability to excrete waste products effectively. As Gerchman et al. (2009)
stated, visceral adipose tissue found in the abdomen reduces the glomerular filtration rate,
which reduces the clearance of creatinine from the kidney.
LDL was inversely related to three measures of lean tissue (total lean, gynoid
lean, and visceral fat body lean) and positively related to total percent fat and gynoid
percent fat. The relationships found with these compartments of lean tissue are consistent
with previous findings that an increased lean body mass in the hips and thighs reduces
LDL and increases the levels of HDL, thereby reducing the risk for CVD (Hioki et al.,
2015; Hoenig, Cowin, Buckley, McHenery, & Coulthard, 2011). Likewise our findings
related to LDL, total percent fat, and gynoid percent fat are consistent with previous
findings which reported that higher total percent is associated with LDL (Chiu, Williams
& Krauss [2017]) and findings by Min and Min (2014) that gynoid percent fat was
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positively correlated with LDL, indicating that an increase in gynoid percent fat
accompanies an increase in LDL and, in return, an increased risk of CVD.
Diastolic BP was found to be related to both android fat (r = 0.30; p = 0.05) and
android mass (r = 0.33 p = 0.03) as well as visceral fat and mass (Tables 4-22 to
4-26), indicating that increased weight in both android and visceral fat may contribute to
increased diastolic BP. This finding is consistent with George et al. (2016), who studied
the role of body fat and fat distribution in hypertension risk in urban Black South African
women and found that trunk fat mass and arm fat mass accompanied increased diastolic
BP levels. In the follow-up study to George et al. 5-8 years posttransplant, diastolic BP
increased by 20.5%. Yano et al. (2016) also studied regional fat distribution and found
that an increase in VAT leads to an increase in diastolic pressure
An inverse relationship was found with systolic BP and android gynoid ratio (r =
-0.40; p = 0.01), suggesting that a high A/G ratio is associated with systolic BP. This
finding is surprising since one would expect that a high A/G ratio would increase systolic
BP rather than lower systolic BP.
Strengths and Limitations
This is the first longitudinal study of weight changes that occur in kidney
transplant recipients to employ DXA scans to quantify measures of body composition.
Although previous longitudinal studies have been conducted with similar samples, none
have employed the same detailed measures of changes that occur in individual
compartments of the body. In addition, this study expands upon the extant knowledge by
examining the association and changes in body composition for their association with
clinically important outcomes obtained 5 years plus posttransplant. The relationships
found in this study provide important implications for practice and guidance for future
research. Lastly, the BCAM model introduced to guide this study proved to be helpful in
conceptualization, conduct, and analysis of the study findings. In addition to the BCAM
model providing a valuable role in guiding future research, it may also aid HCPs in
selecting the best methods to evaluate changes in BC and to more accurately tailor
interventions considering individual biological and pathological conditions, thereby
improving patient outcomes.
Despite the strength of the current study, some limitations existed. First, the small
sample size (N = 45) may affect generalizability to a larger kidney transplant population.
Second, study participants were not randomly selected but were selected from a parent
study in the same transplant center of a large midsouth university-affiliated transplant
institute, further threatening the generalizability of study findings. However, as an early
exploratory study that is the first to use this longitudinal approach with detailed DXA
scanning of body compartments, replication of this research should be undertaken. Third,
a small sample size may increase the possibility of a Type II error (Burns & Grove, 2009;
Polit, 2010). A Type II error exists when the null hypothesis is false but is accepted as
true from the statistical testing (Burn & Grove, 2009; Polit, 2010). However, this is
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balanced to some degree by the large number of body composition measures, which
could contribute to a Type I error. However, as an exploratory study, it is important to
identify all potential contributing factors so they can be included in future, more fully
powered and sophisticated explanatory modeling studies.
Clinical and Practice Implications
The results of the current study could serve as a work in process for future studies
to target specific tissue measures for body fat and weight gain in the general and postkidney transplant population. Our work has found that commonly used indirect methods
may be inappropriate for accurately accessing body fat and weight gain in the postkidney transplant population. In addition to the unique physiological conditions
accompanying transplant that may affect distribution of weight, age, ethnicity/race,
lifestyle, other clinical conditions influence the distribution of lean and fat mass across
body compartments and thereby should also influence the choice of methods used to
monitor body fat and weight. Clinical conditions may make certain indirect methods
unsuitable for accurately assessing %BF in individuals. For example, BIA measures
assume total body water measurement is the same for all individuals; therefore, in obese
or dehydrated individuals %BF is overestimated (Dehghan & Merchant, 2008; Heyward
& Wagner, 2004).
The BCAM is a science- and system-based model designed to guide practice
decisions regarding selection of the best methods for measuring and monitoring weight.
The BCAM illustrates a scientific-technological linkage between factors that influence
weight gain and shows how the adverse changes in body composition affect the postkidney transplant population health outcomes. The conceptual framework of the BCAM
can describe how body composition variation influences biological, lifestyle, healthrelated, and biometric factors in the presence of weight gain. The physiological changes
affect body composition variation in the presence of abnormal lab levels of serum
glucose, lipid, coronary artery ratio, and creatinine and long-standing elevated blood
pressure, which could lead to mortality and morbidity. The findings from the current
study show an association between weight gain and obesity-related cardiovascular
disease and abnormal cardiac variables of the blood values.
Recommendations for Future Research
As a prospective correlational study, our results provide direction for future
research on how the BCAM could support healthcare professionals in finding an
appropriate indirect method to measure body fat and weight gain in the post-kidney
transplant population. Additional research with larger representative samples of the postkidney transplant population is needed in order to generalize the study findings and to
conduct more sophisticated multivariate analysis or predictive modeling. These additional
studies will help provide more statistical insights into the measurement of components of
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body fat and weight gain and provide theoretical insight that will help to further develop
the BCAM.
Conclusion
Postoperative weight gain is a common phenomenon in the kidney transplant
population and is higher than in the general population. A weight gain of 10 kg in the first
year and doubling to 32 kg in the second year is not unusual and often leads to obesityrelated complications. One of the obesity-related complications is the risk of developing
cardiovascular disease that may lead to mortality in the kidney transplant population.
Although various methods are used to measure and monitor weight gain over time, the
literature lacks a consensus on which methods, specifically anthropometric or dualenergy x-ray absorptiometry, are most accurate in the assessment of weight gain in the
presence of diseases in the kidney transplant population. Furthermore, limited studies
have addressed the association between changes in body composition as measured by
dual-energy x-ray absorptiometry or anthropometric indices and serum glucose, lipids,
and blood pressure as predictors of cardiovascular disease after kidney transplantation.
The results from this study show several significant emerging risk factors of
developing post-kidney transplant cardiovascular disease from excessive weight gain and
obesity-related complications. Excessive weight gain and obesity-related complications
are concerns in the kidney transplant population due to increased morbidity and
mortality. Furthermore, the significant relationships found among the dual-energy x-ray
absorptiometry and cardiac-related outcomes suggest that dual-energy x-ray
absorptiometry provides a better assessment of body fat, weight gain, and potential
cardiac risk factors than do the currently used anthropometric measures of weight and
waist circumference. Thus, future research scientists and clinical practitioners should
continue to examine the use of dual-energy x-ray absorptiometry for understanding the
emerging coronary risk that accompanies weight gain and as a basis upon which more
precise targeted interventions could be designed that would improve the health and life
expectancy of kidney transplant patients.
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